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Abstract 
Malaria and malnutrition are causes of high morbidity and mortality in developing 
countries especially in sub-Saharan Africa and Asia. Malnourished children are at 
higher risk of developing malaria, a problem compounded by the fact that 
malnutrition affects the metabolism of different antimalarials including chloroquine 
and quinine. Emerging resistance to chloroquine, which was the drug of choice, has 
led to the widespread use of artemisinin combination therapy in the population 
including children. To date, no studies have been undertaken on the 
pharmacokinetics of artemisinin compounds in malnourished children. This thesis 
aims to fill this evidence gap by studying patients with uncomplicated malaria of 
different nutritional status in The Gambia. 
Analysis of the nutritional status of 97 children in The Gambia with uncomplicated 
malaria showed that 30% were both underweight and wasting, while 28% were 
categorised into stunting. This was much higher than the national average which has 
been estimated to be 17.4%, 9.5% and 23% for underweight, wasting and stunting, 
respectively, demonstrating a potential relationship between malaria and Protein 
energy malnutrition.  
In-vitro studies showed that although pre-treatment of HL-60 cells with the iron 
chelator (DFO) did not affect the bioactivation of artesunate, there was a 20% 
increase in cell viability with IC50 increasing from 7.0 ± 4.3 to 33.3 ± 2.9. This is 
believed to be as a result of DFO chelating the toxic iron generated as a result of 
artesunate bioactivation which increased from 0.32 ± 0.6 ng/mol in the control 
incubations to 0.84 ± 0.1ng/mol at 100 µmol artesunate concentration. In light of the 
fact that iron was important in the mechanism of action of these compounds, and the 
fact that iron deficiency is commonly in malnourished children, the effect of both 
PEM and anaemia on plasma drug levels of artemether and DHA was also studied.  
LC-MS/MS method was optimised and validated for the simultaneous analysis of 
artemether and DHA in plasma with ≥80% precision and accuracy. Plasma 
artemether and DHA concentration analysed 2h post first dose was 138.4 ± 80.9 
ng/ml and 58.8 ± 43.7 ng/ml respectively. Severely wasted and wasted children had 
the highest artemether (156.5 ±69.6 ng/ml) and DHA (84.1 ±62.6) plasma 
concentrations respectively but values were not statistically significant. Anaemic 
status of children did not have an influence on drug plasma concentration with 
anaemic children having artemether and DHA plasma concentration of 138.5 ± 73.7 
and 57.9 ± 36.6, respectively, and 138.43 ± 85.3 and 59.3 ± 46.8 for non-anaemic 
children respectively. However, conclusive results were limited by sample size. 
In conclusion, this thesis has demonstrated a relationship between malaria and 
Protein energy malnutrition, and highlighted the possible effects pathophysiological 
changes as a result of protein energy malnutrition can have on drug pharmacology 
and therapeutic effects in these children. There is a need for further studies in larger 
cohorts of children with protein energy malnutrition to determine whether 
therapeutic efficacy of artemisinin combination therapy is affected in an adverse 
manner, and whether there is a need for changes in dosing recommendations.  
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I  General Introduction 
1.1 Malaria 
The word malaria comes from the Latin word “mal aria” meaning “bad air”. 
This was because people living around the Roman swamps would come down with 
recurrent and debilitating fever. They thought the disease emanated from the gases 
from the swamp. The first clinical description of malaria was made by Hippocrates in 
400 BC, but it was not until the 1700s that malaria was discovered to be caused by a 
protozoan infection of the blood (Carter and Mendis, 2002). 
Among the two billion people at risk of malarial infection in 2008, WHO 
estimated 243 million cases of malaria resulting in 863,000 deaths. 85% of the cases 
were in Africa followed by South-East Asia with 10%. 89% of the deaths occurred in 
Africa and 85% of all deaths were in children under 5 years of age (WHO, 2009). 
Table 1.1 shows the number of malaria case and deaths by region in 2008.  
Malaria is an infectious disease of the blood caused by a protozoan parasite of 
the genus Plasmodium, and is transmitted from one human to another by the female 
anopheles mosquito. Although there are more than 400 species of plasmodium, only 
four species cause malaria infection in humans: Plasmodium vivax, falciparum, ovale 
and malaria. P vivax and P falciparum are the most commonly encountered malaria 
parasites (Tangpukdee et al., 2009). 
Chapter 1:-Introduction 
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Table 1.1 Estimated number of malaria cases, 2008. 
WHO Region 
Cases Deaths 
Estimates Estimates 
 Number % 
P.falciparum 
(%) 
Number % 
Under 
5 % 
Africa 208 85 98 768 89 88 
Americas 1 0.4 32 1 0.1 30 
Eastern Mediterranean 9 3.7 75 52 6 77 
Europe 0 0 4 0 0 3 
South-East Asia 24 10 56 40 4.6 34 
Western Pacific 2 0.8 79 3 0.3 41 
Total 243 100 93 863 100 85 
Estimated number of malaria cases (in millions) and deaths (in thousands) by WHO region 
in 2008.  
Adapted from WHO World Malaria Report, 2009. 
 
P falciparum and P vivax account for 95% of all malaria infections, but 
almost all severe and deadly cases are caused by P falciparum (Schlitzer , 2007). P 
falciparum is the most prevalent and is normally found in tropical, subtropical and 
warm temperate regions whilst P vivax is more prevalent in Asia and the Latin 
American subcontinents and account for 10% of malaria cases in Africa (Carter and 
Mendis, 2002). 
1.1.1 Life Cycle of Malaria Parasite 
Transmission of the malaria parasite from mosquitoes to the human body takes 
place in the form of a cycle (Figure 1.1) through the bite of a female Anopheles 
mosquito. It comprises two phases, the asexual phase which takes place in humans, 
and the sexual phase which takes place in the body of the mosquito. The asexual 
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stage (human stage) of the life cycle begins with the exo-erythrocytic stage and ends 
with the formation of non-multiplying sexual forms or gametocytes called the 
erythrocytic phase (Suh et al., 2004). 
Figure 1.1 Life cycle of a malaria parasite 
Schematic diagram of the life cycle of a malaria parasite in the human host and mosquito 
vector (Adapted from labspace, The Open University) 
The infected female anopheles mosquito injects the parasites (sporozoites) in 
the bloodstream whilst taking a “blood meal”. Parasites invade and develop in the 
liver cells where they begin a phase of asexual reproduction called the hepatic or pre-
erythrocytic phase, resulting in the formation of schizonts (Beeson and Brown, 
2002). The mature schizonts rupture to release the merozoites which then enter the 
blood stream and invade red blood cells, thus starting the erythrocytic phase of the 
life cycle. In the red blood cells, merozoites mature to form trophozoites which then 
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again develop to schizonts. As the parasites mature and replicate during the 
erythrocytic phase of malaria infection, it ingests a huge amount of haemoglobin for 
its own protein production. The heme is digested in the parasites food vacuole (FV) 
releasing toxic heme moiety which the parasite has the ability to detoxify. Protein 
synthesis and nuclear division of the parasites causes red blood cell distortion and 
rupture releasing more merozoites and continuing the cycle of infection (Elliot et al., 
2007). 
1.1.2 Clinical manifestation 
The severity of the symptoms of malaria depends largely on the nature and 
load of the parasite, and the immune status of an individual towards malaria. Partial 
immunity against malaria is progressively acquired in adults living in malaria 
endemic areas usually due to repeated infections (Doolan et al, 2009). 
Symptoms are generally more severe in children, pregnant women and non-
immune individuals. The most common symptoms of uncomplicated malaria are 
non-specific and include prodromal symptoms like headache, nausea, fever, general 
body pain and vomiting. Fever, chills and headache can come in bursts which 
correspond with the release of the merozoites and toxins from the red blood cells to 
the blood stream. Complicated malaria is said to occur in the presence of life 
threatening conditions (Suh et al., 2004). Table 1.2 summarises the signs and 
symptoms of complicated malaria.  
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Table 1.2 Signs and Symptoms of complicated malaria 
- Impaired consciousness  
- Unrousable coma not associated to any other cause - Glasgow coma scale ≤ 9 
- Repeated generalised convulsion -  ≥ 3 episodes in 24 H 
- Prostration or weakness 
- Acute respiratory distress syndrome 
- Pulmonary oedema (radiological) 
- Abnormal spontaneous bleeding or disseminated intravascular coagulation 
- Metabolic acidosis - arterial pH < 7.25 or plasma 
- bicarbonate < 15 mmol/l 
- Circulatory collapse/shock 
- Hyperpyrexia - Core body temperature > 40 
- Hyperparasetaemia - >5 % parasitised erythrocytes or > 250000 parasites/µl 
- Severe anaemia - Haemoglobin < 50g/dl in the presence of parasite count > 
10000/µl 
- Hypoglycaemia - Blood glucose concentration < 2.2 mmol/l 
- Renal failure - Urine output < 400 ml/24 hour in adults (< 12 ml/kg/24 hour 
in children), serum creatinine > 265 µmol/l (> 3.0 mg/dl) despite adequate 
volume repletion 
- Hyperbilirubinaemia - Total bilirubin > 43 µmol/l (2.5 mg/dl) 
- Macroscopic haemoglobinuria - Haemolysis not secondary to glucose-6-
phosphate dehydrogenase deficiency 
 
1.1.3 Diagnosis of malaria 
Rapid and correct diagnosis is important in malaria treatment as delays in 
diagnosis can lead to complicated malaria, and inevitably be fatal. In areas of high 
malaria transmission, clinical diagnosis is very common and is based on the signs 
and symptoms of the patient. This form of diagnosis might not be reliable due to the 
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non-specific symptoms of malaria leading to high number of false positives and 
mistreatment (Tangpukdee et al., 2009). 
Light microscopy by Giemsa stain of thick and thin blood smears remains the 
most commonly used method for the diagnosis of malaria (Moody and Chiodini, 
2000). Thick smears are sensitive for screening for plasmodium parasites whilst thin 
smears allow for species identification, parasite quantification and the different 
developmental stage of the parasite (schizonts and gametocytes) (Trampuz et al., 
2003). Alternative diagnostic methods have been developed to overcome the 
limitations of microscopy. These include polymerase chain reaction, rapid diagnostic 
test (RDT), automated malaria pigment detection, quantitative buffy coat (QBC) 
(Bhandari et al., 2008), OptiMal, Para HIT-f, ParaScreen, SD Bioline and Paracheck. 
With the exception of RDTs, these methods are relatively more expensive and need 
specialised equipment. RDT on the other hand detects malaria antigen in blood and is 
quick, simple, accurate and cost effective for Plasmodium detection (Tangpukdee et 
al., 2009). 
1.1.4 Treatment for malaria 
1.1.4.1 Drugs used in the treatment of malaria 
Antimalarials used in the treatment of malaria include 7 drug classes namely; 
4-aminoquinolones, 8-aminoquinolones, arylaminoalcohols, antifolates, inhibitors of 
the mitochondrial respiratory chain, antibiotics and artemisinins (Schlitzer, 2008). 
Table 1.3 lists the different drugs in each class and summarises the mode of action of 
the different classes of antimalarials.  
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Chloroquine and sulphadoxine-pyrimethamine have been used for many 
decades as the drug of choice for the treatment of uncomplicated malaria but the 
emergence of parasite resistance to these traditional antimalarials saw a rise in 
malaria morbidity and mortality especially in children. In response to this serious 
situation, steps were taken to deliver more effective interventions. This included drug 
combinations with an artemisinin derivative and anti-vector measures (Greenwood et 
al., 2008).  
Artemisinin (1) and its derivatives are a class of antimalarial drugs which 
may meet the challenges posed by drug-resistant parasites and the rapid progression 
of malarial illness. They are the most rapidly acting and potent of all the antimalarial 
drugs and have been used successfully in malaria treatment. With the rising 
resistance to malaria, the use of the drug has become important (White, 2005).  
1.1.4.1.1 Artemisinins 
Artemisinins are derived from a plant called sweet worm (or sweet Annie; 
Artemisinin annua) in China where they were first discovered. “Ginghae” extracts 
were reported to have antipyretic properties more than 1500 years ago. A co-
ordinated programme was started by the Chinese government in 1967 to discover 
antimalarial principles in various medical herbs including “qinghao” (Woodrow et 
al., 2005). 
Chapter 1:-Introduction 
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Table 1.3 Drugs used in the treatment of malaria and their mode of action 
Drug class Drug(s) Mode of action Active against 
4-Aminoquinolones Amodiaquine, chloroquine, 
hydroxychloroquine 
Form complexes with ferriprotopophyrin 
IX (FPPIX) to prevent polymerisation to 
non-toxic hemozoin 
trophozoytes 
8-Aminoquinolones Piperaquine Disrupts mitochondrial internal structure Different developmental 
stages including hypnozoites 
and sexual stages 
Arylaminoalcohols Halofantrine, lumefantrine, 
mefloquine, quinine 
Believed to interfere with heme digestion Different developmental 
stages 
Antifolates Chloroproguanil1, dapsone2, 
pyramethamine1, 
sulphadoxine2 
Inhibition of tetrahydrofolate biosynthesis 
by inhibiting either dihydro-folate 
reductase1 (DHFR) or dihydropteroate 
synthetase2 (DHPS) 
Erythrocytic stage 
Antibiotics Clindamycin, doxycycline Interacts with protein biosynthesis of the 
mitochondria  
 
Inhibitors of the 
respiratory chain 
Atovaquone Inhibits the mitochondrial transport chain 
resulting in rapid breakdown of 
mitochondrial memebrane potential 
Hepatic and erythrocytic 
stages 
Artemisinins Artemether, artesunate, 
dihydroartemisinin 
Inhibition of PfATPase6, inhibition of 
hemozoin formation 
Early and late ring stages 
Chapter 1:-Introduction 
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Artemisinin is a phyto-constituent obtained from aerial portions of the herb. 
The antimalarial activity was re-discovered in China in 1971, when low temperature 
ethyl ether extraction of the plant produced encouraging results in mice infected with 
the malaria Plasmodium berghie (Medhi et al., 2009). 
Since artemisinin is poorly soluble in water and oil, semi synthetic 
derivatives of artemisinin were developed to circumvent the problem of parenteral 
administration due to its low water and oil solubility (Meshnick et al., 1996). These 
derivatives include a water soluble hemisuccinate artesunate (3) and artelinate, and 
oil soluble ethers, artemether (2) and arteether. They have a greater antimalarial 
activity than their parent compound. The most widely used derivatives in clinical 
practice are artemether and artesunate, and though they have different 
physicochemical properties they are both pro-drugs of dihydroartemisinin (4) (Hien 
et al., 2004). 
1.1.4.1.2 Mechanism of action of the artemisinin compounds 
Its antimalarial mechanism of action depends on its endoperoxide bridge 
(Navaratnam et al., 2000). Although the exact mode of action is still debatable, and a 
couple of theories have been proposed, it is believed that haem iron within the 
parasite, a bi-product of haemoglobin digestion, catalyses the cleavage of the 
endoperoxide bridge.  
The parasite digests and detoxifies host haemoglobin in its food vacuole 
through polymerisation to form hemozoin, which is a rich source of Fe2-heam 
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believed to be responsible for the activation of artemisinin compounds in the parasite 
(Niles et al., 2009). The Fe2-heam rich environment is believed to be an important 
factor for the selective toxicity of artemisinin toxicity towards the malaria infected 
red blood cells compared to non-infected red blood cells (Meshnick et al., 1996, 
Meshnick et al., 1991).  
Figure 1.2 Structures of the artemisinin compounds 
 
The structures of artemisinin (1), artemether (2), artesunate (3) and dihydroartemisinin (4). 
 
This is followed by the formation of highly reactive free radicals that 
rearrange to form more stable carbon cantered-radicals. It has been suggested that 
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these centred-radicals alkylate and damages macromolecules in the parasite (Medhi 
et al., 2009). 
The inhibition of the enzyme sarcoplasmic-endoplasmic reticulum ATPase 
(PfATP6), critical for parasite survival, has been widely accepted (Woodrow et al., 
2005, Haynes et al., 2007) The PfATP6 enzyme is the only SERCA-type calcium-
ATPase responsible for maintaining calcium ion concentration critical in calcium-
mediated signalling and post-translational processing of proteins (Golenser et al., 
2006). Eckstein-Ludwig (2003) has demonstrated the inhibition of PfATP6 outside 
the food vacuole following artemisinin activation (Eckstein-Ludwig et al., 2003).  
Figure 1.3 Proposed artemisinin mechanism of action 
 
The proposed mechanism of action of the endoperoxide compounds 
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The interaction of P falciparum histidine-rich protein with artemisinin-
derived radicals to inhibit hemozoin formation has also been suggested (Pandey et 
al., 1998, Kumar et al., 2007) but other findings have contradicted this method 
(Meshnick 1996, Haynes et al., 2003).  
1.1.4.1.3 Artemisinin pharmacokinetics 
Whilst artemisinin can only be administered intravenously due to its water 
solubility, artemisinin, artemether and artesunate can all be administered orally, 
intramuscularly and rectally (Silamut et al., 2003). Although artemisinin is thought to 
pass through the gut membrane fairly easily, there is low bioavailability resulting 
from high first-pass metabolism of the compound. Mean oral bioavailability of 
artesunate is relatively lower (15%) with a high variability when compared to 
intravenous administration (82%) (Batty et al., 1998). This was also observed in 
artemether, with intramuscular and intra rectal bioavailabilities of 25% and 35% 
respectively in relation to oral administration in healthy volunteers (Teja-Isavadharm 
et al., 1996). This further suggests the involvement of high first pass metabolism in 
both the gut and liver (Karbwang et al. 1997, Teja-Isavadharm et al., 1996). 
Peak plasma levels are reached within minutes after oral administration of 
artesunate (Olliaro et al., 2001), whilst artemether peaks at about 2 hours with a half-
life of 1-3 hours (White et al., 1999). Because red blood cells are host cells for the 
malaria parasite, levels of drug concentration in them would have an important 
therapeutic effect (Asawamahasakda et al., 1994).  In-vitro studies have 
demonstrated higher uptake of artemisinin and its derivative by malaria infected red 
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blood cells when compared to non-infected red blood cells (Shah et al., 2009, Vyas et 
al., 2002). Membranes of parasitised red blood cells are modified as a result of the 
malaria parasite invasion causing structural and functional changes (Pasvol et al., 
1992), resulting in increased permeability to higher molecular weight solutes thus 
causing passive but facilitated uptake drug uptake (Shah et al., 2009).  Saturation 
levels of artemisinin and selective derivatives have shown saturation levels in 
parasite infected red blood cells compared to between 33 – 43% partitioning in non-
parasite infected red blood cells (Shah et al., 2009, Vyas et al., 2002) 
 Tissue distribution of the artemisinin compounds in rats showed that whilst 
artemether was seen to cause the highest concentration in rat brain, both artemisinin 
and artesunate also cross the blood brain barrier. Artesunate levels were highest in rat 
intestines followed by brain, liver and kidney (Navaratnam et al., 2000). 
Dihydroartemisinin is the active metabolite of the artemisinin derivatives (De 
Vries and Deen, 1996). Metabolism of artemisinin in liver microsomes is mediated 
mainly by CYP2B6 with contributions from CYP2A6 and CYP3A4. Figure 1.4 
illustrates the cytochrome (CYP) enzymes involved in the metabolism of artesunate 
and its derivatives.  
The CYP enzyme family plays an important role in phase-1 metabolism of 
many drugs. Clinical case reports or studies usually provide the first evidence of 
interaction between drugs. Central to this point is an understanding of the catalytic 
importance of individual CYP isoenzymes in particular metabolic pathways (Badyal 
et al., 2001). 
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Figure 1.4 Metabolism pathways of artemisinin and its derivatives 
 
Proposed metabolic pathway of artemisinin, artesunate, artemether, arteether and 
dihydroartemisinin. 
A study done by Elsherbiny et al. (2008) showed that the production rate of 
CYP2B6 was increased by 79.9% by artemisinin, 61.5% by arteether, 76.1% by 
artemether, 19.9%  and 16.9%  by dihydroartemisinin and artesunate respectively. 
The production rate of CYP2C19 was increased 51.2% by artemisinin, 14.8% by 
arteether and 24.9% by artemether. These different inductive capacities among the 
artemisinin drugs are important in selecting drugs in combination therapies to 
minimise drug-drug interactions (Elsherbiny et al., 2008). 
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Four metabolites (Figure 1.5) namely 3 α-hydroxydeoxy-DHA (5), 
tetrahydrofuran (THF) acetate (6), deoxy-DHA (7) and deoxy-DHA glucoronide (8) 
have been identified in human urine following oral administration of artemisinin. 
Studies using rat liver microsomes have shown the conversion of DHA to other 
inactive metabolites (figure 1.7) including 3 α-hydroxydesoxy-DHA glucoronide (5), 
the glucoronide of tetrahydrofuran acetate isomer of DHA (6) deoxy-DHA (7) and its 
glucoronide (8) (Maggs et al., 1997, 2000).  
α-DHA-β-glucoronide (α-DHA-G) and the tetrahydrofuran isomer of α-
DHA-G were the metabolites identified in human urine with DHA-G being the only 
liver metabolite (Ilett et al., 2002). This process is catalysed by UDP-
glucoronosyltransferase, in particular UGT1A9 and UGT2B7 in both rats and 
humans (Maggs et al., 1997, Ilett et al., 2002).  
1.1.4.1.4 Artemisinin toxicity 
Although the safety profiles of these drugs are thought to be excellent in 
humans (Nontprasert et al., 2002), concern about their possible neurotoxicity and 
embryotoxicity remains based on studies confirming embryotoxic effects in animals, 
including primates, with risk being confined to a defined period of gestation 
(Dellicour et al., 2007).  
Fetal resorption was observed in rats and rabbits exposed to relatively low 
doses of artemisinin during early pregnancy (Boareto et al., 2008). In vivo studies 
have shown artesunate, dihydroartemisinin, artemether and arteether ten day post 
conception caused embryolethal and teratogenic effects (White et al., 2006). The 
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signs of toxicity of artemisinin family of compounds in laboratory animals, and lack 
of such findings in human subjects, can be explained by persistent drug 
concentrations after repeated intramuscular concentrations using oil based vehicles in 
animals. Another possible explanation may be the relatively high doses used in pre-
clinical experiments (Clark et al., 2006).  
Figure 1.5 Structures of artemisinin metabolites 
The structures of 3 α-hydroxydesoxy-DHA (5), tetrahydrofuran (THF) acetate (6), deoxy-
DHA (7) and Deoxy-DHA glucoronide (8). 
 
Several clinical trials indicate that artesunate is far less toxic than the 
quinolones with common adverse effects observed are nausea, vomiting, and 
diarrhoea all of which are also characteristics of acute malaria (Clark 2009). Large 
scale human studies with artemisinin compounds have not shown any neurotoxic side 
effects but there are isolated case reports of possible neurological dysfunction after 
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administration of associated artemisinin compounds (Li et al., 1998). Because of 
limited safety data, WHO recommended that they should only be used in 2nd and 3rd 
trimester of pregnancy, but should only be used in the 1st trimester only if it is the 
only effective treatment (WHO, 2006). 
1.1.5 Artemisinin combination therapy  
The main advantage of the artemisinin compounds against the other 
antimalarials is the rapid mode of action against all stages of the plasmodium and 
excellent tolerability in humans (White, 2005). However, the main limitation of this 
class of drugs is its short half-life requiring frequent administration. When used as 
monotherapy, optimum cure rates are observed with 7-day treatment regiments. 
However compliance with 7-day treatment is very low and 5 and 3-day treatment 
regimens showing low cure rates and high failure rates respectively (Yeung et al., 
2004).  
Table 1.4 Drug combinations in artemisinin combination therapy (ACT) 
- Artemether/lumefantrine 
- Artesunate plus amodiaquine - in areas where the cure rate of 
amodiaquine monotherapy is greater than 80% 
- Artesunate plus mefloquine - insufficient safety data to recommend its 
use in Africa 
- Artesunate plus sulfadoxine/pyrimethamine - in areas where the cure 
rate of sulfadoxine/pyrimethamine is greater than 80%  
- Dihydroartemisinin plus piparaquine 
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In order to both improve cure rates and reduce the development of drug 
resistance, WHO recommended the use of artemisinin combination therapy as the 
first line treatment for uncomplicated malaria. artemisinin derivatives are combined 
with another longer-acting antimalarial drug which eliminates the residual malaria 
parasite. A combination of artemisinin derivative with a longer acting drug, a shorter 
course of treatment of 3 days provides effective therapeutic outcomes (WHO, 2006). 
The current artemisinin combination therapies (ACT) recommended by WHO are 
listed in table 1.4. 
1.5.1 Artemisinin Combination Therapy (ACT) in Children 
 Artemisinin derivatives are safe and well tolerated in children and ACT is 
currently the recommended treatment for uncomplicated malaria in children > 6 
months/ >5kg. Although the differences in the pharmacokinetics of drugs between 
children and adults have been recognised, dosing guidelines have been deduced from 
adult-based regiments adjusted for body weight (WHO, 200. Few pharmacokinetic 
studies of ACT have been carried out in children with some of them suggesting that 
children may be receiving suboptimal doses of ACT (Sidhu et al., 1998). Sidhu et al. 
(1998) investigated potential differences between adults and children and reported 
that adults had slightly lower CL rates than children, which may explain the reported 
longer half-life of artemisinin in adults (2.6 h) compared to children (1.8 h). 
 Physiological processes during childhood development which control the 
pharmacology, absorption, metabolism, distribution and excretion of drugs differ 
between infants and young children. The exact effect of the developmental 
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differences is drug specific and depends on the lipophilicity, solubility, protein-
binding capacity and route of administration. Drug absorption is generally slower in 
children due to increased gastric pH, slow intestinal motility and decreased gastric 
emptying (Tetelbaum et al., 2005, Kearns et al., 2003).  
Rapidly absorbed water soluble drugs like artesunate may be reduced in 
children leading to sub-optimal plasma drug concentration. In addition, changes in 
total body water composition and body fat content in children of different ages might 
affect the volume of distribution (Vd) impacting differently on drugs depending on 
their physiochemical properties and route of administration (Johnson et al., 2006, 
Kearns et al., 2003). 
 Metabolism of drugs, including the CYP450 enzymatic system is thought to 
be age dependent. CYP3A4 and CYP2A6, which are involved in the metabolism of 
ACT, are reported to have decreased activity in neonates and young children, 
increasing with age (Edginton and Willmann, 2006, Benedette and Bates, 2003). Full 
CYP1A2 and CYP2B6 enzymatic maturation are not reached until around puberty 
(Johnson et al., 2006). 
 In addition to age related and maturational differences in children, 
malnutrition affects the absorption, distribution, metabolism and excretion of drugs 
(Murphy et al., 2002, Oshikoya and Senbenjo, 2009). The effect of malnutrition on 
the pharmacokinetics of ACT is important due to the prevalence of malnutrition in 
many areas worst affected by malaria, with a strong correlation between malaria and 
malnutrition (Müller et al., 2003).  
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1.2 Protein energy malnutrition (PEM) 
 Protein-energy malnutrition (PEM) refers to a nutritional problem 
resulting from different degrees of protein and calorie insufficiency, most commonly 
seen in infants and young children (Mora, 1999, Oshikoya and Senbanjo, 2009). It 
encompasses a range of nutritional disorders ranging from mild moderate to severe. 
The mild forms can be hidden in that they are subclinical and can usually be detected 
only thorough anthropometric and or biochemical tests. It is likely to be undiagnosed 
and as a result can lead to long-term problems (Ahmed et al., 2009). The 
interchangeable term of PEM and malnutrition will be used throughout the thesis but 
will mean the same thing. 
 Malnutrition accounts for about 54% of the 10.8 million deaths per year and 
contributes directly or indirectly to about half of the deaths associated with infectious 
diseases among children under 5 years of age in developing countries (Schaible and 
Kaufmann, 2007, Caulfield et al., 2004). Although the relative risk of mortality is 
highest for severe malnutrition with 8.4 compared to moderate and mild nutrition 
which are 4.6 and 2.5 respectively, the majority of deaths occur in children with mild 
and moderate malnutrition. This is due to the fact that most of the children with 
malnutrition are classified either mild or moderate (Grover and Ee, 2009, Pelletier 
and Frongillo, 2003, Pelletier et al., 1995). 
 In 2005, the global estimate of wasting (weight for height z-score< -2) in 
children below the age of 5 years was 10% with south-central Asia having the 
highest prevalence estimated at 16%. 20% of children below the age of 5 years in 
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low and middle income countries were estimated to be underweight (weight for age 
z-score < -2) and 32% of children in developing countries were estimated to be 
stunted (height for age z-score < -2). The prevalence of underweight was highest in 
south central Asia (33%) and eastern Africa (28%), whilst the highest prevalence of 
stunting was in central Africa and south central Asia with 50% and 41% respectively 
(WHO, 2006, Grover and Ee, 2009, Black et al., 2008). 
Figure 1.6 Global prevalence of protein energy malnutrition, 2005. 
Estimates of prevalence of underweight (A) and stunting (B) by region in children under five 
years of age in 2005 
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1.2.2 Classification of Protein Energy Malnutrition 
 There are different classifications of malnutrition (Table 1.3). WHO 
classifies acute malnutrition as low weight for height below -2 Standard deviation of 
the median WHO growth standard. Other methods of protein-energy malnutrition 
classification have been used in clinical studies. The Gomez, Waterlow and 
Wellcome Trust classifications of protein-energy malnutrition are more widely used 
according to previous studies evaluating drug disposition in children with protein-
energy malnutrition (Oshikoya and Senbanjo, 2009). 
1.2.2.1 Gomez Classification 
Gomez was a Mexican paediatrician who classified malnutrition into degrees 
based on the percentage body weight of children. First degree malnutrition occurs 
when under-nutrition is moderate, or for a short period, and the body weight for age 
of the patient ranges between 76-90 %. As under feeding becomes progressive, the 
body weight for age drops (61-75%) resulting in second degree malnutrition. Third 
degree malnutrition occurs when the body weight for age becomes less than 61% 
(Gomez et al., 1956).  
Although the main use of the Gomez classification was to standardise 
reference values and allow meaningful comparison between and within populations 
at different times, it did not take into consideration children whose birth weight was 
low, children who were born prematurely or small children from small parents (Gueri 
et al., 1980). 
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The percentage weight for age of the patient is calculated by using the equation  
𝑎
𝑏
 × 100 
where  𝑎 is the weight of the patient 
   𝑏 is the expected weight of a normal child of the same age 
1.2.2.2 The Wellcome classification 
Because the Gomez classification did not take into account the clinical 
features associated with malnutrition, the Wellcome working party in 1969, 
classified malnutrition based on the most clinically obvious forms of malnutrition 
found in an undernourished population. It evaluates the child for the presence or 
absence of oedema, combined with the Gomez classification system (Waterlow, 
1972). 
1.2.2.3 The Waterlow Classification 
The Waterlow classification concentrates on the much larger group of 
children described as underweight in the welcome classification. It is based on height 
for age and weight for height and concentrates on the determination of stunting and 
wasting (Waterlow et al., 1977, Waterlow, 1972). 
 Stunting is said to occur when a child is below the median height for age of 
the reference population and is determined by using the equation 
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𝑐
𝑑
 × 100 
 where  𝑐 is the height of the patient 
   𝑑 is the expected height of normal child of the same age  
Wasting occurs when a child is below the median weight for height of the 
reference population. Wasting is determined using the equation  
𝑒
𝑓
 × 100 
 where   𝑒 is the weight of the patient 
  f is the expected weight of a normal child of the same height 
 Alternative methods have been proposed in assessing malnutrition. Mid 
upper arm circumference (MUAC) and head circumference can be used in the place 
of weight and height respectively where these measurements are not possible. The 
degree of malnutrition in this case is calculated by dividing MUAC by head 
circumference (Grover and Ee, 2009). 
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Table 1.5 Classification summary of protein energy malnutrition 
Classification Definition Grading Change 
Gomez % body weight for 
Age 
Normal 
Grade I: mild 
Grade II: moderate 
Grade III: severe 
 
90% – 110% WA 
75% - 89% WA 
60% - 74% WA 
< 60% WA 
Waterlow Z-score (SD) 
weight for height 
 
 
 
Z-score (SD) 
height for age 
Normal 
Mild 
Moderate 
Severe 
 
Normal 
Mild 
Moderate 
Severe 
 
> 90% WH 
80% - 90% WH 
70% - 80% WH 
< 70% WH 
 
> 95% HA 
90% - 95% HA 
85% - 90% HA 
< 85% HA 
Wellcome Weight for age 
with edema 
 
Weight for age 
without edema 
Kwashiorkor 
Marasmic-
kwashiorkor 
 
Undernutrition 
Marasmus 
 
60% - 80% WA 
<60% WA 
 
60% -80% WA 
< 60% WA 
WHO Z-score (SD) 
weight for height 
Moderate 
Severe 
 
-3 ≤ Z-score <-2 WH 
Z-score <-3 WH 
 Z-score (SD) 
height for age 
Moderate 
Severe 
 
-3 ≤ Z-score <-2 HA 
Z-score <-3 HA 
 MUAC divided by 
OHC 
Mild 
Moderate 
Severe 
< 0.31 
< 0.28 
< 0.25 
WA, weight for age; WH, weight for height: WA weight for age; SD, standard deviation; 
WHO, World Health Organisation; MUAC, mid upper arm circumference; OFC, occipito-
frontal circumference. 
 
1.2.3 Clinical Syndromes 
The clinical signs and symptoms (Table 1.6) present in protein energy 
malnutrition are believed to be linked to its pathogenesis and can be defined as 
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marasmus or kwashiorkor based on specific signs and symptoms at presentation 
(Balint, 1998, Jahoor et al., 2008). 
Table 1.6 Clinical features of protein energy malnutrition 
Syndrome Clinical features 
 
Marasmus 
- loss of subcutaneous fat 
- Muscle wasting 
- Wrinkled skin 
- Hypotonia 
- Subnormal body temperature 
- Decreased basal metabolic rate 
- Alert and irritability 
- Constipation/diarrhea and dehydration 
 
Kwashiorkor 
Constant features 
- Oedema 
- Muscle wasting 
- Growth retardation 
- Psychomotor changes 
Usual features 
- Moon face 
- Hair changes 
- Skin depigmentation 
- Diarrhoea 
- Anaemia 
Occasional features 
- Dehydration 
- Dermatitis 
- Hepatomegaly 
- Cardiomyopathy 
- Signs of vitamin deficiency 
- Signs of infection 
 
 
Marasmus is the most common syndrome and occurs when there is primarily 
energy deficiency as a result of inadequate intake of both protein and calories in a 
diet (Tatli et al., 2000). This leads to wasting as a result of the body’s adaptation to 
starvation (Ece et al., 2007). 
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Figure 1.7 Distinct features of a child with marasmus 
 
Adapted from WHO pocket book of hospital care for children 2005, pp. 364. 
 
Kwashiorkor on the other hand is the opposite spectrum of the disease and 
occurs due to protein deficiency. There is usually adequate calorie intake but marked 
protein deficiency often aggravated by superimposed infection. The decreased 
protein intake leads to decreased protein turnover, increased free fatty acid, fatty 
liver (Franco et al., 1999) and increased oxidative stress (Manary et al., 2000, Golden 
and Ramdath, 1987). 
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Figure 1.8 Distinct features of a child with kwashiokor 
Adapted from WHO pocket book of hospital care for children 2005, pp. 364 
The milder forms of malnutrition may present as a mixed picture of 
marasmus and kwashiorkor. Marasmic-Kwashiokor manifests as concurrent gross 
wasting and edema with mild hair and skin changes. Milder forms are particularly 
likely to be undiagnosed and as a result can lead to long-term problems (Golden and 
Ramdath, 1987). 
1.2.4 Pathophysiological changes in protein energy malnutrition 
Insufficient intake of protein and energy leads to physiological adaptations 
which include growth restriction, loss of muscle, fat and visceral mass, reduced basal 
metabolism and total energy expenditure. It has been suggested that marasmus 
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represents the adaptive process of low energy intake whilst the features seen in 
kwashiorkor represents a failure in adaptation (Grover and Ee, 2009). 
The most conspicuous pathological changes are seen in children with 
kwashiorkor which includes oedema and fatty infiltration of the liver (Doherty et al., 
1992). Atrophy of the pancreas and the mucosa of the small intestines is also a 
common feature in kwashiorkor. This leads to the malabsorption of fat resulting in 
steatorrhea and fatty infiltration of the liver. Decreased dietary proteins in 
combination with malabsorption causes decreased plasma protein concentrations 
leading to fluid retention and oedema (Oshikoya and Senbanjo, 2009, Krishnaswamy 
et al., 1989). 
1.2.5 Biochemical changes in protein energy malnutrition 
A number of biochemical changes have been observed in protein energy 
malnutrition. Malabsorption of different fat fractions leads to decreased plasma 
levels of cholesterol, triglycerides and fat soluble vitamins and hypernatremia. Serum 
albumin level is one of the most useful indicators of protein energy malnutrition as it 
is relatively easy to measure and can be an indicator for the effectiveness of 
treatment. It might be normal or slightly reduced in marasmus but markedly reduced 
in kwashiorkor (Shaaban et al., 2005). Low blood glucose level is a common feature 
in protein energy malnutrition. It is mostly seen in kwashiorkor (Wharton, 1970, 
Buchanan et al., 1976) but can also occur in marasmus (Das et al., 1998, Kerpel-
Fronius and Kaiser, 1967), commonly attributed to decreased glucose absorption, 
30 
 
increased glucose clearance or impaired hepatic endogenous glucose production 
(EGP) (Das et al., 1998).  
Increased intracellular fluid with water and electrolyte imbalance, present in 
children with PEM, can lead to potassium and magnesium deficiencies. This often 
leads to reduced serum sodium and osmolarity resulting in simultaneous presence of 
oedema and signs of malnutrition (Akuyam, 2007). 
1.2.6 Micronutrient Deficiencies in Protein Energy Malnutrition 
The most common micronutrient deficiencies in children with PEM include 
iron, vitamin A, zinc and iodine (Grover and Ee, 2009, Bhutta, 2008, Pollitt, 1995, 
Macdougall et al., 1982). Anaemia is a common feature in PEM with several studies 
showing high incidence of iron deficiency anaemia in these children (Chen et al., 
2009, Van Nhien et al., 2008, Castejon et al., 2004) 
1.2.7 Management of protein energy malnutrition 
Management of PEM depends on the type and severity. Children with mild 
and moderate malnutrition can successfully be treated at home or in an outpatient 
health facility (Groove and Ee, 2009). Cases of severe acute malnutrition present 
with life threatening conditions and are usually associated with high fatality rates, 
making a clinical inpatient approach crucial. The most common life threatening 
conditions include infections, hypoglycaemia and hypothermia, accounting for 26.3, 
3.6 and 2.4% respectively (Bernal et al, 2008). 
 
31 
 
Table 1.7 Guidelines for the treatment of severely malnourished children 
Activity Initial treatment Rehabilitation Follow-up 
Day 1-2 Day 3-7 Wk 2-6 Wk 7-26 
Treat or prevent    
- Hypoglycaemia     
- Hypothermia    
- Dehydration    
Correct electrolyte imbalance   
Treat infection    
Correct micronutrient deficiency       without iron with iron  
Begin cautious feeding    
Increase feeding to catch up  
Growth 
   
Emotional and sensory  
Stimulation 
   
Prepare for discharge and  
Follow-up 
   
The ten step guidelines for the inpatient treatment of severely malnourished children 
 
 
WHO (1999) has developed guidelines to help improve the quality of care 
given to malnourished children in health facilities in a three phase management 
approach with a recommended time frame of ten essential steps (table 1.9). Quality 
of care and case fatality rates improved with the use of WHO guidelines in Africa 
(Ashworth et al., 2004, Deen et al., 2003), Bangladesh (Ahmed et al., 1999) and 
South America (Bernal et al., 2008, Cavalcante et al.,1998). 
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1.2.9 Protein Energy Malnutrition and Infection / Immunity 
Various studies have demonstrated the association between malnutrition and 
increased risk of infection and death (Berkley et al., 2005, Norton et al., 2004). 
Chronic PEM during childhood affects the development of the thymus which reduces 
peripheral lymphocytes compromising immunity. In addition, there is a decrease in T 
cell function, cytokine production and the ability of lymphocytes to respond 
appropriately to cytokines. This affects both innate and acquired immunity and can 
lead to most children with PEM having opportunistic and asymptomatic infection 
(Schaible et al., 2007).  
The relationship of PEM and infection is complicated by the effect of 
infections on nutrition causing a vicious cycle of events (Figure 1.9) Infection can 
lead to decrease food intake, diarrhoea, malabsorption and diversion of nutrients for 
immune response leading to impair growth further contributing to malnutrition. In 
addition, the metabolic demands of repeated infection increase catabolic state leading 
to further weight loss (Katona and Katona-Apte, 2008, Schaible and Kaufmann, 
2007).  
More than half of the five leading causes of infectious diseases in children 
under five years of age, which include pneumonia, diarrheal diseases and malaria are 
associated with some form of PEM (Katona and Katona-Apte, 2008). A study by 
Man et al. (1998) in a large population of hospitalised Gambian children showed 
lower mean admission weights compared to the control population. Malaria was the 
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leading cause of admission and mortality with death rates for infectious diseases 
rising with decreasing admission weights (Man et al., 1998). 
Although studies have proposed malnutrition to provide protective factor 
against malarial infection (Genton et al., 1998, ) or have seen no association between 
the two (Ghosh et al., 1995, Snow et al., 1991), more recent studies have 
demonstrated that chronically malnourished children may be at a higher risk for 
developing malarial episodes (Deen et al., 2002, Danquah et al., 2009). In addition, 
children with PEM have double the risk of dying from malarial infection compared 
to their normally nourished counterpart (Danquah et al., 2009, Muller et al., 2003). 
Figure 1.9 Vicious cycle of malnutrition and infection 
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1.2.10 Effect of PEM on Pharmacokinetics of Drugs in Children 
Most of the pathophysiological changes seen in protein energy malnutrition 
either directly or indirectly affect drug disposition. Various studies have analysed the 
pharmacokinetics of drugs in children with PEM. Results of the different 
pharmacokinetic parameters obtained in these studies have been summarised in 
tables 1.7, 1.8 and 1.9. Various studies have indicated major pharmacokinetic 
differences in some drugs as a result of PEM (Pussard et al., 1999, Bolme et al., 
1995, Ashton et al., 1993, Salako et al., 1989., Eriksson et al., 1983.). 
In general, PEM can affect drug absorption, distribution, metabolism and 
elimination (Oshikoya and Senbanjo, 2009). In addition to vomiting and diarrhoea, 
malnutrition is also associated with villous atrophy of the jejunal mucosa (Brewster, 
2006) which might lead to impaired drug absorption. The oral absorption of 
chloroquine (Walker et al., 1987) and carbamazepine (Bano et al., 1986) has been 
reported to decrease significantly in children with PEM compared to normally 
nourished children which is attributed to the morphological changes in the jejunum 
(Oshikoya and Senbanjo, 2009). 
Total body water increases in proportion to the degree of malnutrition so a 
significant reduction in adipose mass, often observed in marasmus and marasmic-
kwashiorkor, can alter the volume of distribution of drugs (Hansen et al., 1965). 
Drugs that are protein bound might also be affected by PEM as a result of reduced 
serum albumen and glycoproteins. As a result, there is an increase in plasma free 
35 
 
drug resulting in either variable drug response or increased risk of drug toxicity.  
(Krishnaswamy, 1989).  
In addition, the CYP450 enzymes are heme-containing proteins and iron 
deficiency can directly or indirectly affect CYP450 (Pai et al., 2007). As a result of 
iron deficiency, malnourished children may display altered metabolism due to altered 
intestinal and hepatic drug biotransformation via the cytochrome P450 enzymes. In a 
rodent model, PEM reduced total hepatic CYP by 55% with individual CYP enzymes 
affected by different amounts (Cho et al., 1999). Glucuronidation, which is a major 
pathway in the metabolism of DHA, is also inhibited in PEM due to a lack of glucose 
which is critical in the synthesis of glucuronic acid (Hamberg et al., 1990, Aw and 
Jones, 1984).  
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Table 1.8 Pharmacokinetic parameter of drugs in children with PEM 
Source Age 
(months) 
Degree of 
malnutrition 
Drug Dose and 
Route  
Mean CL 
(ml/min/kg) 
Mean t1/2 (h) 
 
Controls        PEM           Controls           PEM 
Pussad et al 
(1999) 
24-72 M Quinine 6mg/kg 
IV 
4.0±2.1 1.7±1.5* 5.1±2.6 7.2±5.9* 
Treluyer et al 
(1996) 
9-60 M, M-K Quinine 16mg/kg 
IM 
2.3±1.4 4.4±3.6* 10.1±3.4 6.3±1.8* 
Bolme et al 
(1995) 
7-78 U Penicillin 20mg/kg 
oral 
  0.65±0.1 0.7±0.1 
Bolme et al 
(1995) 
7-78 M Penicillin 20mg/kg 
oral 
   0.9±0.04 
 7-78 K Penicillin 20mg/kg    2.3±0.8 
Bolme et al 
(1995) 
 U Penicillin 30mg/kg 
IV 
22.2±0.9 15.1±0.9** 0.7±0.1 1.1±0.55 
  M Penicillin 30mg/kg 
IV 
 14.0±0.5**  0.8±0.1 
  K Penicillin 30mg/kg 
IV 
 16.9±1.0**  0.8±0.2 
Ashton et al 
(1993) 
9-120 U Chloramphenicol 25mg/kg 
IV 
 5.9±1.6  2.4±0.9 
Ashton et al 
(1993) 
9-120 M Chloramphenicol   4.8±1.5  3.7±1.7 
 K    2.9±1.5***  4.9±4.6 
N – normal, SM – severe malnutrition, M – marasmus, K – kwashiorkor, U – undefined 
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Source Age Degree of 
malnutrition 
Drug Dose and 
Route  
Mean CL (ml/min/kg) Mean t1/2 (h) 
 
Controls        PEM        Controls               PEM 
Blome et al 
(1998) 
6-144 U Streptomycin 20mg/kg 
IM 
79±2 63±20 1.69±0.4 2.4±0.2 
  M    83±18  1.77±0.2 
  K    51±7  5.36±2.5** 
  U Streptomycin 30mg/kg 
IM 
67±15 74±8 2.6±0.4 2.1±0.3 
  M    91±14  2.3±0.2 
  K    49±7  9.7±2.6** 
Salako et al. 
(1989) 
17-36 K Quinine 10mg/kg 
oral 
108.5±34.8 31.5±8.5*** 8.0±1.3 15.0±4.4*** 
Eriksson et al 
(1983) 
6-72 M chloramphenicol 25mg/kg 
IV 
7.5±1.1 8.2±2.3 2.9±0.3 2.9±0.5 
  K    4.2±0.7**  3.8±0.4* 
  M chloramphenicol 25mg/kg 
oral 
  2.07±0.4 3.2±0.5 
  K      3.97±0.9 
N – normal, SM – severe malnutrition, M – marasmus, K – kwashiorkor, U - undefined 
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Table 1.9 Pharmacokinetic parameter of drugs in children with PEM 
Source Age  
(months) 
Degree of 
malnutrition 
Drug Dose and 
Route 
Cmax (mg/L) 
 
AUC0 – 24 (mg/h/L) 
 
     Controls PEM Controls PEM 
Pussard et al. 
(1999) 
24 – 72 M Quinine 6mg/kg / IV 6.6 7.7 40.9 43.0 
Lares-Asseff 
(1997) 
 U Cyclosporine 3/mg/kg 387.5 136.1 856.0 1481.4 
Tréluyer et al. 
(1996) 
9 -  60 M, M-K Quinine 16mg/kg 10.7 9.9   
Bolme et al. 
(1995) 
 U Penicillin 20mg/kg / 
oral 
  423.4 396.0 
  M-K      323.2 
  K      319.5 
  U Penicillin 30mg/kg / IV   1351 1993.3 
  M      2138.2 
  K      1769.2 
Ashton et al. 
(1993) 
9 – 120 M Chloramphenicol 25mg/kg/ IV  11.1 20.4  
  K     39.9  
Lares-Assef et al. 
(1992) 
4 – 43 M Metronidazole 30mg/kg / 
oral 
 9.9 153.7  
N – normal, SM – severe malnutrition, M – marasmus, K – kwashiorkor, U - undefined 
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Table 1.10 Pharmacokinetic parameter of drugs in children with PEM 
 
Source 
Age Degree of 
malnutrition 
Drug Dose and 
Route  
Volume of distribution 
 
Controls           PEM 
Pussad et al 
(1999) 
24-72 M Quinine 6mg/kg 
IV 
1.6±1.05 0.6±0.3* 
Treluyer et al 
(1996) 
9-60 M, MK Quinine 16mg/kg IM 1.7±0.4 2.0±0.8 
Bolme et al (1995) 7-78 U Penicillin 20mg/kga oral   
Bolme et al (1995) 7-78 M Penicillin 20mg/kga oral   
Bolme et al (1995) 7-78 K Penicillin 20mg/kga   
  U Penicillin 30mg/kg IV 1.39±0.2 1.47±0.6 
  M Penicillin 30mg/kg IV 1.39±0.2 0.91±0.1 
  K Penicillin 30mg/kg IV 1.39±0.2 1.18±0.2 
Ashton et al 
(1993) 
9-120 U Chloramphenicol 25mg/kg IV  1.2±0.5 
Ashton et al 
(1993) 
9-120 M Chloramphenicol   1.3±0.4 
  K    0.7±0.3** 
Lares-Assef et al 
(1992) 
4-43 SM metronidazole 30mg/kg oral 1.6±1.0 1.5±0.8 
Blome et al (1998) 6-144 U streptomycin 20mg/kg IM 0.3±0.03 0.3±0.1 
  M    0.3±0.02 
  K    0.4±0.02* 
  U Streptomycin 30mg/kg IM 0.3±0.02 0.2±0.02 
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N – normal, SM – severe malnutrition, M – marasmus, K – kwashiorkor, U -undefined 
  M    0.3±0.02 
  K    0.7±0.1** 
Eriksson et al 
(1983) 
6-72 M chloramphenicol 25mg/kg IV 1.9±0.2 2.1±0.5 
      1.33±0.2 
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1.3 Aims 
Artemisinin combination therapy is now the standard treatment for malaria 
however little is known regarding the pharmacokinetics of the artemisinin 
compounds in children. With over 45 countries having adopted ACT as the first line 
therapy, it is expected that millions of doses of these drugs will be administered in 
the coming years. Despite this massive deployment, relatively limited data exists 
regarding the PK of these drugs in the most vulnerable population, young children. 
Studies have shown that children may exhibit distinct PK characteristics (Pussard et 
al., 1999, Bolme et al., 1995, Ashton et al., 1993, Salako et al., 1989., Eriksson et al., 
1983.). that must be considered for optimum dosing to preserve these valuable 
classes of antimalarial drugs. Accurate dosing strategies are necessary to achieve 
optimum drug exposure which will minimise risk of treatment failure, drug toxicity 
and the development of drug resistance. 
The effects of malnutrition in children have the potential to greatly affect the 
pharmacokinetic properties and, therefore, efficacy and safety of ACTs. However, to 
date, this has not been studied and the complex drug-dependent inter-play among 
physiological changes in absorption, metabolism and Vd has not been addressed. This 
is part of a general trend that, despite the high morbidity and mortality of patients 
with PEM, pharmacokinetic studies of essential drugs used to treat these children 
have dramatically declined since the 1970 (Cohen-Kohler, 2007). Given the high 
incidence of malnutrition and PEM in the areas most severely affected by malaria 
with, therefore, high deployment levels of ACTs, and the susceptibility of 
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malnourished children to contracting malaria, it is essential that the consequences of 
malnutrition and specifically PEM on the pharmacological and toxicological activity 
of the artemisinin drugs are investigated further. 
In addition there are almost 20 dietary minerals and trace elements essential 
for proper functioning of the body among which are iron, zinc and iodine (Stein, 
2009). Of particular interest is the low level of iron stores seen in children with PEM 
predisposing them to a higher risk of developing iron deficiency anaemia 
(Macdougall et al., 1982). As described, the activation of the endoperoxide group in 
ARTs by an iron (II) source is essential for both pharmacological and toxicological 
activity and is also involved in systemic activation by red blood cells. Therefore, the 
reduction of physiological iron levels could have several pharmacological and 
toxicological consequences including a decrease in pharmacological activity in 
infected cells, a decrease in direct cytotoxicity against susceptible cells or a decrease 
in extracellular detoxification which may in turn lead to increased plasma 
concentrations that may alter the benefit: risk ratio. 
1.3.1 Primary hypothesis 
The primary hypothesise was that the pharmacokinetics of artemisinin might 
differ in malnourished children when compared with children with no evidence of 
malnutrition.  
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1.3.2 Secondary hypothesis 
 The secondary hypothesis was that deferoxamine (DFO), an iron chelator, 
decreases artesunate toxicity  
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2 The Mechanism Underlying Protection Against Artesunate 
Toxicity by The Iron Chelator Deferoxamine 
2.1 Introduction 
The rapid emergence of resistance to the traditional antimalarials prompted 
WHO to recommend the use of artemisinin combination therapy as the first line of 
treatment for uncomplicated malaria (Suh et al. 2004). In addition to its effectiveness 
in the treatment of drug resistant malaria, it offers rapid malaria parasite clearance 
and has a high tolerability. Despite no reported serious adverse effects in humans, 
concerns remain due to reported neurotoxicity and embryotoxicity in animal studies 
(Boareto et al. 2008; Clark 2009). 
Its characteristic endoperoxide bridge is essential for its antimalarial activity 
as well as its toxicity (Navaratnam et al. 2000). This is reinforced by the fact that 
analogues without a peroxide oxygen atom do not have antimalarial activity 
(Meshnick et al, 1996, Beekman et al 1997). The mechanism of action of artemisinin 
and that of its analogues is still a matter of intense debate but it is widely believed 
that it is iron (II) or heme mediated, generating reactive oxygen species (Stocks,  et 
al. 2007; Mercer 2009).  
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Artemisinin binds to low valent transition irons (ferrous heme/non heme, 
exogenous Fe2+) leading to electron transfer induced reductive scission of the 
peroxide bridge to produce oxygen centred radicals (Figure 2.1) (Messori et al. 
2006). These oxygen centred radicals rearrange to form carbon centred radicals. 
Because of the asymmetrical nature of the endoperoxide bridge, iron interacts with 
peroxide in different ways to produce either a primary or secondary carbon centred 
radicals. The generation of free radicals by the artemisinin compounds may be 
critical for killing the parasite as is consistent with the importance of the 
endoperoxide bridge for drug efficacy (Krishna et al., 2008). 
Figure 2.1 Proposed mechanism of action of the endoperoxides 
 
A proposed mechanism of action in malaria parasites include the interference 
with protein export pathways of the malaria tubulovesicular network inhibiting the 
parasite endocytic pathway thus interfering with mitochondrial membrane potential 
(Hoppe et al., 2004, Li et al., 2005). The reactive oxygen carbon species may target 
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essential parasite organelles such as the mitochondria, endoplasmic reticulum and 
food vacuole causing cell death. Some molecular targets may include inhibition of 
the parasites sarco/endoplasmic reticulum calcium ATPase known as PfATP6 
(SERCA/PfATP6). This was based on the antagonistic nature of thapisgargin 
towards artemisinin inhibition of PfATP6 (Eckstein-Ludwig 2003, Krishna et al 
2010). This alternative mechanism has been challenged due to the fact that 
insensitivity to artemisinin was observed in purified PfATP6 (Cardi et al, 2010). 
The idea that iron is required for the activation of the artemisinin compounds 
appears to rely in large measure on reports from earlier studies that iron chelators 
such as deferroxamine B (DFO) antagonize its antimalarial activities in vitro 
(Meshnick et al., 1993, Wei and Sadrzadeh 1994). The protective role of DFO in the 
cytotoxicity against the endoperoxides was determined using an MTT assay which 
measured the activity of cellular dehydrogenase enzyme (Mosmann 1983).  
Meshnick et al (1993) showed that iron chelators decrease the toxic effects of 
artemisinin in mice and that those that were dosed with artemisinin and iron chelator 
DFO-HES lived considerably longer than those who received equal doses of only 
artemisinin, especially high dose artemisinin (Meshnick et al., 1993). Stocks et al 
have shown that both DFO and DFP (both selective for ferric iron) caused 
antagonism towards the artemisinin compounds suggesting that either bioactivation 
of the endoperoxide bridge is mediated by a ferric iron source in combination with an 
endogenous reducing agent or that these chelators alter the equilibrium between iron 
stores within the parasite (Stocks et al,. 2007). DFO also inhibits parasite protein 
targets in parasite infected erythrocytes with abrogation of artemisinin induced 
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inhibition of PfATP6. This resulted in reduction of antimalarial activity by the 
endoperoxide compounds (Haynes et al. 2007, Uhlemann et al. 2007).  
The selectivity of artemisinin compounds to parasites and certain cancer cells 
is rationalised by their high iron content. The malaria parasite is rich in heme-iron, 
derived from the proteolysis of host cell haemoglobin. Cancer cells, like malaria 
parasites, also contain high levels of iron and have demonstrated increased toxicity 
against their normal cell counterparts (Singh and Lai, 2001, Chen et al., 2009, Hou et 
al., 2008). Iron is essential for ATP production and DNA synthesis and its uptake by 
cells from transferrin (Tf) is controlled by transferrin receptor (TfR), which is 
controlled by intracellular iron levels. TfR levels are normally low in most normal 
human cells (Nadadur et al., 2008).  
The role of heme in the bioactivation of artemisinin compounds has been 
investigated and has been shown that inhibition of heme synthesis caused a reduction 
in toxicity with decreased activation of the endoperoxide to the THF acetate 
biomarker (fig 2.1) whilst an addition of a heme precursor increased toxicity and 
bioactivation (Mercer 2011, Zhang and Gerhad 2009). THF acetate isomer is a stable 
metabolite of PFDHA that can be used as a biomarker for bioactivation (Maggs et 
al., 1997). This has reinforced the fact that free or protein bound heme is responsible 
for the intracellular activation of the endoperoxides stimulated by the electron 
transport chain in the mitochondria, leading to a cascade of processes which include 
the generation of reaction oxygen species, mitochondrial membrane depolarisation, 
caspase-3 and -7 activation which finally leads to DNA degradation resulting in cell 
death (Figure 2.2) (Mercer et al, 2011 Wang et al., 2010,). Mercer et al., observed 
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that although the addition of  extrinsic iron did not induce cytotoxicity, it did cause 
bioactivation of endoperoxides suggesting that cytotoxicity can only occur when 
bioactivation is heme or heme-containing protein mediated (Mercer et al., 2011). 
It is the intended aim of this study to identify the position on the artemisinin 
activation pathway where DFO inhibits. The study will develop an understanding of 
the mechanism underlying protective effects of iron chelators against artemisinin 
induced cytotoxicity and thus provide further information on the mechanism of 
action of the artemisinin compounds. In order to achieve this, artesunate was used in 
HL60 cells. HL-60 cells are human leukemic cell lines known to be high in iron 
content and show cytotoxicity with the endoperoxides (Mercer et al., 2007). 
Artesunate, which is a water soluble semi-synthetic derivative of artemisinin, was 
used. Deferoxamine, the iron chelator used in this study, is a siderophore with high 
affinity for ferric (Fe3+) and stored iron in cells. DFO binds to Fe3+ and forms a stable 
complex which is redox inactive thus preventing the generation of reactive oxygen 
species (Dayani et al., 2004).  
Fe (II)-heme is freely oxidized to Fe (III)-heme by deoxygenation. The Fe 
(III) produced is readily reduced to Fe (II) generating reduced oxygen species in a 
catalytic fashion (kalinowski and Richardson, 2005). A significant production of 
ROS might change membrane potential and the electron transport chain of the 
mitochondria in the parasite (Meunier and Robert, 2010). DFO prevents the 
formation of reaction oxygen species by inhibiting the catalytic role of iron in the 
fenton reaction (Arora and Gores, 1996). ROS can react with lipids to induce lipid 
peroxidation process, resulting in the formation of malondialdehyde, a by-product of 
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lipid peroxidation. In-vitro studies have shown that DFO inhibits the production or 
reactive oxygen species.  
Figure 2.2 Proposed mechanism of cell death of the artemisinin compounds 
 
A pool of chelatable iron can accumulate in the mitochondria which can 
cause increased ROS exacerbating oxygen damage (Thomas et al., 2009). It will be 
imperative to investigate the effect of artesunate treatment on intra-cellular heme and 
iron content in HL-60 cells. This will be done by measuring intra-cellular heme and 
iron content in HL-60 cells treated with artesunate and pre-treatment with DFO. 
Reactive oxygen species generation 
Mitochondrial depolarisation 
Cytochrome c release 
Caspase activation 
Cell death 
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Apoptosis is known to precede necrosis via a controlled biochemical 
pathway. Mitochondrial depolarisation is an early occurrence in the intrinsic 
apoptotic pathway whereas activation of the caspase cascade occurs later in the 
pathway and plays a vital role in the apoptotic process. The mitochondrial membrane 
potential will be measured using Tetramethylrhodamine ethyl ester (TMRE). 
Western blot will be used to investigate the activation of caspase-3 and whether pre-
treatment with DFO will have any effect. It is one of the caspases that activate 
destructive enzymes and is activated by both the extrinsic and intrinsic pathways 
(Slee et al., 2001).  
2.2 Materials and Methods 
2.2.1 Materials 
The human cell lines HL-60 cells were obtained from the European 
Collection of Cell Cultures (Salisbury, UK). RPMI-1640 culture media, L-glutamine, 
Hank’s balanced salt solution (HBSS), 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), dimethylsulphoxide (DMSO) and trypan blue 
solution (0.4 %) solution, Tween-20 and non-fat dried milk were all purchased from 
Sigma Aldrich (UK). Foetal bovine serum was from Bio Whittaker. Lymphoprep 
was from Nycomed (Birmingham, UK). Polyacrylamide gel was purchased from 
National Diagnostics (Yorkshire, UK). Hybond-C extra nitrocellulose membrane, 
Hyperfilm ECL photographic film and ECL detection reagents were purchased from 
Amersham (Bucks, UK). Caspase-3 and caspase-7 rabbit polyclonal antibody were 
kindly donated by Prof. G. Cohen (MRC Toxicology Unit, Leicester). Goat anti-
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rabbit IgG secondary antibody conjugated to HRP was purchased from 
DakoCytomation (Cambs, UK). BCA reagent was purchased from Sigma. Artesunate 
was kindly donated by Dafra Pharma International (Belgium). PFDHA and the THF-
acetate isomer of PFDHA was synthesised in the Department of Chemistry 
(University of Liverpool). 
2.2.2 Cell culture  
HL-60 cells were maintained in RPMI 1640 medium which was 
supplemented with FBS (10% v/v) and L-glutamine (1% w/v). On reaching a density 
of 1 x 106 cells/ml in a 75 cm2 flask, cells (2 x 106) were seeded in 30 ml of freshly 
supplemented media. The cells were incubated at 37 °C under humidified air 
containing 5% CO2. Cell growth was maintained below 1 x 10
6 cells/ml. This was 
done to ensure exponential growth and avoid differentiation of the cells.  
Cell viability was maintained above 95 % for all experiments. The viable cell 
count was based on trypan blue exclusion from the cells performed in a 
haemocytometer using a light microscope (x 10; Zeiss Axioskop, Welwyn Garden 
City, UK). To 90µl of HL-60 cells, 10µl of trypan blue 0.4% solution was added and 
an aliquot was counted. Stock solutions of the drugs were made up in DMSO and the 
final solvent concentration was below 0.5% (v/v) for each incubation. Every 
concentration in each experiment was carried out in triplicate and the experiments 
were all repeated on at least three separate occasions. 
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2.2.3 Measurement of Cytotoxicity Using the 3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium Bromide (MTT) Assay  
The MTT assay is based on the ability of dehydrogenase enzymes within 
viable cell lines to form an insoluble formazan salt (Mosmann, 1983). The amount of 
formazan present is directly proportional to the number of viable cells. HL60 cells (5 
x 105) were plated in triplicate, in flat-bottomed 96-well plates and exposed to 0.01 
µM to 100 µM of artesunate and incubated for 24 h. After the 24 h incubation, 20 µL 
of MTT solution (5 mg/ml in HBSS) was added to each well. The plate was 
incubated for 2 h at 37 °C. 100 µL of lysis buffer (20 % w/v sodium dodecyl 
sulphate; 50 % v/v n-dimethylformamide) was added to each well, to dissolve the 
formazan crystals, and was incubated overnight. The absorbance of the wells was 
read using a test wavelength of 570 nm and a reference wavelength of 590 nm with a 
plate reader (MRX, Dynatech Laboratories). The results were expressed as a 
percentage of vehicle-only treated cells. The IC50 was estimated from individual 
inhibition curves plotted by GraFit software (Erithacus, West Sussex, UK).   
2.2.4 Determination of the protein content of cellular samples 
The protein content of the cellular samples was assayed using BCA protein 
assay. The BCA Protein Assay combines the protein-induced biuret reaction with the 
highly sensitive and selective colorimetric detection of the resulting cuprous cation 
(Cu1+) by bicinchoninic acid (BCA). A standard curve of 0 – 18 µg BCA was 
prepared using a stock solution of 2mg/ml BCA. Samples were analysed by 
spectrophotometric analysis (MRX microplate reader, Dynatech Laboratories) 
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2.2.5 Analysis by Flow Cytometer 
A flow cytometer (Canto, BD Biosciences Beckman Coulter, Oxford, U.K) 
was used to analyse the cells. Parameters were set using control cells. The forward 
scatter (FS) and side scatter (SS) were adjusted to obtain a population of viable cells 
with a voltage threshold set to exclude cell debris. FS determines cell size and SS 
determines granularity. At least 5000 cells were analysed in all experiments. 
2.2.6 LC-MS/MS Analysis and Quantification of Intracellular Endoperoxide 
Bioactivation 
Intracellular activation of the endoperoxides was monitored by LC-MS/MS. 
The instrument was an API 2000 triple-quadrupole mass spectrometer (AB Sciex, 
Warrington, UK) interfaced to a PerkinElmer Series 200 autosampler and a 
PerkinElmer pump. The data were collected and analysed by the Analyst 1.3 
software (AB Sciex). Cells (4 ml of 1 × 106 HL-60 cells/ml) were either incubated 
with PFDHA alone or pretreated with DFO (10µM) at 37 °C. Following 24 h 
incubation, artesunate (1nmol) was added as an internal standard before the samples 
were prepared. 
 Cells were extracted with chloroform (4ml, three times). Anhydrous 
magnesium sulphate was added to the extracts to dry. The mixture was then filtered 
through a glass funnel to remove the magnesium sulphate and cell debris. The 
organic phase was dried under nitrogen gas at 37°C. The residue was dissolved with 
50% methanol immediately before analysis by LC-MS/MS multiple reaction 
monitoring (MRM). Chromatographic separation was achieved on an Agilent 
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ZORBAX Eclipse XDB-C8 column (150 × 3.9 mm inner diameter, 5 μm; Agilent 
Technologies, Santa Clara, CA). The mobile phase consisted of methanol with 10 
mM aqueous ammonium acetate (70:30, v/v) delivered at a flow rate of 0.4 ml/min. 
The mass spectrometer was operated in positive ion mode. The operating parameters 
were optimized via the quantitative optimization facility in Analyst software as 
follows: ion spray voltage of +5.0 kV, back pressures for the collision gas of 2 p.s.i., 
curtain gas of 20 p.s.i., nebulizer gas (GS1) of 30 p.s.i., and turbo gas (GS2) of 65 
p.s.i.; the turbo gas temperature was 300 °C. Analyte-specific parameters and 
fragmentation transitions are detailed in table 2.1. All of the gases used were 
nitrogen. Calibration curves of peak area versus analyte mass (5–5000 pmol) were 
generated from solutions of synthetic PFDHA, PFDHA THF acetate, and artesunate 
in methanol, and the limit of quantification was calculated to be 50 pmol using the 
method of least squares line fit. The efficiency of PFDHA and PFDHA THF acetate 
recovery was corrected for by the quantification of the internal standard, artesunate.  
Table 2.1 Analyte specific parameters and precursor ions for artesunate, 
PFDHA and PFDHA THF acetate 
 DP EP CE CxP 
PFDHA, 396.0/163.0 6 8 17 10 
PFDHA THF-acetate, 396/266.7 21 5 30 14 
Artesunate, 401.1/163.1 21 12 30 26 
DP is declustering potential, EP is entrance potential, CE is collision energy, CxP is collision 
exit potential 
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2.2.7 Determination of oxidative stress in HL60 cells  
In order to measure artesunate induced ROS production in HL-60 cells, 2’,7’-
dichlorodihydrofluorescein diactetate (DCFH-DA) was used. DCFH-DA is a cell 
permeable flurogenic dye. It diffuses into cells and is converted to a non-fluorescent 
dye (DCFH) by cellular esterases. DCFH is then rapidly oxidised to a highly 
fluorescent 2’,7’-dichlorodihydrofluorescein (DCF) by intracellular ROS and other 
peroxides. The fluorescence intensity is proportional to the ROS levels in the cells. 
DCFH-DA is not specific but is sensitive to various ROS and reactive nitrogen 
species (RNS) (Rastogi et al., 2010). HL60 cells (0.5 x 106) were first washed in 
serum free media before DCFH-DA (5 µM) was added and incubated for 45 min. 
Cells were then washed again and treated with artesunate (0 – 100 µM) alone or pre-
treated with DFO (10 µM, 10 min). After the desired incubation time, cells were 
washed and resuspended in HBSS. Duplicate samples were prepared without the 
addition of DCFH-DA for all incubations to correct for the intrinsic fluorescence of 
the drugs. Samples were analysed by flow cytometry (Section 2.2.6) 
2.2.8 Lipid peroxidation assay 
Following incubation of HL-60 cells (10 x 106 cells) with artesunate alone or 
pre-treated with DFO (10 µM, 10 min), samples were prepared for lipid peroxidation 
assay. Cells were resuspended in ice cold HBSS (200µl) and sonicated to disrupt the 
cell membrane and release the cellular components. Ice cold TCA (200 µl, 10% w/v) 
was added to the cell lysates, vortexed and incubated for (5 min) on ice. Samples 
were then centrifuged (14,000 rpm, 5 min) and the supernatant were used for the 
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assay. Standards were made from 500 nM MDA stock solution (0 – 1.5 µM) and 
treated the same as the samples. TBA solution (200 µl, 0.67% w/v) was added to 
both samples and standards and incubated (100 °C). After 60 min incubation, 
samples (100 µl) were loaded on a black plate in duplicate and read on a plate reader 
(530 nm excitation and 550 nm emission). Values were normalised to protein 
content, determined by the BCA assay. 
2.2.9 Western Blot analysis Caspases-3 processing 
Cell lysate samples were prepared by washing incubated cells (2 x 106) with 
PBS (4 mls) and resuspended in RIPA buffer (30 µl) and vortexed to lyse the cells. 
The samples were than assayed for protein content using a BCA protein assay. The 
protein (20 µg in SDS loading buffer) was denatured at 95 °C for 3 min. It was then 
loaded on to 14 % SDS polyacrylamide gels. The gel was run initially at a voltage of 
70V for 10 min (until samples pass stacking gel) and then 170V for 1 h.  
Following separation of the protein complexes, the gel was placed onto a 
filter paper and nitrocellulose membrane was placed on top of it followed by another 
filter paper. They were then sandwiched between sponges and loaded into a transfer 
cassette (Bio-rad, U.K.). The samples were transferred onto the nitrocellulose 
membrane (230amps, 1 h in transfer buffer). Following protein transfer, the 
membrane was stained with Ponceau red to ensure equal protein loading and transfer 
of cellular extracts, and briefly washed with TBS(T). Membranes were then blocked 
(10 % w/v non-fat dried milk in TBS(T) for 1 h) and washed (TBS(T), 5 min ) before 
incubating with rabbit serum antibody (1: 1000 dilution, 2 % milk in TBS(T))  and 
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left overnight to recognise the caspase-3 proform (p32) and the p19 subunits. 
Following this, the membranes were  washed with TBS(T) and protein detection was 
attained using anti-rabbit antibody (secondary antibody) (1:5000 dilution, 2% milk in 
TBS-T). The membrane was blocked in mouse antibody (1:10,000 dilution, 2% milk 
in TBS(T)) for ten minutes and then in anti-mouse antibody (1:10,000 dilution,2% 
milk in TBS(T)) for 1 h. This was followed by two quick washes of both membranes 
and three consecutive washes (TBS-T, 5 min x 3). Blotting was also done for actin. 
The protein-antibody conjugate was visualised using ECL Western blotting detection 
reagents. This was followed by the exposure of membranes to photographic film and 
band volumes quantified by UVI band software (UVI Tech, Cambridge, U.K.) 
2.2.10 Determination of Mitochondrial Depolarisation with TMRE 
TMRE (tetramethylrhodamine, ethyl ester) is a fluorescent compound that 
accumulates in the mitochondrial matrix of live cells. The amount of fluorescence 
can be measured by flow cytometry and the accumulation of TMRE is proportional 
to the mitochondrial membrane potential of cells (Scaduto et al., 1999). Cells (5 x 
105 cells) were treated with desired drugs. After 24 h incubation, they were 
centrifuged (1400 rpm, 5 min). The cell pellets were washed in HBSS and 
resuspended in 500 µl of TMRE solution (50 nM in HBSS) and incubated in a 37 °C 
water bath for 10 min. A minimum of 5000 cells were analysed by flow cytometry 
(section 2.2.6). TMRE fluorescence was measured on fluorescence channel, FL-3. 
The data was analysed using cyflogic. 
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2.2.11 Determination of Cellular Heme Content 
The method was based on the protocol of Sassa (1976). An aqueous solution 
of oxalic acid (2 M, 500 µL) was added to a pellet of cells (1 × 105) treated with 
artesunate (1 – 100 µM) only or pre-treated with DFO (10 µM, 10 min) for 24h. The 
samples were shaken before heating (100 °C, 30 min). Standard solutions of hemin 
(0.01–10 mM) were prepared (water/methanol, MeOH 1:1, v/v containing 1% bovine 
serum albumin) and heated with oxalic acid, as above. The samples and standard 
solutions (200 μl) were plated onto a white 96-well plate, and the fluorescence of the 
deferrated heme was measured (excitation, 400 nm; emission, 662 nm). The results 
were corrected for non-heme endogenous porphyrins by preparing cell blanks in 
oxalic acid without heating. 
2.2.12 Cellular iron content assay 
The ferrozine based colorimetric assay by Reiner et al. (2004) was validated 
for HL-60 cells. The cells (2 x 106) were incubated with artesunate alone or pre-
treated with DFO (10 µM, 10 min) for 24 h. Cell pellets were lysed with NaOH (50 
mM, 200 µl) and shaken in a humidified atmosphere (2 h, room temperature). HCL 
(10 mM, 100 µl) was added to cell lysates (100 µl).  HCL (10 mM) solution was also 
used as the iron standard FeCl3 solvent (0 – 300 µM). Iron releasing agent (freshly 
made solution of 1.4M HCL and 4.5 % (w/v) KMnO4 in H2O, 100 µl,) was added to 
both sample and standard solutions. The mixtures were incubated in a fume hood (2 
h, 60 °C). The HCL/KMnO4 pre-treatment releases iron from iron-storage protein 
and heme proteins (Riemer et al., 2004). The mixtures were then cooled at room 
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temperature and incubated with iron detection reagent (6.5mM ferrozine, 6.5mM 
neocuproine, 2.5M ammonium acetate and 1M ascorbic acid dissolved in water, 30 
µl). After incubation (30 min), the solution (280 µl) was transferred in 96 well plates 
and read with a microplate reader at 550nm absorbance. The iron content of the cells 
were calculated from standard concentrations and normalised for protein content. 
2.2.13 Statistical analysis 
Values are expressed as a mean ± standard deviation (SD), represented as 
error bars on graphs. Data were analysed for non-normality using a Shapiro-Wilk 
test. Student’s t-test was used when data were normally distributed. A Mann-
Whitney U test was used for non-parametric data. All calculations were performed 
using Stats Direct statistical software. Results were considered to be significant when 
two-sided P-values were less than 0.05. Significance is indicated as follows: * P < 
0.05, ** P < 0.01, *** P < 0.001 
2.3 Results  
2.3.1 DFO pre-treatment decreases artesunate induced toxicity 
The effect of DFO on HL 60 cell viability was first assessed. This was to 
ensure that the right concentration of DFO was used in order to avoid any cytotoxic 
effect on the cells when incubated with artesunate (Figure 2.3A). It was observed that 
DFO on its own did not influence HL 60 cell viability at low concentrations but 
reduces cell viability at high concentration (100 µM) with an IC50 of 96.6 ± 5.3 
(Table 2.2). 10 µM of DFO was chosen as the concentration for the experiments.  
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Figure 2.3 Dose response curve of HL 60 cells treated with artesunate and DFO 
24 h A: DFO. B: Artesunate and Artesunate with DFO. Results are the mean ± SD of three 
independent sets of experiment. * P < 0.05, ** P < 0.01, *** P < 0.001, significance of 
treated HL 60 data compared to blank. ++ P < 0.01, significance of artesunate alone 
compared to artesunate with DFO data tested by Mann – Whitney U test 
Table 2.2 IC50 values of artesunate 
Drugs IC50 (µM) 
DFO 96.61 ± 5.3 
ART 6.96 ± 4.3 
ART+DFO 33.35 ± 2.9 
IC50 values IC50 values ± S.D, n = 3. Results are the mean of three independent sets of 
experiments 
 
HL60 cells were incubated with artesunate (0 – 100 µM) for 24hr. The result 
obtained showed significant reduction in HL 60 cell viability (Figure 2.3B). This was 
shown to be dose dependent manner (IC50 – 6.96 ± 4.3 uM). The cytotoxic effects 
were blocked by the addition of DFO (10 µM) with a 20 % increase in cell viability 
(Table 3.2). DFO had little effect on cell viability at lower concentrations of 
artesunate but enhanced cell survival at high concentrations of artesunate. The 
 
 A B 
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difference was significant at higher concentrations of artesunate (10 – 100 µM) 
p<0.001. 
2.3.2 Effect of DFO on endoperoxide bioactivation 
Figure 2.4 Effect of DFO on PFDHA bioactivation  
 
 
% Parent Cmp  THF 
PFDHA 35.12 67.46 
PFDHA+DFO 31.40 39.38 (p = 0.01) 
 
 A. PFDHA B THF acetate. Results are the mean ± SD of three independent sets of 
experiments. * P < 0.01significance of data tested by Mann – Whitney U test. 
 
The effect of DFO on the intracellular bioactivation of the endoperoxide 
bridge in HL 60 cells was measured using PFDHA (1 µM) and DFO (10 µM) pre-
treatment. PFDHA underwent bioactivation (Figure 2.4A) which is shown by a 
significant decrease in the parent compound (64.8 ± 3.54 %) and the formation of the 
THF biomarker (fig 2.4B) (67.5 ± 5.62 %). The addition of DFO (Figure 2.4B) did 
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not have an impact on the bioactivation of the parent compound (68.6 ± 3.59 %) but 
significantly decreased the THF acetate biomarker (39.4 ± 3.79 %). 
2.3.3 Mitochondrial membrane depolarisation 
The role of mitochondria and the effect of DFO were investigated by 
examining the mitochondrial membrane depolarization potential which was 
measured by flow cytometry (Figure 2.5). Tetramethylrhodamine ethyl ester (TMRE) 
was used to label cells with increased mitochondrial membrane potential. Artesunate 
induced dose-dependent mitochondrial membrane depolarisation in HL 60 cells 
reaching a maximum of 77 ± 8.1 (100 µM) of cells with depolarised MMP. The 
addition of DFO (10 µM) was seen to significantly reduce MMP reaching a 
maximum of only 22 ± 9.3 % cells with depolarised mitochondria at 100 uM 
artesunate. 
2.3.4 The measurement of Caspase-3 activation 
Western Blot was used to measure the effect of DFO upon caspase-3 
processing of artesunate (0 – 100 µM) in HL 60 cells. Representative gel showing 
concentration dependent caspase-3 processing is shown in Figure 2.6. The activation 
of caspase-3 resulted in a decrease in the amount of intact 33 kDa preform (p33) and 
the formation of the catalytically active subunit of 17kDa fragment (p17) (Anuradha 
et al., 2000). Artesunate induced caspase 3 processing in a dose-dependent manner. 
Pre-treatment with DFO (10 µM) has shown to reduce the processing of caspase 3. 
The formation of the active form (p17) was inhibited by DFO but was only seen in 
DFO pre-treated cells at high artesunate concentration (100 µM) 
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Figure 2.5 Effect of DFO on artesunate induced mitochondrial 
depolarisation 
 
HL 60 cells treated with artesunate and DFO (10 µM) and the amount of depolarisation 
assessed with TMRE. Results are the mean ± S.D of three independent sets of experiment. 
** P < 0.01 significance of data compared to the control. ++ P < 0.01 significance of 
artesunate alone compared to artesunate with DFO data tested by Mann – Whitney U test 
 
Figure 2.6 Western blot of caspase-3 processing in HL 60 cells 
 
Representative of a western blot gel of dose dependent caspase-3 processing. HL 60 cells 
were treated with artesunate and pre-treated with DFO (10 µM). 
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2.3.5 The effects of artesunate on intracellular iron content 
The colorimetric feroxine based assay measures all cellular iron including 
protein bound iron (Reiner et al., 2004). This study demonstrated that artesunate 
caused a significant dose dependent increase in intracellular iron especially at high 
concentrations showing almost a 3 fold increase at 100 µM compared to the control. 
Intracellular iron content increased at concentrations as low as 1 µM. With the 
addition of DFO, the increase in intracellular iron content induced by artesunate was 
reduced significantly (Figure 2.7). HL 60 cells pre-treated with DFO (10 µM) did not 
show a dose-dependent increase in iron-content with increasing concentrations of 
artesunate (0.4 – 0.5 ng/mol) 
Figure 2.7 Effect of artesunate and DFO on intracellular iron content 
 
Results are the mean ± S.D of three independent sets of experiment. * P < 0.05, ** P < 0.01, 
significance of data compared to the control. ++ P < 0.0, significance of artesunate alone 
compared to artesunate with DFO data tested by Mann – Whitney U test. 
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2.3.6 Effect of DFO on intracellular heme content of artesunate treated HL-60 cells 
The role of heme in the bioactivation of artemisinin compounds has been 
strongly suggested. The effect of artesunate in the intracellular heme content in HL 
60 cells was analysed by flurometric detection (Table 2.3). Artesunate treatment (0 – 
100 µM) did not have any effect on intracellular heme in HL 60 cells. 
Succinylacetone (SA) was added as a positive control to confirm the validity of the 
test. SA is a potent permanent inhibitor of heme biosynthesis (Bourque et al., 2010). 
When HL 60 cells were treated with DFO (10 µM), a decrease in heme content was 
observed at high concentrations of artesunate (10 – 100 µM) although it was not 
significant. 
Table 2.3 Intracellular heme content in HL 60 cells  
 
 
Artesunate DFO 
Conc. 
µmol 
Heme content 
(ng/106 well) 
P value Heme content 
(ng/106 well) 
P value 
0 14.83±6.6  14.04 ±0.95 0.1 
3 14.43 ±2.77 0.8 14.61 ±0.6 0.6 
10 14.82 ±1.01 0.2 11.56 ±2.4 0.1 
100 14.32 ±1.7 0.7 11.84 ±0.9 0.3 
SA 0.6± 3.16 0.008**   
HL 60 cells treated with artesunate and DFO (10 µM) Results are the mean ± S.D of three 
independent sets of experiments. ** P <0.01 significance of the positive control compared to 
the vehicle control. SA used as +ve control. 
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2.3.7 Measurement of levels of reactive oxygen species (ROS) 
2.3.7.1 Artesunate induced the formation of ROS measured by DCFH-DA 
Figure 2.8 Effect of DFO on artesunate induced reactive oxygen species 
 
 
 
 
 
A: 16 hr. B: 24 hr. HL-60 cells treated with artesunate alone or pre-treated with DFO 
(10µM). Results are mean ± S.D of three independent sets of experiments. *** P < 0.001 
significance of data compared to control. ++ P < 0.01, significance of artesunate alone 
compared to artesunate with DFO data tested by Mann – Whitney U test. 
 
The generation of reactive oxygen species is one of the mechanisms proposed 
in artemisinin toxicity. DCFH-DA dye was used to measure the amount of ROS 
generated by artesunate. ROS production started at 16 h artesunate incubation in a 
dose dependent manner (Figure 2.8A), reaching 1.98 ± 0.52 fold increase at 100 µM 
concentration. ROS production peaked at 50 µM (24 h) artesunate concentration (2.6 
± 0.47 fold increase) and started decreasing at higher concentrations (100 µM). ROS 
generation was reduced when HL-60 cells were pre-treated with DFO (10 µM). 
Reduction of ROS by DFO was significant at 16 h incubation but more significant 
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reduction levels were observed at 24 h incubation starting at from 10 µM artesunate 
concentration (Figure 28B). 
2.3.8 Lipid peroxidation assay 
Figure 2.9 Effect of DFO on artesunate induced lipid peroxidation 
 
HL 60 cells treated alone or pre-treated with DFO (10 µM).Results are mean ± S.D of three 
sets of independent experiments. 
 
 
To determine the extent of oxidative damage in HL-60 cells caused by 
artesunate, lipid peroxidation assay was performed. This assay measures 
malondialdehyde, a by-product of lipid peroxidation. The results obtained showed no 
significant increase in malondialdehyde in HL-60 cells after 16 h incubation with 
artesunate (Figure 2.9). There was slight increase seen at 100 µM artesunate 
concentration but it was not statistically significant (0.4 fold increase). The addition 
of DFO did not significantly alter the levels of malondialdehyde product in HL-60 
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cells. These results demonstrate that artesunate might not have an impact on lipid 
peroxidation. 
2.4 Discussion 
The cytotoxic mechanism of action of the artemisinin antimalarials has been 
controversial but the involvement of heme has been demonstrated in previous studies 
(Mercer et al., 2011, Zang et al., 2009, Messori et al., 2006). Iron chelators such as 
DFO have been used both in vivo and in vitro to both probe the involvement of iron 
in artemisinin activation and toxicity. 
 It is hypothesised that DFO functions to chelate iron needed for the 
bioactivation of the artemisinin compounds thus inhibiting their bioactivation and 
subsequent toxicity (Meshnick et al., 1993), however the chemistry underlying this 
hypothesis has not been measured. The aim of this research was to define the 
mechanisms underlying the protective mechanism against artemisinin induced 
toxicity by the iron chelator, DFO. Pre-treatment with DFO protected HL-60 cells 
against artesunate toxicity when analysed by cell the viability assay. The IC50 value 
increased from 6.96 to 33.35.  
The ability of DFO to decrease artemisinin toxicity has also been documented 
in various studies (Uhlemann et al., 2007, Haynes et al., 2007, Stocks et al., 2007, 
Meshnick et al., 1993).  These results are in line with other studies involving the 
endoperoxides in HL-60 cells (Lu et al, 2008) and other cell lines including parasite 
infected human red blood cells (Stocks et al., 2007). Although these results are 
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important, they have not defined whether DFO actually inhibits the bioactivation of 
the artemisinin antimalarials or inhibits cytotoxicity through another mechanism.  
Due to the proposed iron-dependent bioactivation by the Meshnick group, it 
was believed that DFO might inhibit artemisinin induced toxicity by chelating iron 
needed to initiate the bioactivation process. With this in mind, quantitative LC-
MS/MS analyses of PFDHA and heme content assay were performed. PFDHA 
undergoes bioactivation to form THF acetate which is a stable biomarker of carbon-
centred radical production. THF-acetate is formed when c-centred radicals arrange in 
the absence of biomolecular targets (Mercer, 2009). Bioactivation of the 
endoperoxide group was studied by Mercer et al using different modulators of heme 
synthesis. They demonstrated that cellular heme was important for the bioactivation 
of the endoperoxides. The heme biosynthesis inhibitor, succinyl acetate (SA), 
decreased cellular heme content resulting in decreased bioactivation of the 
endoperoxide and reduced toxicity. The addition of a heme precursor (PPIX) had the 
opposite effect and showed an increase in cellular heme content with increased 
endoperoxide bioactivation and cytotoxicity. The addition of HTF, which is an 
extrinsic source of iron, caused a significant increase in the bioactivation of PFDHA 
but did not necessarily translate to increased toxicity (Mercer et al., 2011). 
In this study, we have seen that the addition of DFO did not have much effect 
on the bioactivation of the endoperoxide but it is important to note the significant 
decrease in the THF acetate biomarker. The absence of an effect on bioactivation 
might be due to the fact that the chelating activity of DFO is almost limited to ferric 
iron (Fe3+), and not ferrous iron (Fe2+), which is essential for the activation of 
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artemisinin and their compounds (Efferth et al., 2004). The reduction of THF acetate 
isomer might be explained by the chemical rearrangement which can be affected by 
iron chelatable by deferroxamine. The proposed mechanism of the formation of 
THF-acetate (figure 2.10) involves the presence of Fe (III) (Maggs et al., 1997), 
explaining the reduction of THF-acetate formation with DFO treatment.  
Figure 2.10 Proposed metabolism of THF formation 
 
 
Mercer et al. (2009) which demonstrated that bioactivation of the 
endoperoxides, which results to cytotoxicity, is heme or a heme-containing protein 
mediated. Exogenous iron, HTF, did increase bioactivation but there was no increase 
in cytotoxicity. This study showed no effect of artesunate on intracellular heme 
content with slight decrease in heme content at high concentrations of artesunate. On 
the other hand, this study shows that artesunate produced a significant dose 
dependent increase in cellular iron producing more than two and a half fold increase 
at high concentration (100µM) when compared to the control.  
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Figure 2.11 Proposed mechanism underlying DFO protection against artesunate 
toxicity 
 
 
 
Pre-treatment of cells with DFO significantly reduced artesunate induced iron 
accumulation. The artemisinin compounds induce an iron dependent vesicle 
clustering at the perinuclear region of lysosomes (Hamacher-Brady et al., 2011). Iron 
is usually stored in a stable form as transferrin and ferritin but lysosomal iron is in a 
labile state. The large amount of redox active iron only stays in the lysosomes 
temporarily for further transit to places that require iron but that also makes it an 
important place for Fenton-type reaction, resulting in the formation of reductive 
hydroxyl radicals (Kurz et al., 2007).  
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Being a hydrophilic compound, DFO does not cross through cell membranes 
but enters cells by endocytosis ending up in the lysosome. It chelates iron present in 
the lysosomes and in the absence of excess iron starves cells of iron resulting in cell 
death. DFO protects against early and late lysosomal rupture (Kurz et al.,2006). 
Lysosomal iron has been shown to be a toxic source of artemisinin generated 
ROS (Crespo-ortiz et al., 2011) and oxidative damage has been implicated in the 
mechanism of action of artemisinin and is an important factor in artemisinin-induced 
cell death (Efferth et al., 2007, Bedelle et al., 2011).  
ROS production by artesunate was seen from 16 h incubation showing a dose 
dependent increase by 24 h and DFO significantly reduced artemisinin induced ROS 
production. Since the generation of reactive oxygen species is an important aspect in 
artemisinin induced toxicity, chelating the toxic iron by DFO prevents ROS 
formation by inhibiting the catalytic role of iron in the fenton reaction (Molina-Jijon 
et al 2012). Treatment with DFO in the absence of iron overload can itself cause 
oxidative damage (Reeder and Wilson, 2005, Reeder et al., 2008) as evident in these 
investigations but when artesunate was added, its effect was negated. This might be 
due to the fact that the treatment of cells with artesunate caused significant iron 
production thereby giving DFO the iron to chelate rather than the iron the cells need 
to function.  
Lipid peroxidation does not seem to be affected by artesunate treatment and 
thus might not contribute to artesunate induced ROS formation. This is in line with 
Berman and Adams (1997) who demonstrated that artemisinin treatment had no 
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effect in basal malondialdehyde production in human erythrocyte membranes but 
importantly, addition of heme with artemisinin caused a spike in MDA formation 
(Berman and Adams, 1997). 
The dose dependent loss of mitochondrial membrane potential confirms the 
role of mitochondria in artemisinin induced cell death. The generation of reactive 
oxygen species causes mitochondrial membrane potential loss and disrupts normal 
mitochondrial function eventually leading to cell death (Wang et al., 2010). The 
inhibition of mitochondrial membrane potential loss through pre-treatment with 
DFO, at an early time point before the induction of apoptosis (16 h) further 
reinforces the contribution of ROS in the cascade of events leading to artesunate 
induced cell death. The inhibition of artesunate induced ROS formation protects 
mitochondria from damage and in turn inhibits caspase activation that leads to cell 
death.  The activation of the caspase cascade is regarded as the hallmark of apoptotic 
cell death (Elmore, 2007). The endoperoxides have previously shown to induce 
cleavage of pro-caspase-3 (32kDa) to the active subunit (17kDa) (Mercer et al., 
2007).  
The work presented in this chapter demonstrates that artemisinin induced 
cytotoxicity can be inhibited by the iron chelator DFO.  The bioactivation of the 
artemisinin compounds, which is believed to be Fe 2+/iron mediated was not inhibited 
by DFO but the subsequent mechanisms involved in the apoptotic process of the 
artemisinin compounds were inhibited. The results from this study seem to suggest 
that DFO chelates artemisinin induced accumulation of iron in cells probably in the 
lysosome. Reactive oxygen species formation is catalysed by artesunate induced iron 
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accumulation which in turn triggers a downstream cascade of mitochondrial damage 
resulting in caspase formation and cell death. This work has identified the 
mechanism of action of the artemisinin compound where DFO blocks the cascade of 
events leading to cell death. The results obtained are in line with Hamacher-Brady 
and group (2011) who identified artemisinin induced lysosomal iron as causing ROS 
formation. The ROS formation was blocked by DFO, a lysosomal iron chelator.  
Although the safety profile of the artemisinin compounds is thought to be 
excellent in human, a definitive statement on their safety cannot be made due to 
reported toxicity in animal studies (Efferth and Kaines 2010). This chapter has 
demonstrated and identified the process by which DFO inhibits artemisinin 
compound toxicity in cells, and with reports that DFO reduces artemisinin induced 
toxicity in animals (Meshnick et al., 1993), there might be its potential use in clinical 
practice if human toxicity was to be identified. However, further studies need to be 
carried out. With the knowledge that malnutrition can alter drug safety profile, the 
rest of the chapters of this thesis will be to identify potential effect of malnutrition on 
artemether safety. 
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3. Incidence of Protein Energy Malnutrition in Children With 
Uncomplicated Malaria in The Gambia 
3.1 Introduction 
 Infectious diseases account for more than 65% of deaths in children under 
five years of age in Sub-Saharan Africa. Pneumonia, diarrheal disease and malaria 
are responsible for more 50% of those mortalities, with malnutrition believed to be 
directly or indirectly responsible for around half of the mortalities (Black et al., 
2010). In 2011, malaria alone accounted for 7 % of total mortality from infectious 
diseases (WHO, 2012). 
Figure 3.1 Global causes of mortality in children under five years of age, 2011 
Malnutrition was a contributing factor to almost half of all infant mortality in children under 
five years of age in 2011. 
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There is substantial evidence that malnutrition causes decreased immunity, 
including cell mediated immune responses, immunoglobulins, antibodies, cytokine 
production and phagocyte function. This causes significant alteration to immunity 
and predisposes to infection. Conversely, infectious diseases can precipitate 
childhood malnutrition (Schaible and Kaufman, 2007).  
Plasmodium falciparum malaria and malnutrition are both a major health 
problem in many tropical countries and are thought to be sometimes associated 
(Fillol et al., 2009). They both cause high infant mortality and morbidity especially 
in rural sub-Saharan Africa. Control clinical trials of Vitamin A and zinc 
supplementations in under nutrition have shown to significantly reduce malaria 
incidence (Owusu-Agyei et al., 2013, Zeba et al., 2008), further supporting the 
association between malnutrition and malaria.  
Malnutrition has been shown to influence susceptibility and manifestation of 
malarial infection and the association and impact of this combination and interaction 
is still contradictory (Nyakeriga et al., 2004). However, some have found an 
increased risk of malaria in malnourished children (Friedman et al., 2005, Deen et 
al., 2002, Verhoef et al., 2002, Man et al., 1998). Studies looking into the 
relationship between malaria, malnutrition and specific immunity have different 
results regarding antibody (Ab) responses to P. falciparum (Genton et al., 1998, Blair 
et al., 2003, Fillol et al, 2008). Blair et al (2003) showed no impact of malnutrition 
on antibody response to malaria infection. In contrast to this, other authors have 
Chapter 3: Incidence of Protein Energy Malnutrition 
77 
 
reported lower specific antibody levels in children with malnutrition compared to 
their normally nourished counterpart (Fillol et al., 2008, Genton et al., 1998). 
Table 3.1 summarises the relationship between protein energy malnutrition 
and malaria from selected studies. Stunting, a measure of prolonged malnutrition, has 
been associated more with malarial infection than either wasting or underweight. A 
longitudinal study of rural children in The Gambia reported no association between 
malaria and wasting but discovered increased risk of malarial episodes in stunted 
children (Deen et al., 2002). The same findings were also reported in Kenya were a 
cross sectional studies shown stunting to be associated with concurrent malaria, high 
parasitemia and malarial anaemia. On the contrary, other studies in Kenya and 
Congo have shown stunting to protect children from malaria (Mitangala et al. 2013, 
Mitangala et al., 2008, Genton et al., 1998). Fillol et al (2009) on the other hand 
observed wasting to be protective against clinical malaria whilst stunting and 
underweight had little association with malarial episodes (Fillol et at, 2009).  
A couple of studies have highlighted no association between PEM and the 
incidence of malaria (Deribew et al., 2010, Danquah et al., 2010, Muller et al., 2010), 
but discovered that malnourished children had more than double the risk of dying 
from malaria than their normally nourished counterpart (Danquah et al., 2009, Muller 
et al., 2003). Intermittent preventive treatment (IPT) in malnourished children 
offered less immunity to malarial episodes compared to the normally nourished 
children (Danquah et al., 2009).  
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Anaemia is also associated with malaria and malnutrition, with underlying 
anaemia contributing to the severity of malaria and malnutrition, leading to increased 
mortality. Red blood cell destruction and reduced production, associated with the 
pathophysiology of malaria, causes a reduction of haemoglobin levels leading to 
anaemia (Menendez et al., 2000). Continued malaria infection and further destruction 
can result in severe malarial anaemia (Haldar and Mohandas, 2009). Severe malarial 
anaemia is defined as Hb concentrations <5 g/dl in the presence of any density 
anaemia (WHO, severe falciparum malaria, 2000) and is one of the leading causes of 
malaria related mortalities (Menendez et al., 2000). 
This chapter will evaluate the prevalence of malnutrition in children under 
five years of age with malaria in The Gambia. Malaria and malnutrition are major 
public health problems in The Gambia. According to The Gambia’s Multiple 
Indicator Survey (MICS) 2010, stunting was 23.4%, wasting 9.5% and underweight 
estimated to be 17.4% in children under five years of age (MICS, 2010). Although 
the incidence of malaria is declining in The Gambia, it is still a major cause of 
morbidity and mortality among children under five years of age (Ceesay et al., 2010). 
Malaria is the highest cause of death in children in The Gambia accounting for 60% 
of all under five years of age mortality, followed by pneumonia, malnutrition and 
diarrhoea (National Health Policy, The Gambia).  
It is the primary aim of this chapter to investigate the prevalence of 
malnutrition in children under five years of age presenting with uncomplicated 
malaria compared to the prevalence of malnutrition in children under five years of 
age in The Gambia. The prevalence will be measured as the percentage of children 
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with malnutrition according to the WHO classification against the total number of 
children with uncomplicated malaria.  
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Table 3.1 Association between malaria and protein energy malnutrition 
 
WHZ – weight-for age Z score (underweight), WAZ – weight for height z score (wasting), HAZ – height-for-age z score (stunting), IPT – 
intermittent preventive treatment.
Source Country Number 
Age 
Indicator for 
malnutrition 
Interpretation 
Danquah et al. 
2009 
Ghana N = 1200 
2 – 24 months 
WHZ, WAZ, 
HAZ, 
Protective efficacy of IPT halved in malnourished 
children 
No malarial association between nutritional status 
Fillol et al. 
2009 
Senegal N = 874 
2 - 59 months 
WHZ, WAZ, 
HAZ 
Wasting associated with clinical malaria  
Friedman et al. 
2005 
Kenya N = 1862 
0 – 36 months 
WHZ, WAZ, 
HAZ 
Stunted children had more parasitaemia, increased 
incidence of clinical malaria and severe anaemia 
Muller et al. 
 2003 
Burkina Faso N = 686 
0 – 30 months 
WHZ, WAZ, 
HAZ 
No incidence in malaria incidence 
Deen et al 
2002 
Gambia N = 487 
< 5 years 
WHZ, WAZ, 
HAZ 
Stunted children had higher risk of malaria 
incidence 
Genton et al. 
1998 
Papua New Guinea N = 136 
10 months – 10 years 
WHZ, HAZ Stunted children at lower risk of malaria incidence 
Tshikuka et al 
1997 
Zaire N = 558 
4 months – 10 years 
WHZ, HAZ Stunting and wasting had higher risk of malaria 
infection 
Snow et al. 
 1991 
Gambia N = 138 
1 – 4 years 
WHZ, WAZ, 
HAZ 
No malarial association between nutritional status 
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The generation of free radicals have been associated with the pathogenesis of 
PEM. The major sources of anti-oxidants are dietary intake and nutritional 
supplements (Ece et al., 2007), thus malnourished children are believed to be in a 
state of oxidative stress (Granot et al., 2004). Studies of malnourished children have 
demonstrated increased pro-oxidant and decreased antioxidant (perampalli et al., 
2010, Catal et al., 2007, Ece et al., 2007, Shabaan et al., 2002, Reid et al., 2000,), 
putting them is a state of oxidative stress. It is believed that the higher pro oxidants 
found in malnourished children are responsible for the pathological changes such as 
edema, fatty liver and skin lesions (Golden et al., 1990). Plasma malondialdehyde 
(MDA), an end-product of lipid peroxidation, is a one of the most reported 
biomarkes of oxidative stress. The secondary aim of this chapter will be to measure 
MDA levels in the study population to ascertain their oxidative status. 
3.2  Materials and methods 
3.2.1  Materials  
 Sulphuric acid (H2SO4), Phosphotungstic acid, thiobarbituric acid (TBA), 
glacial acetic acid and n-butanol were all purchased from Sigma Aldrich (UK). 
Distilled water was obtained from the laboratory distilled water taps. All the 
chemicals were HPLC grade. 
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3.2.2 Study Area 
 Research participants were recruited from Serrekunda Hospital and Brikama 
Health centre in The Gambia. The Gambia is located on the coast of West Africa and 
stretches about 350km from the coast to the inland, with 20% considered as wetland 
(Sallah and Williams, 2011). According to the 2003 census, the population of the 
Gambia was about 1.3 million people with a projected population of over 1.7 million 
in 2009. The population is heavily concentrated around Banjul, Kanifing 
municipality and Brikama. Brikama has the highest population with 28% followed 
by Kanifing Municipality with 24%.  
Serrekunda hospital is situated in a relatively modern area and the population 
there are relatively well off. On the other hand, Brikama Major Health Centre covers 
a wide catchment area for many villages where villagers go to the health centre for 
first line treatment. The health centre also serves as a referral place for minor health 
centres and health posts around the catchment area. The patients going to the health 
centre are economically and socially diverse. 
The study was conducted between October and December 2010. Malaria 
transmission peaks between the months of August and November. At the time of the 
studies, Artemether/Lumefantrine was the first line of treatment for uncomplicated 
malaria. Local ethics approval was obtained from the Gambia Government/MRC 
Joint Ethics Committee. Approval was also obtained from the management of 
Serrekunda health centre, and the divisional health committee to conduct the study at 
Brikama health centre.  
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3.2.3 Participants  
Parents of children diagnosed with uncomplicated malaria from the out-
patient department were approached for inclusion. Parent information leaflets were 
given to the adult accompanying the identified child. The information on the leaflet 
was explained in detail to parents that were not literate in English. Questions and 
enquiries were answered by study leaders. Consent was obtained from the 
parents/guardians who accepted for their children to be part of the study. Those who 
could sign were given a consent form to sign and those that could not sign put their 
thumb print on the signature area. 
3.2.4 Inclusion criteria 
• Diagnosis of uncomplicated malaria  
• Age between 12 – 59 months 
• Weight ≥ 5kg 
• Blood film of Plasmodium falciparum infection of 1,000   
parasites/µL 
• No medication containing artemisinin 4 weeks prior 
• Willing to give informed consent  
3.2.5 Exclusion criteria 
• Diagnosis of complicated malaria 
• Age < 12 and ≥ 60 months 
• Weight < 5kg  
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• Medication containing artemisinin within 4 weeks 
• Unwilling/ unable to give informed consent 
3.2.6 Ethical Approval 
Ethical approval of the study was approved by The Gambia 
Government/MRC Joint Ethics Committee. This approval covered the recruitment of 
participants in health facilities in The Gambia. 
3.2.7 Informed Consent 
 Parent information leaflets and patient information leaflets for children ≥ 48 
month of age were written in English. A proportion of people in The Gambia are 
illiterate (WHO, world health statistics 2012) so verbal translation to a local language 
they understand was done in the presence of an independent member of staff. 
Agreement was documented by signature for those that were literate in English or a 
thumbprint for those who were not. 
3.2.8 Measurement of clinical parameters 
Anthropometric measurements (weight, height) were taken. Weight was 
measure on a digital scale.  Length was taken for children under the age of two years 
on a platform with a sliding headboard. Standing height was measured for children 
above two years with a height scale. Weight-for-height z scores (WHZ), weight-for-
age z scores (WAZ) and height-for-age z scores (HAZ) were calculated on the basis 
of the National Centre for Health Statistics (NCHS/WHO) reference data set, version 
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3.2.2 software (WHO 2011) Z scores < -2 are suggestive of wasting (WAZ), 
underweight (WHZ) and stunting (HAZ). Scores < -3 show severe malnutrition. Age, 
sex and axillary temperature was recorded for every child.  
3.2.9 Malondialdehyde Analysis 
MDA concentration was measured by thiobarbituric acid-reactive substances 
(TBARS) method (Yagi, 1998). The assay was performed in glass tubes. To 50µl of 
plasma was added 12N H2SO4 (4ml) and mixed gently. 10% phosphotungstic acid 
(0.5ml) was added to the mixture, left to stand at room temperature (5 min) and then 
centrifuge (3000 rpm, 10 min). 12N H2SO4 (2ml) and 10 % phosphotungstic acid 
(0.3 ml) was added to the sediment, vortexed, and centrifuged again (3000 rpm, 
10min). 0.5nmol tetramethoxypropane was used as the standard solution. The 
standard solution and sediment were suspended in distilled water (4 ml) and TBA 
reagent (a mixture of equal volumes of 0.67 % TBA aqueous solution and glacial 
acitic acid, 1 ml). The mixture was heat in a heating block (95°C, 60 min) and 
immediately cooled under running tap water. Butanol (5 ml), was added to the cooled 
mixture and shaken vigorously. The mixture was centrifuged (3000 rpm) and the top 
layer was taken for fluorescent measurement at 550nm with excitation at 530nm. 
Plasma peroxide levels was measured using the formula 
0.5 ∗ 𝑓
𝐹
∗  1.0
0.05 = 𝑓𝐹 ∗ 25 (nmol/ml of plasma) 
 where f is the results of samples 
    F is the results of the standard  
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3.2.10 Statistical Analysis 
  Data was entered in excel and statistical analysis was performed using 
statistical package, SPSS. Nutritional status was assessed using WHO Standardised 
Z-scores used as per WHO guidelines: weight-for-age z-score (WAZ) for 
underweight, weight-for-height z-score (WHZ) for wasting and height-for-age z-
score (HAZ) for stunting. Measures of malnutrition were categorised as z-score >1, 
<-1, <-2, <-3 for normally nourished, mild, moderate and severely malnourished 
respectively. SPSS statistic for windows, version 20.0 was used. Normality was 
tested using t test and chi-square test. ANOVA was used to test for significance of 
data in different nutritional status. Interaction between potential confounders was 
examined by analysis of covariance. Post-hoc analysis was carried out where 
significance was observed using independent sample t-test. 
3.3 Results  
350 parents/guardians of children diagnosed with uncomplicated malaria 
were approached during the period of the study. Consent was obtained for 105 
children to be part of the study.  Five children developed complicated malaria and 
had to be withdrawn and a further three parents withdrew their children from the 
studies. A total of 97 participants (age range; 12-59 months) were recruited, of whom 
49 were boys (50.5%) and 48 (49.5%) were girls. The mean age was 33.5 months 
(SD – 15.2) and the mean axillary temperature was 37.2°C (± 0.27).  
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Table 3.2 Demography of study participants 
Age (months) No. (%) Gender No. (%) Hb (g/dl) No. (%) 
12-17 15 (15.5) Male 49 (50.5) ≥ 11 3 (3.1) 
18-23 18 (18.6) Female 48 (49.5) 10.9–10 66 (68.0) 
24-29 13 (13.4)   9.9-7 28 (28.9) 
30-35 6 (6.2)   <7 0 (0) 
36-41 11 (11.3)     
42-47 9 (9.3)     
48-53 12 (12.4)     
54-59 13 (13.4)     
Demographic summary of study participants according to age groups, gender and 
haemoglobin (Hb) level. 
 
Table 3.2 summarises the participants in relation to age groups, gender and 
haemoglobin levels. Malaria was highest in the younger age groups with 18-23 
months age group accounting for 18.6% (n=18) followed by 12-17 months age group 
(15.5%). The least malaria incidence was seen in the 30-35 months age group 
(6.2%). The mean haemoglobin (Hb g/dl) level was 9.5g/dl (± 0.92) with 96.9% of 
the children classified as anaemic according to the WHO definition. 28.9% of 
children were mildly anaemic (10-10.9 g/dl) and 68% of children were moderately 
anaemic (7-9-9g/dl). 
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The mean Z-scores (SD) for weight-for-age, weight-for-height and height-
for-age of the study population were -1.483 (1.602), -1.178 (1.573) and -1.297 
(1.602) respectively. Using the WHO classification of malnutrition, 30.9% of 
children in the study were malnourished.  
The prevalence of underweight (WAZ) and wasting (WHZ) were both 30.9%, 
and stunting (HAZ) was 28.9% (Table 3.3). Their corresponding severe nutritional 
condition (Z score < -3) was observed in 13.4%, 12.4% and 9.3% in children 
respectively. There was no statistical difference in malnourished status between boys 
and girls however, there were more malnourished boys compared to girls. Tables 3.4 
summarises the type of PEM in relation to age groups in months.  
Table 3.3 Summary of Nutritional Indices (Z score) 
 Weight-for-age 
(WAZ) 
Weight-for-height 
(WHZ) 
Height-for-age 
(HAZ) 
No. below <-2 (%) 30 (30.9) 30 (30.9) 28 (28.9) 
Sex    
No. of girls <-2 (%) 12 (25) 13 (27.1) 11 (22.9) 
No. of boys <-2 (%) 18 (36.7) 17 (34.7) 17 (34.7) 
Characteristics of the study population in relation to nutritional indicators using z-score. 
Malnutrition is categorised as weight-for-age (WAZ), weight-for-height (WHZ) and height-
for-age (HAZ). 
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Table 3.4 Category of protein energy malnutrition according to age groups 
Prevalence of wasting (WHZ), underweight (WAZ) and stunting (HAZ) according to age 
groups in months. 
 
Underweight 
Underweight is indicated by weight-for-age less than 2 SD of the population 
using the NCHS/WHO reference data set and severe underweight is indicated by 
weight-for-age less than 3 SD. Table 3.5 shows the demographics of underweight in 
relation to age groups, gender and Hb levels. The prevalence of underweight among 
children with uncomplicated malaria was 30.9% with the severe form being 13.4%. 
There was no significant difference between gender (p =0.56).  
Underweight was highest in the youngest age group (12-17 months) 
accounting for 8.2% of the study population. This also constituted more than half 
(53.3%) of the population of that age group. 14.4% of the total study group were 
severely underweight. The highest percentages seen in the two youngest age groups 
(12-17, 18-23) and the eldest age group (54-59) in equal proportion (21.4%). 
 
Age (months) 
Category of PEM 
WHZ WAZ HAZ 
12–17 (%) 6 (20) 8 (26.7) 6 (21.4) 
18-23 (%) 4(13.3) 4 (13.3) 6 (21.4) 
24-29 (%) 2 (6.7) 3 (10) 7 (25) 
30-35 (%) 1(3.3) 2 (6.7) 1 (3.6) 
36-41 (%) 2 (6.7) 2 (6.7) 2 (7.1) 
42-47 (%) 3 (10) 2 (6.7) 0 (0) 
48-53 (%) 5(16.7) 4 (13.3) 3 (10.7) 
54-59 (%) 7 (23.3) 5 (16.7) 3 (10.7) 
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Underweight was least between 30 – 47 months and there was no observed trend of 
underweight in relation to age group. 
Table 3.5 Demographics of weight-for-age category 
Prevalence of the degree of underweight in children by age, gender and haemoglobin levels. 
1including weight as confounding factor 
5Chi-square test 
6ANOVA 
7Analysis of covariance 
 
 Z score value No.  
Age groups 
(months) 
Normal < -1 < -2 < -3 p value 
12–17 (%) 5 (16.7) 2 (5.4) 5 (31.2) 3 (21.4) NA 
18-23 (%) 7 (23.3) 7 (18.9) 1 (6.2) 3 (21.4) 
24-29 (%) 2 (6.7) 8 (21.6) 2 (12.5) 1 (7.1) 
30-35 (%) 2 (6.7) 2 (5.4) 2 (12.5) 0 (0) 
36-41 (%) 5 (16.7) 4 (10.8) 1 (6.2) 1 (7.1) 
42-47 (%) 4 (13.3) 3 (8.1) 0 (0) 2 (4.3) 
48-53 (%) 3 (10.0) 5 (13.5) 3 (18.8) 1 (7.1) 
54-59 (%) 2 (6.7) 6 (16.2) 2 (12.5) 3 (21.4) 
Gender 
No. (%) 
    0.565 
Male 15 (50.0) 16 (43.2) 9 (56.2) 9 (64.3) 
Female 15 (50.0) 21 (56.8) 7 (43.8) 5 (35.7) 
Weight 13.05±2.63 11.22±2.15 9.98±2.32 8.67±2.10 < 
0.0016 
Height 90.36±12.1
0 
90.08±2.15 84.94±12.0
7 
85.59±14.1
5 
0.326 
Age 
continuous 
31.93±14.2
0 
35.57±14.5
2 
32.25±17.1
2 
33.07±17.9
2 
0.286 
Hb1 mean 10.29±0.66 9.65±0.50 8.90±0.65 8.19±0.52 <0.001
7 
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Wasting  
Wasting is indicated by weight-for-height less than 2 SD of the population 
using the NCHS/WHO reference data set and severe wasting is indicated by weight-
for-height less than 3 SD. Table 3.6 shows the demographics of wasting in relation to 
age groups, gender and Hb levels. The prevalence of wasting was 30.9% with no 
significant gender difference (p = 0.59). Wasting was highest in the older age group 
(54-59), accounting for 7.2% of the overall study group. More than half (53.8%) of 
children in this age group were wasted. Severe wasting accounted for 12.4% of the 
study population and was highest in the 18-23 months and 54-59 months age group. 
Wasting was least observed in the 30-35 age group (3.3%) but also low between 23 – 
41 months. 
Stunting 
Stunting and severe stunting were indicated by height-for-age less than 2 SD 
and 3 SD respectively, of the population using the NCHS/WHO reference data set. 
Table 3.7 shows the demographics of stunting in relation to age groups, gender and 
Hb levels. The prevalence of stunting was 28.9% with no significant difference (p = 
0.58) in relation to gender. 24-29 month age group accounted for the highest 
percentage of stunting (25%).  Severe stunting was 9.3% of the study population with 
the highest percentage seen in the 24-29 age group. It accounted for just under half 
(44.4%) of total severely stunted children, followed in equal numbers by 12-17 
months and 18-23 months age groups (7.1%).  
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Table 3.6 Demographics of weight-for-height category 
 Z score value No.  
Age groups  
(months) Normal < -1 < -2 < -3 p value 
12–17 (%) 8 (14.5) 1 (8.3) 5 (27.8) 1 (8.3) 
NA 
18-23 (%) 14 (25.5) 0 (0) 1 (5.6) 3 (25.0) 
24-29 (%) 9 (16.4) 2 (16.7) 1 (5.6) 1 (8.3) 
30-35 (%) 4 (7.3) 1 (8.3) 1 (5.6) 0 (0) 
36-41 (%) 6 (10.9) 3 (25.0) 1 (5.6) 1 (8.3) 
42-47 (%) 5 (9.1) 1 (8.3) 1 (5.6) 2 (16.6) 
48-53 (%) 6 (10.9) 1 (8.3) 4 (22.2) 1 (8.3) 
54-59 (%) 3 (5.5) 3 (25.0) 4 (22.2) 3 (25.0) 
Gender  
No. (%)     
0.595 
Male  28 (50.9) 4 (33.3) 10 (55.6) 7 (58.3) 
Female 27 (49.1) 8 (66.7) 8 (44.4) 5 (41.7) 
Weight 11.89±2.57 12.14±2.30 11.02±3.07 9.01±2.03 
< 
0.0066 
Height 86.32±10.58 93.67±11.48 91.68±14.98 89.93±13.03 0.146 
Age  
continuous 30.49±13.38 40.25±14.10 36.33±18.18 36.58±17.34 0.286 
Hb1  9.95±0.76 9.51±0.76 9.05±0.53 8.18±0.53 <0.0017 
Prevalence of the different degrees of wasting in children by age, gender and Haemoglobin 
levels.   
Results are expressed as mean±SD 
1including weight as confounding factor 
5Chi-square test 
6ANOVA 
7Analysis of covariance 
 
Although boys were more underweight (P = 0.56), wasted (P = 0.59) and 
stunted (P = 0.58) compared to the girls, the difference was not statistically 
significant. Half of the underweight boys were severely underweight accounting for 
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18.4% of boys whilst 10.4% of girls were severely underweight. Severe wasting and 
stunting was also higher in boys accounting for 14.3% and 12.2% respectively 
compared to 10.4% and 6.3% in girls.  
Table 3.7 Demographics of height-for-age category 
 Z score value No.  
Age groups  
(months) Normal < -1 < -2 < -3 p value 
12–17 (%) 4 (11.8) 5 (14.3) 4 (21.1) 2 (22.2) 
NA 
18-23 (%) 3 (8.8)  9 (25.7) 6 (31.6) 0 (0) 
24-29 (%) 3 (8.8) 3 (8.6) 3 (15.8) 4 (44.4) 
30-35 (%) 1 (2.9) 4 11.4) 0 (0) 1 (11.1) 
36-41 (%) 7 (20.9) 2 (5.7) 0 (0) 2 (22.2) 
42-47 (%) 5 (14.7) 4 (11.4) 0 (0) 0 (0) 
48-53 (%) 5 (14.7) 4 (11.4) 3 (15.8) 0 (0) 
54-59 (%) 6 (17.6) 4 (11.4) 3 (15.8) 0 (0) 
Gender No. 
(%)     
0.585 
Male 15 (44.1) 17 (48.6) 11 (57.9) 6 (66.7) 
Female 19 (55.9) 18 (51.4) 8 (42.1) 3 (33.3) 
weight  13.16±2.51 10.87±2.43 10.38±2.25 9.02±2.28 < 0.0016 
Height  97.24±9.96 
86.61±10.1
4 
82.62±11.1
7 77.07±7.04 0.0016 
Age 
continuous 
38.32±14.4
1 
32.37±15.1
8 
30.53±17.3
5 
26.33±9.34 0.106 
Hb2  9.92±0.86 9.45±0.92 9.36±0.65 8.52±0.81 <0.0017 
Prevalence of the different degrees of stunting in children by age, gender and haemoglobin 
levels. Results are expressed as mean±SD 
2including weight and height as confounding actors 
5Chi-square test 
6 ANOVA 
7Analysis of covariance 
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Haemoglobin levels 
Hb levels showed significant difference in relation to nutritional status. Hb 
levels of malnourished children were significantly lower (p <0.001) than the 
normally malnourished children in all three categories of malnutrition (Table 3.8). 
Hb levels progressively decreased with the severity of malnutrition. The mean 
difference (95% CI) for underweight and wasting were 1.39 (0.90, 1.02) and 0.90 
(0.39, 1.41). Significant difference of Hb levels in the stunting group was only 
observed in children with severe stunting. There was a mean difference (95% CI) of 
1.40 (0.55, 2.25) for severe stunting and 2.10 (1.59, 2.01) and 1.77 (1.17, 2.37) for 
severe underweight and wasting respectively. 
Table 3.8 Analysis of haemoglobin levels in relation to nutritional status 
Nutritional 
Status 
Individual 
differences (Z 
score) Mean difference 
95% Confidence 
Interval8 
WAZ Normal < -1 0.64 0.25, 1.02 
 Normal <-2 1.39 0.90, 1.87 
 Normal <-3 2.10 1.59, 2.61 
 < -1 < -2 0.75 0.28, 1.22 
 < -1 < -3 1.46 0.97, 1.96 
 < -2 <-3 0.71 0.14, 1.29 
WHZ normal < -2 0.90 0.39, 1.41 
 normal < -3 1.77 1.17, 2.37 
 < -1 <-3 1.33 0.56, 2.09 
 < -2 < -3 0.87 0.17, 1.57 
HAZ normal < -3 1.40 0.55, 2.25 
Post-hoc analysis for haemoglobin levels testing each pair of PEM category with 
haemoglobin concentration 
8Independent sample t-test 
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Malondialdehyde (MDA) levels 
In order to assess the relationship between pro-oxidants and PEM, lipid 
peroxide levels expressed in terms of MDA were measured. Plasma MDA levels in 
malnourished children of all three categories were significantly higher (p <0.001) 
compared to the normally nourished children. The mean difference of MDA levels in 
relation to each PEM category is summarised in Table 3.9 and Table 3.10. The 
increase in MDA levels was in relation to the degree of severity of malnutrition with 
the severe forms showing the highest.  
Table 3.9 Malondialdehyde levels in children with different nutritional 
status 
MDA (nmol/ml) normal < -1 < -2 < -3 p value 
WAZ1 0.59±0.25 0.73±0.18 1.05±0.32 1.67±0.71 <0.001 
WHZ1 0.67±24 0.84±0.50 0.99±0.28 1.69±0.73 <0.001 
HAZ2 0.69±0.27 0.87±0.44 0.93±0.36 1.49±0.97 <0.001 
Malondialdehyde levels in different degrees of underweight (WAZ), wasting (WHZ) and 
stunting (HAZ). Results are expressed as mean±SD 
1 including weight as a confounding factor 
2 Including weight and height as a confounding factor 
 
The MDA levels of both wasting and underweight (0.99±0.28 and 1.05±0.23 
nmol/ml), with their severe forms (1.69±0.73 and 1.67±0.71), were significantly 
higher compared to levels in normally nourished children (0.67±24 and 0.59±0.25). 
The mean difference (95% CI) for wasting and severe wasting were -0.32 (-0.59, -
0.04) and -1.02 (-1.34, -0.69) respectively, and underweight and severely 
underweight were -0.45 (-0.74, -0.17) and -1.07 (-1.37, -0.77) respectively, compared 
to normally nourished children. Stunting on the other hand, was only significantly 
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higher in the severe category with a mean difference (95% CI) of -0.80 (-1.25, -0.34) 
when compared to the normally nourished children. The MDA levels in children with 
normal height-for-age, stunting and severe stunting was 0.69±0.27, 0.93±0.36, 
1.49±0.97 nmol/ml respectively. 
Table 3.10 Analysis of malondialdehyde  
Nutritional 
Status 
Individual 
differences (Z 
score) Mean difference 
95% Confidence 
Interval8 
WAZ Normal < -2 -0.45 -0.74, -0.17 
 Normal <-3 -1.07 -1.37, -0.77 
 < -1 < -2 -0.31 -0.59, -0.03 
 < -1 < -3 -0.93 -1.23, -0.64 
 < -2 <-3 -0.62 -0.96, -0.28 
WHZ normal < -2 -0.32 -0.359, -0.04 
 normal < -3 -1.02 -1.34,- 0.69 
 < -1 <-3 -0.85 -1.26, -0.43 
 < -2 < -3 -0.70 -1.08, -0.32 
HAZ normal < -3 -0.80 -1.25, -0.34 
 < -1 < -3 -0.62 -1.07, -0.17 
 < -2 < -3 -0.56 -1.05, -0.07 
Post-hoc analysis for malondialdehyde levels. testing each pair of PEM category with 
malondialdehyde levels 
8Independent sample t-test 
 
3.4 Discussion 
Malaria is endemic in The Gambia with cases occurring throughout the year, 
but peaks during the months of September to November. 39% of infant visits to the 
health facilities are due to malaria infection (GMSP, 2009). Protein energy 
malnutrition affects about 20% of the population in the developing world (FAO, 
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2000). It is mostly seen in children, with 70% from Asia, and Africa and Latin 
America accounting for 26% and 4% respectively (WHO, 2006). 54% of the 10.8 
million deaths per year is attributed to PEM and is directly or indirectly associated 
with infectious diseases among children under 5 years of age in developing countries 
(Schaible et al., 2007). Malaria and malnutrition are sometimes associated in African 
children and both cause high morbidity and mortality (Danquah et al., 2009, Deen et 
al., 2002). 
It was the aim of this chapter to assess the prevalence of malnutrition in 
children with malaria in The Gambia. Using the WHO classification of malnutrition, 
it was observed that 31.6% of children with uncomplicated malaria were 
malnourished. Underweight, wasting and stunting accounted for 30.9%, 30.9% and 
28% respectively. According to The Gambia’s 2010 Multiple Indicator Cluster 
Survey (MICS4), stunting in The Gambia is 23.4%, wasting 9.5% and underweight 
estimated to be 17.4% 16% (MICS4, 2012). The prevalence of stunting has 
decreased when compared to the 2005/2006 MICS3 where stunting was 28% 
(MICS3, 2006). However, wasting and underweight has increased by 2.5% and 1.4% 
respectively.  
Stunting is a measure of chronic malnutrition indicating long term food 
deficiency. Wasting on the other hand is mainly caused by acute or short term food 
deficiency and severe infections and is mostly reversible (Khatab, 2010). Infectious 
diseases can directly or indirectly affect nutritional status of children as is observed 
in children with HIV infection. Krawinkel et al (2012) reported a higher incidence of 
malnutrition in HIV infected children (Krawinkel et al., 2012). The demands of 
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immune responds to infection increase the metabolic demand of the body thus 
increasing anabolic metabolism. Infection can aggravate symptoms like diarrhoea, 
malabsorption and loss of appetite altered metabolism (Katona and Katona-Apte, 
2008).  
The higher prevalence of wasting obtained in this study, compared to the 
national data, might be due to the effects of malarial infection. Children presenting to 
the health facilities usually present late allowing the progression of the infection and 
the initiation of the cascade of malnutrition. Fever, a common symptom of malaria, 
increases the metabolic demands on the body. Other symptoms of malaria like 
diarrhoea and vomiting can cause acute nutrient loss and coupled with loss of 
appetite, might contribute to acute weight loss. 
On the other hand, the higher prevalence of wasting might be associated with 
general food shortage during the malaria season in The Gambia. Both malarial 
infection and food shortage are usually higher during the rainy season, which runs 
from June to October, when food stocks in the rural arears are running low and 
harvest season has not yet started (Jawara et al., 2008, Moore et al., 2001). Food is 
most abundant in The Gambia in November when crop harvest has started (Deen et 
al., 2001), which was in the middle of the study period. Although harvest started 
during most of the study period, the effect of food shortage cannot be excluded as a 
cause of the high prevalence of acute malnutrition. 
There was no significant difference in the prevalence of malnutrition between 
genders. The same was reported by Ubesie et al (2012) in a review covering a period 
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of ten years. Wasting was more prevalent in the older age groups but underweight 
and stunting was higher in the younger age groups (Ubesie et al., 2012). The non-
significant gender difference is in line with WHO figures (WHO). This study 
observed no significant gender difference and there was no age trend in regards to 
the different categories of malnutrition. This might suggest that gender might not be 
a risk factor for developing malnutrition. 
Iron plays a critical role in the oxygen transportation and cellular processes of 
growth division throughout the body. Iron deficiency leads to a decrease in 
haemoglobin concentration, generally known as anaemia. Anaemia is also cause or 
aggravated by infections especially malaria, further increasing mortality risk 
(Bhargava et al., 2001). 96.9% (n=94) of children in the study group were considered 
anaemic with an Hb level <11g/dl. This is significantly higher than results obtained 
from other studies where the prevalence of anaemia was seen in about half of the 
children infected with the malaria parasite (Oladeinde et al., 2012, Bouyou-Akotet et 
al., 2009).  
It would be important to note that anaemia is multifactorial and these children 
might have other underlying comorbidities and malnutrition is one of the most 
important factors. Iron deficiency is the most prevalent micronutrient deficiency 
causing anaemia in 45% of under five years of age (Black et al., 2008). A study in 
Brazil discovered that 88% of children with malnutrition were anaemic with 30% 
having Hb levels < 7g/dl (Caminha et al., 2011). Hb levels were significantly lower 
(p <0.001) in malnourished children regardless of category, and progressively 
decreased with severity of malnutrition. 
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The safety of iron supplementation has also been controversial especially in 
severe malnourished children. Whilst some studies reported an increase 
predisposition of malarial infection with iron supplementation, others have seen no 
harmful effects. Studies have suggested that iron deficiency anaemia might be a 
protective factor for malarial infection and iron supplements might increase 
morbidity and mortality of malaria. A study in Zanzibar, Tanzania prompted the 
WHO and UNICEF in a joint statement recommending that iron should only be 
given to children with anaemia and not as a preventative measure in children in 
malaria-endemic areas (Harding and Neufeld, 2012). It was discovered during the 
process of the investigations that iron supplementation in children led to higher 
hospitalisation or deaths (Sazawal et al., 2006). However, a recent study discovered 
that use of micronutrient powder with iron supplementation was not a risk factor for 
increased malaria incidence in malaria endemic countries with the use of insecticide 
treated bed nets with appropriate malaria treatment (Zlotkin et al., 2013).  
 Even though the specificity of using TBARS assay has been controversial, it 
is still a popular method for the assessment of MDA levels in serum and plasma 
(Catal et al., 2007). Plasma malondialdehyde levels were significantly higher in 
malnourished children in all three categories (p <0.001) compared to normally 
nourished children. These results might suggest increased lipid peroxidation and 
oxidative damage in children with PEM. It is believed that the higher pro oxidants 
found in malnourished children is responsible for the pathological changes such as 
edema, fatty liver and skin lesions (Golden et al., 1990). Although a number of 
studies show children with kwashiorkor to have higher biomarkers of oxidative stress 
when compared to marasmic children (Fuchs et al., 2005, Manary et al., 2000), Catal 
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et al (2010) found high levels of plasma malondialdehyde in marasmic children. Jain 
et al (2008) on the other hand, showed a progressive increase of plasma 
malondialdehyde with severity of PEM regardless of which spectrum of PEM. The 
severe malnourished group in his study were composed of both marasmic and 
kwashiorkor children as well as those who were marasmic-kwashiorkor. The same 
trend was observed in this study where plasma malondialdehyde levels were 
progressively higher with the severity of PEM. This provides evidence that 
malnourished children have less anti-oxidant defence system and increase oxidative 
damage, further predisposing them to infections and other co-morbidities. 
 The data presented in this chapter has shown a high level of wasting and 
underweight in children presenting with uncomplicated malaria, when compared to 
the local data. Progressive increase in plasma malondialdehyde levels with PEM 
severity is a biochemical confirmation of the presence of PEM. Various studies have 
confirmed PEM as a major cause of risk factor in the morbidity and mortality of 
infectious diseases in children, including malaria. The aetiology of PEM however, is 
multifactorial and follows a vicious cycle with infection. The high level of PEM 
observed might be as a result of the combination of the pathophysiology of malaria 
infection, confirming infection as a risk factor for developing PEM. Both malaria and 
malnutrition are known to cause anaemia, thus the high level of anaemia in the study 
population might be multifactorial. 
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4. A High Performance Liquid Chromatography/Tandem Mass 
Spectrometry Method for the Simultaneous Determination of 
Artemether and Dihydroartemisinin in Human Plasma 
4.1 Introduction 
Over the past decades, a number of methods have been developed for the 
analysis of artemisinin and its derivatives in biological samples (Edwards, 1994). 
Developing a sensitive and accurate quantification method had for some time posed 
problems because of their lack of ultraviolet or fluorescent chromophores. They are 
also thermally labile and do not contain functional groups for derivatisation (Tija-
Isavadharm et al., 2004).  
Methods previously used included high performance liquid chromatography 
(HPLC) with UV detection (Batty et al., 1996, Chimanuka et al., 2002, Navaratnam 
et al., 1995,), HPLC with electrochemical detection (Karbwang et al., 1997, 
Melendez et al., 1991), gas chromatography mass spectrometry (Sipahimalani et al., 
1991, Mohamed et al., 1999) and the most recent and sensitive method, liquid 
chromatography with mass spectrometry (Wiesner et al., 2011, Magalhaes et al., 
2010, Huang et al., 2009, Hanpithakpong et al., 2009, Souppart et al., 2002). 
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The need to define and evaluate pharmacokinetic and pharmacodynamics 
(Lindegardh et al., 2011) as well as monitoring plasma drug levels of artemisinin for 
the optimisation of artemether dose treatment (Thuy et al., 2008) has become even 
more important since the publication of a report showing possible drug resistance 
(Yeung et al., 2009). Thus a highly sensitive and specific analytical method for the 
quantification of artemisinin and its derivative is necessary. 
Artemether/Lumefantrine combination was the first fixed dose of Artemisinin 
combination therapy (ACT) and is one of the most widely used therapies (Abdulla et 
al., 2010, Kokwaro et al., 2007). It is a formulated tablet combination comprising 20 
mg artemether and 120 mg lumefantrine (Lefevre et al., 2001).  Artemether is a fat 
soluble semisynthetic derivative of artemisinin. Like other artemisinin compounds, it 
is rapidly absorbed, reaching a maximum plasma concentration at about 2 hours. It is 
extensively metabolised to its active form, dihydroartemisinin, by cytochrome P450 
(CYP) enzymes CYP3A4 with secondary contributions from CYP2B6 AND 
CYP1A2 (). Both artemether and DHA exhibit short elimination half-lives between 2 
to 3 hours (Kokwaro et al., 2007).  
4.1.1 HPLC methods 
 Previously, HPLC with UV detection (HPLC-UV) was used for the 
quantification of artemisinin derivatives and its metabolite. Acid or base hydrolysis 
of the compound was necessary to produce UV chromophores prior to HPLC 
analysis (Lindegardh et al., 2011, Gu et al., 2008). Another HPLC-UV method 
reported LLOQ levels of 10 – 30 ng/ml of artemisinin in plasma. These values were 
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not deemed to be low enough to qualify for bioanalytic quantification according to 
the committee for medicinal products for human use (Gordi et al. 2000).  
The use of electrochemical detection (HPLC-ECD) has become the most used 
technique over the past decades for the determination of these metabolites. This 
detection technique takes advantage of the presence of a peroxide bridge in their 
structure for reductive electrochemical detection (Mohamed et al., 1999), which uses 
electronic capture detection and was shown to enhance sensitivity with limits of 
detection as low as 3ng/mL (Sandrenen et al., 1997, Navaratnam et al., 1997, 
Karbwang et al., 1997). Although the HPLC-ECD method is sensitive and selective, 
it has its limitations. Large sample volumes are needed which might not always be 
possible. The maintenance and cleaning of the electrochemical detector, which is 
needed to keep the sensitivity of the equipment, can be difficult, challenging, 
expensive and time consuming (Megalhaes et al., 2010, Gu et al., 2008, 
Hanpithakpong et al., 2008). HPLC-ECD was the technique of choice until the 
introduction of more sensitive and improved liquid chromatography mass 
spectrometric techniques. 
4.1.2 Mass spectrometry  
Recent more sensitive methods include the use of gas and liquid mass 
spectrometry. Liquid chromatography mass spectrometry (LC-MS) and liquid 
chromatography tandem mass spectrometry (LC-MS/MS) are now considered to be 
the preferred quantification method for the analysis of most drugs including 
artemisinin and its derivatives in biological fluid (Grebe and Singh, 2011). It is 
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proven to be more sensitive and selective whilst using less volume of plasma for 
quantification when compared to HPLC-ECD. It offers the capability of 
simultaneous identification and quantification of several compounds by using their 
mass-to-charge ratio. 
 A triple quadrupole mass spectrometer is the instrument of choice for 
quantitative analysis. It offers different scan types such as neutral loss, precursor ion, 
product ion and multiple reaction monitoring (MRM). The latter is employed for 
quantification purposes and it involves the use of electrospray ionisation followed by 
two stages of mass selection. The first stage (MS 1) selects the mass of the parent ion 
and the second stage (MS 2) selects a specific fragment of the parent (called product 
or daughter ion) after collision with inert gas atoms (Pitt, 2009). Several LC-MS/MS 
methods have been developed and validated for the quantification of artemether and 
its metabolite, dihydroartemisinin. 
A range of LC-MS/MS instruments have been validated successfully for the 
simultaneous analysis of artemether and DHA in human plasma (Wiesner et al., 
2011, Magalhaes et al., 2010, Hunag et al., 2009, Shi et al., 2006, Souppart et al., 
2002), using different extraction techniques. Mass spectrometers used included AB 
Sciex API 4000 (Weisner et al., 2011), PE Sciex API 2000 triple quadrupole (Huang 
et al., 2009), Finnigan Quanum Discovery system (Shi et al, 2006) and a TSQ AP II 
spectrometer equipped with an atmospheric pressure APCI interphase (Souppart et 
al., 2000).  
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Although these studies all reported acceptable precision and accuracy, LLOQ 
obtained ranged from 2 ng/mL (Wiesner et al., 2011, Huang et al., 2009) to 5 ng/mL 
(Shi et al., 2006, Souppart et al., 2002) using different plasma volumes. Results from 
both Haung et al. (2009) and Weisner et al. (2011) showed higher instrument 
sensitivity but Huang et al., concentrated the plasma sample preparation by 
approximately 5 fold. Weisner et al. (2011) on the other hand obtained the same 
values without concentrating plasma samples. This might indicate the superiority of 
the API 4000 over other mass spectrometers 
4.1.3 Sample preparation 
A number of methods exist for preparing plasma samples for analysis by 
mass spectrometry and they depend on the chemical characteristics of the analytes to 
be measured. Blood and blood products contain relatively low analyte 
concentrations, due to in vivo metabolism. This combined with sample matrix effects 
influences the choice of sample preparation (Strathmann and Hoofnagle, 2011). 
Sample preparation methods for artemether analysis include liquid-liquid extraction 
(LLE) (Wiesner et al., 2011, Souppart et al., 2002), solid phase extraction (SPE) 
(Huang et al., 2009), and liquid phase micro extraction (LPME) (Magalhaes et al., 
2010).These methods have been used by different studies in determining artemether 
and DHA in plasma samples.  
LLE is also known as solvent extraction. It is used to separate compounds, 
based on their relative solubility, into aqueous and organic solvents. The two 
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solvents have to be immiscible for separation to occur (Zang et al., 2008). It is 
simple, cheap and is compatible with most analytical systems (Raikos et al., 2009) 
SPE is an affinity-based method used in separating analytes from unwanted 
matrix components. Unlike liquid-liquid extraction which uses two immiscible liquid 
phases, it involves separating unwanted matrix components from the analytes 
between a liquid and a solid phase. The analytes, which have high affinity with the 
solid phase interact with and are absorbed by it, whilst the matrix components have 
the opposite effects. (Zwir-Ferenc and  Biziuk, 2006). 
LPME is a modified form of LLE that uses microliters of solvents for the 
extraction process. The development of LPME was brought about to overcome the 
limitations observed with LLE. These included the tedious multistep technique which 
offered a possible source of contamination or analyte loss with a possible effect on 
measurement outcomes and the use of large amounts of toxic organic solvents 
(Lucena et al., 2009). LPME method is based on diffusion, in which a high partition 
coefficient is used for extraction. Several factors can influence the extraction 
outcome and they include the volume ratio of extractant (acceptor) and sample 
(donor) phases, pH of the phases, ionic concentration of the donor phase, extraction 
time, organic solvent properties and sample agitation. The chemical nature of some 
analytes can give poor partition coefficient thus preventing them from being 
extracted. This has led to the development of various techniques like the supported 
liquid membrane to overcome the problem (Xu et al., 2009). 
 Chapter 4: LC-MS/MS Method 
108 
 
Authors have reported success, though some liquid-liquid extraction methods 
have generated low recoveries prompting many to try solid phase reaction. The 
problem identified in liquid-liquid extraction is the interactions that occur when 
organic solvents are added during sample processing, causing analyte and metabolite 
degradation. Compounds are relatively stable in haemolysed plasma (in the presence 
of iron products) but degrade rapidly when they come into contact with organic 
solvents (Lindergardh et al., 2008). Despite these concerns, the use of liquid-liquid 
extraction is still being used and has proven to be effective (Wiesner et al., 2011) 
4.1.4 Criteria for validation/ Method validation parameters 
Specificity and selectivity 
Specificity is considered as the ability to determine unambiguously the 
analyte of interest in the presence of other compounds. On the other hand selectivity 
refers to the ability to differentiate and measure the analyte in the presence of other 
compounds. 
Linearity 
 The linearity is the ability to test the goodness-of-fit of the model. In other 
words, it is the ability to obtain results that are directly proportional to the 
concentration of analyte in the sample. It is important in validation for the 
exploration of the calibration range for providing an adequate calibration model 
which includes the concentration range within which the method is likely to comply 
with the acceptance requirements. 
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Precision and accuracy 
 The precision is the closeness of agreement between a series of measurements 
obtained from multiple samples taken from the same homogenate sample batch. The 
accuracy is defined as the closeness of test results to the true or reference value. It is 
sometimes referred as bias and it is often measured as a percent deviation from the 
accepted reference value. 
LLOQ and LLOD 
LLOQ corresponds to the lowest concentration that can be quantified within 
acceptable precision and /or accuracy requirements. LLOD is the lowest amount of 
analyte that can be detected. 
Matrix effects 
 It is described as the result of co-eluted matrix components that affect the 
detection capability, precision, or accuracy for the analytes of interest. The main 
manifestation of matrix effect in LC-MS analysis is ion suppression which is 
associated influencing the extent of analyte ionisation. This influence is often 
observed as a loss in response thus the term ion suppression. However, depending 
upon the type of sample it also can be observed as an increase in the response of the 
desired analyte. 
 
 
 Chapter 4: LC-MS/MS Method 
110 
 
Recovery 
 Recovery is related to the extraction efficiency of an analytical method. The 
recovery of a desire analyte compares the detector response obtained from the 
extracted analyte which is spiked into the biological matrix, and the detector 
response obtained for the true concentration of the pure reference standard range 
 The assay range is defined as the interval between the lowest and the highest 
sample concentration for which the quality of precision and accuracy of the method 
is acceptable (Chandramouli et al., 2010) 
4.1.5 Aims 
• To optimise and validate a liquid chromatography mass tandem spectrometry 
to quantify artemether and its active metabolite dihydroartemisinin in human plasma.  
• To optimise and validate liquid chromatography mass tandem spectrometry 
that can be used to analyse patient samples 
4.2 Materials and Methods 
4.2.1 Reagents and materials 
Artemether (ARM), DHA and artemisinin (internal standard, IS) (Fig.1), 
acetonitrile (MeCN), formic acid, methanol, ammonium formate (NH4FA) and water 
were obtained from Sigma Aldrich. All chemicals and water were LC-MS grade. 
Human plasma was obtained from volunteers. 
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4.2.2 Instrument and analytic conditions 
4.2.2.1 HPLC equipment 
HPLC analysis was performed with Dionex Ultimate 3000 micro pump 
system (Thermo Scientific, Warrington, UK). Chromatographic separation was 
performed on C18 XDB analytical column (150mm x 2.1mm, 5µm particle size) 
equipped with its compatible guard column purchased from Agilent. 
4.2.2.2 Chromatographic conditions 
Chromatographic separation was performed according to conditions 
described by Huang et al. (2009) which was modified to improve peak shape for 
accurate quantification. The reported mobile phase used consisted of: solvent A, an 
aqueous 10mM Ammonium formate at a pH of 4.1 and solvent B, Acetonitrile with 
0.1% formic acid. LC elution was accomplished with 20% solvent A and 80% 
solvent B in isocratic mode at a flow rate of 1mL/min for 6mins and the injection 
volume was 50µL. The modified method consisted of the same gradient but solvent 
B was replaced with methanol with 0.1% formic acid at a flow rate of 200µL/min for 
15mins. The pH of NH4FA was adjusted by titration with formic acid. The injection 
volume was 20µL. 
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4.2.3 Optimisation and validation of mass spectrometric conditions 
4.2.3.1 MS instrumentation 
A hybrid triple quadupole/ion trap mass spectrometer (4000 QTRAP) from 
ABSciex (Manchester, UK) was operated in positive mode using the TurbolonSpray 
source.  
4.2.3.3 Tuning and optimisation of source- and compound-dependent parameters 
Source dependent parameters were optimised using flow injection analysis 
(FIA).  Three different values were selected for each of the following parameters: 
Turbo gas (TEM), curtain gas (CUR), nebulizer gas (GS1), auxiliary gas (GS2) and 
the ionspray voltage (IS). Compound dependent parameters defined by the 
manufacturers trademark as declustering potential (DP) and collision energy (CE) 
were optimised by direct infusion. Automatic and manual optimisation was done by 
infusing the mixture of artemether, DHA and the I.S (1µg) at 200 µl/min. 
Ammonium adduct [M+NH4] 
+ ion pairs were selected from Q1. The MRM ion pair 
was m/z 316→267 for artemether, m/z 302→267 for DHA and m/z 300→209 for 
artemisinin (I.S). The optimised acquisition parameters were as follows: Turbo 
(Heater) set at 250°C; Curtain gas (CUR), 40psi (99.9% nitrogen); Nebulizer Gas 
(Gas 1), 60 psi (nitrogen); Auxillary (turbo) Gas (Gas 2), 20 psi (nitrogen); Collision-
Activated Dissociation (CAD) Gas:4: IonSpray Voltage (IS), 5000 v. The optimised 
parameters are summarised in Table 4.1. The scan time was set at 100 ms for each 
transition. Data was processed with analyst software. 
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4.2.3.4 Preparation of calibration standards  
Primary stock solution of artemether, DHA and artemisinin were each 
prepared in methanol at 1 mg/mL. Artemether, DHA and I.S. solutions were diluted 
with 50% methanol in water to prepare working stock solutions (1µg/mL) and 
working solutions. Calibration standards were prepared in concentrations ranging 
from 0.5 - 50 ng/mL. They were prepared in blank human plasma. The I.S. 
concentration was 5 ng/mL. All solutions were kept at -80 °C.  
4.2.3.5 Extraction procedure  
4.2.3.5.1 Method 1 
Analyte extraction was performed according to the liquid-liquid extraction 
method mentioned in Huang et al. (2009). Taking into account the volume of 
samples, 50 µl of plasma was added to 900 µL of methyl t-butyl ether in a glass tube 
instead of the 100 µL.. The mixture was vortexed for 1 min and then placed on a tube 
rotator for 30 min. The extraction tubes were then placed on dry ice until the plasma 
became frozen (~30 sec). The liquid organic phase was then transferred to a clean 
tube and left at room temperature in a vented fume hood overnight to dry. The 
residue was then reconstituted in methanol water (50:50 (v/v) and vortexed for 30 s.  
The samples were then transferred into an auto sampler vial and 20 µl was injected 
into the LC-MS/MS system.  
 Chapter 4: LC-MS/MS Method 
114 
 
4.2.3.5.2 Method 2 
An alternative method for artemether and DHA extraction [17] was employed 
for comparison (Wiesner et al., 2011). The procedure was carried out on ice. 50µl of 
plasma was added to 200µl of Britton Robinson universal buffer (0.1 M, pH 10). 2 
ml ethyl acetate was then added vortexed for 1 min and centrifuged at 16,000 rpm for 
5 min. The organic phase was then transferred to tubes and evaporated under 
nitrogen gas at 30 °C. The residue was reconstituted in methanol water (50:50 (v/v) 
and vortexed for 30 s. The eluents were filtered with 0.25 µm 96 well plate and 
transferred into an auto sampler vial and 20µl was injected into the LC-MS/MS 
system. 
4.2.4 Method validation 
4.2.4.1 Recovery and matrix effects 
The recoveries of the extraction method were prepared by spiking blank 
plasma with known amounts of Artemether, DHA and I.S. Six replicates were carried 
out  at three different levels of concentrations, low 5 ng/mL, medium 15 ng/mL and 
high 50 ng/mL. Recovery was determined by comparing the peak areas of the spiked 
compounds in plasma against their corresponding solutions. 
The recovery of each of the compounds was calculated using the formula below 
Recovery =  
A
B
 x 100 
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Where set A was the mean peak area (n=6) of the compound spiked in plasma prior 
to extraction. Set B was the mean peak area (n=6) of neat solution of the compounds. 
For the matrix effects, six replicates of plasma were post extraction. The 
matrix effects was determined using the formula below 
Matrix effects = ( C
B
 - 1 ) x 100 
Where set A and B is the same as above and set C the mean peak area (n=6) of 
spiked plasma after extraction. 
4.2.5.2 Calibration curve, reproducibility and precision 
Calibration curves were obtained by linear regression of the peak area ratio of 
the analyte to the internal standard (Y-axis) versus the nominal analyte 
concentrations (X-axis). The plots showed linearity (R² ≥0.99). Calibration curves in 
plasma were constructed by spiking blank plasma with standard solutions of 
Artemether and DHA to produce concentrations of 0.5 – 50 ng/mL. I.S was added to 
make 5 ng/mL. Eight point calibration curves were constructed for each run. 
Reproducibility and precision of the method was assessed by determining 
the-inter and intra-day variability of the compounds in plasma.  Intra-assay (within–
day) precision and accuracy was determined by analysing six replicated of three 
concentrations (low, medium and high) 5, 15 and 50 ng/mL, of each analyte in the 
same day and run. The inter assay (day to day) variability was assessed by analysing 
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3 replicates of the three concentrations (5, 15 and 50 ng/mL) of artemether and DHA 
on three different days. The relative standard deviation (RSD) was then calculated.   
The accuracy of the method was assessed by comparing values from the spiked 
plasma at low, middle and high concentrations and comparing them with values from 
the neat solutions using the matrix matched calibration curves.  
4.2.5.3 Lower limit of quantification (LLOQ) and Lower limit of detection (LLOD) 
LLOQ corresponds to the lowest concentration that was quantified within 
acceptable precision and/or accuracy requirements. LLOD is the lowest amount of 
the analyte that can be detected. LLOD were found by injecting 20 µl of spiked 
plasma and solution mixture at decreasing concentrations using signal-to-noise 
approach of 3:1 for LLOD and using the lowest drug concentration that could be 
determined with an accuracy of 80 – 100 % and a precision of ≤ 20 % for LLOQ. 
4.3 Results and discussion 
4.3.1 LC-MS/MS optimisation 
Simultaneous determination of artemether and DHA in human plasma have 
been analysed using a range of different analytical methodologies, but the most 
recent methods  employed are liquid chromatography mass spectrometry (Wiesner et 
al., 2011, Magalhaes et al., 2010, Huang et al., 2009). Initially, a 2000API ABSciex 
mass spectrometer was employed for method optimisation. However, this instrument 
proved to be inadequate for the required sensitivity. 
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The 4000 QTRAP mass spectrometer is characterised for its enhanced 
sensitivity and selectivity compared to previous generations of triple quadrupole 
instruments. MS/MS scans were performed in MRM mode. Reversed-phase 
separation on a C-18 column was achieved for artemether, DHA and the internal 
standard quantitative and qualitative analysis (Huang et al., 2009, Souppart et al., 
2002). The MRM optimisation procedure involves a sequence of experiments where 
the voltages of the various ion optics parameters (i.e DP and CE) are ramped to 
determine the maximum signal intensity for each ion (Grebe and Singh, 2011). 
 
Table 4.1 MS/MS product ion spectra of precursor ions of artemether, DHA 
and I.S 
Name, m/z DP EP CE CxP 
     
ARM, 316/267 30 3 10 8 
DHA, 302/267 30 6 15 10 
Artemisinin 300/209 23 12 15 12 
MS/MS product ion spectra of the precursor ions of artemether, DHA and artemisinin (I.S). 
DP is declustering potential, EP is entrance potential, CE is collision energy, CxP is collision 
exit potential 
The values were first scanned automatically by using an application of the 
software (Analyst. software version 1.5 (AB Sciex)) that operated the instrument. 
Manual optimisation of compound dependent parameters were also performed to 
verify those values obtained automatically. The selected parameters are shown in the 
Table 4.1. Ammonium adducts [M+NH4] 
+ were selected for the detection of the 
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analytes. The precursor-product ion pairs monitored in MRM mode were 316/269 for 
Artemether, 302/267 for DHA and 300/209 for the internal standard Artemisinin.  
The ion pairs obtained were consistent with reports from Huang et al (2009) 
although they used API 2000. The optimised acquisition parameters derived were as 
follows: Curtain gas (CUR) – 40 psi, IonSpray (I.S) voltage – 5000V, Temp - 250°C 
gas 1 (GS1) – 60 psi and gas 2 (GS2) – 20 psi. These parameters were consistent 
with those reported by Weisner et al (2011) who also used QTrap 4000. The organic 
mobile phase was changed from acetonitrile to methanol to obtain better and sharper 
peaks. The run time was then increased 5 min to 13 min because artemether took 
longer to elute in methanol compared to acetonitrile. The average eluting times for 
artemether and DHA were 9.5 and 4.1 min respectively, and 3.9 min for artemisinin 
as shown in figure 4.1. 
4.3.2 Sample preparation 
The extraction procedure of choice in clinical samples is critical because it 
needs to be robust and sensitive (Strathman and Hoofnagle, 2011). Some reports 
have suggested the degradation of compounds when samples came into contact with 
organic solvents during sample preparation especially when employing liquid-liquid 
extraction, which is thought to be minimised in solid phase extraction. Another 
aspect that is critical in sample preparation is the drying step as compound loss might 
occur when using Nitrogen gas (Huang et al., 2009). Nevertheless, several studies 
have shown good recovery levels with liquid-liquid extraction using different organic 
solvents (Wiesner et al., 2011, Malgahaes et al., 2010, Souppart et al., 2002).
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Figure 4.1 Chromatographs of DHA, artemether and I.S 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Representative chromatographs at 20 ng concentration (I.S – 5 ng/ml) of DHA, artemether and artemisinin in drug solution and spiked 
plasma.
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Two liquid-liquid extraction methods were compared. These methods were 
selected on the basis of their low cost, ease of setting up and reproducibility. The 
method mentioned by Huang et al (2009) showed recoveries of more than 80% on 
extraction of samples. A second method by Weisner et al. (2011) was also employed 
for comparison purposes. Both methods were adapted to use less plasma (50 µl) than 
the volume reported. 
4.3.3 Method validation 
4.3.3.1 LLOD and LLOQ 
The LLOD for artemether and DHA were 0.1 ng/ml and 0.4 ng/ml, 
respectively. The LLOQ were determined to be 0.3 for artemether and 1ng/ml for 
DHA. Other published data have showed LLOQ to be 2 ng/mL (Wiesner et al., 2011, 
Huang et al., 2009) and 5ng (Souppart et al., 2002, Mohamed et al., 19990 for both 
artemether and DHA. Huang et al. reported having LLOQ of 1ng/ml with liquid-
liquid extraction but was not reproducible prompting them to use solid phase 
extraction. None of the literature reviewed (Wiesner et al., 2011, Huang et al., 2009, 
Souppart et al., 2002) mentioned their LLOD except one (Mohamed et al., 1999)that 
reported a LLOD of 2ng/ml. The present LC-MS/MS method showed better 
sensitivity compared to previously reported values for LLOD and LLOQ for the 
simultaneous determination of artemether and DHA in clinical samples even using 
lower sample volumes.  
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4.3.3 Linearity 
Figure 4.2 Standard calibration graphs for artemether and DHA 
 
 
Representative graph of standard calibration lines for artemether (A) and DHA (B) 
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An appropriate calibration model is essential in obtaining reliable analyte 
quantification. The relationship between analyte concentration in the samples and 
detection response was investigated by using internal standardisation. Standard 
curves were evaluated and found to be linear in the range between 0.5 to 50 ng/mL. 
Linearity was lost after 50 ng/mL. Representation of calibration lines for artemether 
and DHA are shown in Figure 4.2. Linear regression on the concentration data 
showed that both analytes were linear for the same range of concentrations (R2 
≥0.99). 
4.3.4 Matrix effects and use of internal standard 
Internal standardisation was selected to obtain accurate quantification of the 
analytes. Artemisinin was used as an internal standard because it has similar 
chemical composition as artemether and DHA, and is relatively stable. Artemisinin 
also provides a good intra and inter-assay precision and provides compensation for 
unforeseen matrix effects (Lindegardh et al., 2009) and has also been used previously 
as an internal standard (Huang et al., 2009, Classen et al., 1999) hence its use in this 
study. 
The determination of matrix effect is important for precision, accuracy and 
robustness of a bioanalytical method (Chambers et al., 2007). Matrix effects of the 
compounds were evaluated during the validation of the LC-MS-MS method. Dried 
extracted plasma samples were reconstituted with 50% methanol and spiked with 
artemether, DHA and the I.S. at high (50 ng/mL), middle (15 ng/mL) and low (5 
ng/mL) concentrations. The mean response of each analyte spiked post extraction 
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was compared to the same analyte concentration in solution. The matrix effect for 
artemether, DHA and the I.S are shown in Table 4.2.The results show that the 
analytes and internal standard were not significantly affected by ion suppression. The 
matrix effect for DHA showed 4, 7 and 2 % enhanced for 5, 15 and 50 ng/ml 
concentration and artemether showed 2 % suppression for 5 ng/mL and 0 % and 2 % 
enhancement for 15 and 50 ng/ml.  
4.3.5 Precision and accuracy 
Plasma samples were extracted by using Method 1, described earlier. 
Artemether and DHA spiked drug free plasma samples were prepared at low, 
medium and high concentrations. Six replicates of extracted spiked samples of both 
analytes were run in sequence on three different days. This was performed in order to 
obtain intra and inter-day precision and accuracy. Recovery was calculated by 
comparing the response of plasma samples spiked with Artemether and DHA 
standards prior to extraction, with corresponding standard solution concentrations at 
low, medium and high concentrations. The recoveries for Artemether, DHA and the 
I.S are shown in Table 4.3. Percentage recoveries for artemether (n=6) at low and 
middle concentrations were 82 % and high concentration at 80 %. 
DHA showed recoveries of 102, 97 and 84% for low, middle and high 
concentration and the I.S had recoveries between 73 to 76%. Recoveries by 
published data have shown percentages ranging from 73 to 95% for artemether and 
76 to 99% for DHA (Wiesner et al., 2011,Huang et al, 2009 Souppart et al., 2002, 
Mohamed et al., 1999). Souppart et al. (2002) and Wiesner et al. (2011) employed 
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liquid-liquid extraction and obtained recoveries of 76 and 84% and 80 and 77% and 
86 and 76% for low and high concentrations of artemether and DHA respectively. 
These results are consistent with those obtained in this study. 
Table 4.2 Recovery values of artemether, DHA and I.S  
 Conc 
(ng/mL) 
% Recovery±SD 
(n=6) 
%CV 
ARM 5 82±5.9 7 
 15 82±2.3 3 
 50 80±1.1 1 
    
DHA 5 102±14.6 14 
 15 97±8.4 9 
 50 84±2.1 3 
    
I.S 5 73±4.2 6 
 15 76±2.8 4 
 50 73±0.7 1 
Recovery expressed in % ± SD. Precision is expressed in %CV 
 
Studies that employed solid phase extraction showed recoveries of 95% 
(Mohamed et al., 1999) and  81 and 73% for high concentrations of artemether and 
92% and 99 and 90% for DHA (Huang et al., 2009). Lindegardh et al. (2008) 
discussed in detail the problems that occur during analyte analysis highlighting that 
sample processing is the most critical step during analysis. 
It has been previously mentioned that organic solvent added to plasma during 
sample preparation may cause significant analyte degradation and a solid phase 
extraction method was proposed as an alternative solution (Lindegardh et al., 2008). 
However, a report showed that it might not be superior to liquid-liquid extraction for 
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artemether analysis. Huang et al. (2009) on the other hand obtained significantly 
higher recoveries, from 40-60 % to around 84 %, when the organic solvent was left 
to dry at room temperature. This highlights that low recoveries obtained from liquid-
liquid extraction might not necessarily be due to the addition of organic solvents but 
the drying process.  
Table 4.3 Intra-assay variation of artemether and DHA in plasma 
 Conc 
(ng/mL) 
Mean±SD 
(ng) 
%CV Accuracy 
ARM 5 4.5±0.2 4.4 90 
 15 14.8±0.7 4.7 99 
 50 49.5±2.9 5.8 99 
     
DHA 5 4.2±0.5 11.9 84 
 15 14.6±1.1 7.5 97 
 50 46.1±4.4 9.5 92 
Recovery is expressed in % ±SD n=6. Accuracy is expressed as %. Precision is expressed in 
%CV 
 
Table 4.4 Intra-assay variation of artemether and DHA in plasma 
 Conc 
(ng/mL) 
Mean±SD 
(ng) 
%CV Accuracy 
ARM 5 4.7±0.4 8.5 94 
 15 14.4±0.3 2.1 96 
 50 47.5±1.7 3.6 95 
     
DHA 5 4.5±0.7 8.8 90 
 15 12.4±1.1 8.9 83 
 50 42.7±4.3 10.1 85 
Recovery is expressed in % ±SD n = 6. Accuracy is expressed as %. Precision is expressed 
in %CV 
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The results of intra-day accuracy for the analytes ranged between 92 to 99% 
from low to high concentrations for artemether and 84 to 97% for DHA (Table 4.4). 
Inter-day accuracy ranged between 94 to 96% and 83 to 90% for artemether and 
DHA (Table 4.5). Intra-day precision ranged from 4.4 to 5.8 % for artemether and 
7.5 to 11.9 % for DHA and inter-day precision ranged from 2.1 to 8.5 % for 
artemether and 8.8 to 10.1 % for DHA. 
The percent coefficient of variance (% CV) value for both analytes at low, 
middle and high concentrations were all <15% which is in accordance with the 
suggested guidelines for quantitative bioanalysis provided by the FDA (Viswanathan 
et al., 2007).  
4.4 Conclusions 
 A sensitive and robust LC-MS/MS was developed for the simultaneous 
analysis of artemether and DHA. This method has shown that liquid-liquid extraction 
method can provide good recoveries using relatively low sample volumes and 
showing good accuracy and precision in accordance with the FDA guidelines. The 
extraction method is relatively cheap and simple which are important considerations 
in drug analysis and monitoring in developing countries with limited resources. It 
makes it a reliable methodology for the simultaneous quantification of artemether 
and DHA in plasma in vulnerable population such as children and pregnant women 
where sample collection volume might be limited. 
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5 Plasma level of Artemether and Dihydroartemisinin (DHA) in 
malnourished children 
5.1  Introduction 
 In response to widespread resistance of the malaria parasite to traditional 
antimalarials, the WHO recommended the use of artemisinin-based combination 
therapy (ACT) for the treatment of uncomplicated malaria. ACT is a combination of 
a short acting artemisinin derivative (artemether and artesunate) with a longer acting 
drug. This is designed to impede the emergence of parasite resistance and avoid the 
high recrudescence rate observed in artemisinin monotherapy (WHO, 2001).  
ACTs are known to be efficacious and safe in children and are recommended 
for children from > 6 months and 5kg.  Although there has been a decline in the 
incidence of malaria by 17% between 2000 and 2010, children under the age of 5 
years still account for 85% of the deaths (Mwesigwa et al., 2010, Stepniewska et al., 
2009). 
Of the ACT’s Artemether/lumefantrine combination was the first pre-
qualified fixed dose recommended by the WHO and is the most widely adopted ACT 
in Africa. The two drugs show synergistic action against P. falciparum and act at 
different stages of the parasite life. A tablet contains 80mg of artemether and 120 mg 
of lumefantrine (Premji, 2009). Table 5.1 shows the dosage regimen per kg body 
weight.
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Table 5.1  Artemether/Lumefantrine Dosage Regimen 
Weight (Kg) Number of tablets (0, 8h, 
24h, 36h, 48h, & 60h) 
Artemether/lumefantrine 
5 – 14 1 20 mg A + 120 mg L 
15 – 24 2 40 mg A + 240 mg L 
25 – 34 3 60 mg A + 360 mg L 
>34 4 80 mg A + 480 mg L 
Artemether (A) and lumefantrine (L) combination tablets per dose in milligrams (mg) per 
kilogram (KG) bodyweight. Each tablet contains 20 mg of artemether and 120 mg of 
lumefantrine. 
Artemether is a lipid soluble derivative of artemisinin and is relatively stable 
in biological fluids. Although the exact mechanism of action of the artemisinin 
derivatives in the malaria parasite is still under debate, the involvement of iron for its 
activation is widely accepted (Stocks et al., 2007, Haynes et al., 1996, Meshnick et 
al., 1991). Artemether has extensive first pass metabolism which contributes to its 
incomplete oral bioavailability (Kokwaro et al., 2007). Food has a significant effect 
on artemether bioavailability. There is a two fold increase in artemether in 
individuals who have consumed a high fat meal compared to fasted individuals 
(White et al., 1999). Artemether is readily absorbed and peaks in plasma in 1.5 to 2 h 
(White et al., 1999, Ezzet et al., 1998). It is highly bound to plasma proteins (92 to 98 
%) primarily to α1- acid glycoprotein (33%), albumin (17%), high density 
lipoproteins (12%) and low density lipoproteins (9.3%) (Aweeka and German, 2008, 
White et al., 1991). 
Artemether hydrolyses in vivo to its active metabolite dihydroartemisinin 
(DHA) (A), predominantly via the activity of the cytochrome P450 (CYP) enzymes 
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CYP3A4 and CYP3A5. DHA is intrinsically more active as an antimalarial, (Van 
Agtmael et al., 1999, Lefévre et al., 1999). Figure 5.1 shows a chemical illustration 
of the metabolic pathway of artemisinin, the parent compound of artemether The role 
of intestinal CYP3A4 was established with studies where grapefruit juice, an 
inhibitor of CYP3A4, caused the plasma concentration of artemether to double (Van 
Agtmael et al., 1999). 
Figure 5.1 Metabolic pathway of the artemisinin compounds 
Schimatic diagram of the major and minor metabolic pathway of the artemisinin compound. 
* Sites of CYP-mediated hydroxylation, Gluc: A glucoronide group  
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DHA reaches plasma peak concentrations around 2 h after dosing and is 
converted to inactive metabolites (B) and rapidly cleared by phase II 
glucoronidation, via the uridine 5’-diphosphate-glucuronosyltransferases (UGT) 
family of enzymes, UTG1A1, 1A8/9 and 2B7 (Maggs et al, 2000, Batty et al., 1998). 
In addition, chemical activation of the endoperoxide group can occur in the systemic 
circulation leading to the formation of two minor metabolites, the THF acetate 
isomer (C), and hydroxydeoxo isomer (D) (Figure 5.1) and are excreted as their 
glucoronide counterparts (Maggs et al., 1997). 
Although ACT is the recommended treatment of uncomplicated malaria in 
children > 6 months/ > 5kg, published pharmacokinetic studies are mostly limited to 
adults with little detailed information for children. Paediatric dosing is mainly 
derived from adult-based regiments adjusted for body weight (Mercer and Sarr 
Sallah, 2011). Table 5.2 summarises the findings of pharmacokinetic studies in 
children. Pharmacokinetics of rectally administered artesunate is the most well-
studied dosing regimen in children (Keranjeewaet al., 2004, Halpap et al., 1998, 
Sirivichayakul et al., 2007, Sabchareon et al., 1998, Krishna et al., 2001, WHO, 
2002).  
Differences in study design and blood sampling schedules, in addition to the 
small groups of subject studies, can introduce errors and skew pharmacokinetic 
values. However, despite this, similar values of DHA were reported for each 
paediatric studies. Similar Cmax values were also reported when studies of similar 
designs were compared between adult and paediatric groups but on the contrary, 
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AUC values was higher and tmax values almost double in adults when compared to 
the paediatric population (WHO, 2002).  
Pharmacokinetic properties of several orally administered ACT has also been 
studied in children (Mwesigwa et al., 2010, Abdulla et al, 2008, Sabchareon et al., 
1998, Ramharter et al, 2007, Sidhu et al., 1998, Ramharter et al., 2008), with 
artesunate being the most common ACT. Sidhu et al (1998) investigated potential 
differences between adults and children. It was reported that adults clearance rate  
(CL) in adults were slightly lower compared to children which may explain the 
reported longer half-life in of artemisinin in adults (2.6 h) than children (1.8 h). This 
is comparable to data from intra rectal studies demonstrating that adults may be 
exposed to higher amounts of drugs due to decreased clearance.  
Physiological parameters of development and nutrition in children with 
malaria, in combination with the variable physiochemical properties of the ACT, can 
affect drug absorption, metabolism and excretion and hence determine individual 
drug exposure levels (Van den Anker, 2010, Mahmood, 2007). Malnutrition and 
malaria cause high morbidity and mortality and are sometimes associated, especially 
in Sub-Saharan Africa (Fillol et al., 2009). Morbidity and mortality of malaria is 
increased in children with PEM with the protective efficacy of intermittent 
preventive treatment observed to be 50% compared to normally nourished children 
(Danquah et al., 2009, Deen et al., 2002). 
Chapter 5: Pharmacokinetics of Artemether and DHA 
132 
 
Table 5.2 Summary of pharmacokinetic studies in paediatric patients treated with ACT 
Source Country Dose mg/kg Population Study Design Cmax DHA (µM) Tmax DHA 
(h) 
AUC0-∞ 
(µmol.h.L-1) 
Rectal Administration (Artesunate Montherapy) 
Halpaap et al 
(1998) 
Gabon 1.8 
(median) 
 
7 - 12 years 
12 patients 
(u.m.) 
Blood samples collected 
at 0.5, 1, 3 h following 
first dose and 0.5 h 
following second dose 
at 4 h. 
0.6 (55) 1.1 (51) N.D. 
Sabchareon et 
al 
(1998)  
Thailand 15 
(median) 
 
(+ 
mefloquine) 
5 – 12 years 
9 patients 
(u.m.) 
 
Blood samples collected 
at 0, 0.5, 1, 1.5, 2, 3, 4, 
6, 12, 24, 30, 36, 48, 54, 
60, 72 h following 
administration. 
2.4 (87) (range 0.3 
-5.7) 
N.D. *6 (0.2 – 8.7) 
Karunajeewa et 
al (2004)  
Papua New 
Guinea 
13 5 – 10 years 
47 patients 
(u.m.) 
Blood samples collected 
at 0, 1, 2, 3, 4, 6, 8 ,12 h 
following first dose and 
at 2, 4, 8, 12 h 
following second dose 
at 12 h. 
2.5 (range not 
stated) 
2.3 
(range not 
stated) 
N.D. 
Krishna et al 
(2001) 
Ghana 10 
 
20 
2 – 7 years 
26 patients 
(m.s.m) 
Blood samples collected 
at 0, 0.25, 0.5, 1, 1.5, 2, 
4, 8, 12 h following 
dose. 
2.4 (0.8 – 5.8) 
3.1( 0.7 – 6.8) 
1.7 ( 0.9 – 
3.2) 
1.8 ( 0.6 – 
3.3) 
9.8 (1.4 – 
28.2) 
13.2 (2.9 – 
26.2) 
Sirivichayakul 
et al (2007) 
Thailand 10 
 
 
20 
5 – 10 years  
16 patients 
(u.m.) 
Blood samples collected 
at 0, 0.5, 1, 1.5, 2, 3, 4, 
6, 8 h following dose. 
3.2 (1.2 -6.6) 
 
5.4 (0.7-16.1) 
1.5(1.0-3.0) 
 
2.0 (1.0 -4.0) 
8.5(0.1 – 
50.1) 
 
19.8 (4.4 – 
63.0) 
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WHO (2002) Ghana 
 
 
Thailand 
 
South 
Africa 
10 
20 
 
10 
20 
 
10 
2 – 7 years 
36 patients 
Adults  
96 patients  
 
27 Patients 
(m.s.m.) 
Blood samples collected 
at predose to 12 h post 
dose. 
 
Abbreviated sampling 
predose to 8 h post dose 
. 
2.8 (50) 
4.0 (75) 
 
3.8 (68) 
7.1 (80) 
 
3.0 (79) 
1.8 (49) 
2.2(53) 
 
2.8 (61) 
4.2 (50) 
 
4.4 (52) 
9.8 (72) 
18.6 (130) 
 
15.1 (106) 
40.1 (104) 
 
14.3 (76) 
Oral Administration (ACTs) 
Bethell et al 
(1997) 
Vietnam 3  
 
 
Artesunate 
6 – 15 years 
10 patients 
(m.s.m) 
Blood samples collected 
at 0, 0.25, 0.5, 1, 2, 3, 4, 
6, 8, 10, 12, 24 h 
following 
administration 
2.4 (CI 95% 1.3 – 
3.3; range 0.6 – 
4.9) 
1.7 (CI 95% 
0.8 – 2.6; 
range 0.3 – 
4.0) 
4.5 (CI 95% 
3.1 –6.0; 
range 2.1 – 
8.0) 
Ramharter et al 
(2007) 
Gabon 4 (granules) 
 
 
 
8 (co-blister) 
Artesunate 
 (+ 
mefloquine) 
10 - 20 kg 
 
 
 
 
20 – 40 kg 
12 patients 
(u.m.) 
Blood samples collected 
at 0, 0.5, 1, 1.5, 2, 3, 6 h 
following 
administration 
2.9 (CI 90% 2.4 – 
5.9;  range 0.5 – 
11.9) 
 
3.1 (CI 90% 2.6 – 
5.0;  range 1.0 – 
7.7) 
1.5 (1.1 – 6.1 
 
 
 
1.5 (0.4 – 
4.1) 
10.1 (CI 
90% 7.7 –
14.5; range 
4.9 – 23.5) 
 
9.4 (CI 90% 
7.3 –14.8; 
range 3.7 – 
27.4) 
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Ramharter et al 
(2008) 
Gabon 6:2 (A), 9:3 
(B), 12:4 (C) 
ratio 
(pyronaridine:
artesunate) 
 
Tablets (fixed-
dose 
combination) 
2 -14 years 
10 – 40 kg 
 
 
 
60 patients 
(u.m.) 
Blood samples collected 
at 0, 0.25, 0.5, 1.0, 1.5, 
2.5, 4.0, 8.0, and 12.0 h 
following 
administration of first 
drug. 
A – 1.7 ± 1.1 
 
B - 3.3 ± 1.9 
 
C – 4.2 ± 1.3 
A – 1.4 ± 0.7 
 
B – 1.7 ± 1.9 
 
C – 1.7 ± 0.6 
A – 3.7 ± 1.6 
 
B – 7.0 ± 3.8 
 
C – 10.4 ± 
3.4 
Sabchareon et 
al (1998) 
Thailand 6 
 
Artesunate       
(+ 
mefloquine) 
5 – 12 years 
10 patients 
(u.m.) 
Blood samples collected 
at 0, 0.5, 1, 1.5, 2, 3, 4, 
6, 12, 24, 30, 36, 48, 54, 
60, 72 h following 
administration. 
7.0 (71) (range 1.1 
– 16.0) 
N.D. *13.2 (61) 
(range 2.4 – 
27.1) 
Mwesigwa et al 
(2010) 
Uganda 4 
Artesunate       
(+ 
amodiaquine) 
 
2  
Artemether      
(+ 
lumefantrine) 
5 – 13 years 
45 patients 
(u.m.) 
Blood samples collected 
at 0, 2. 4, 8, 24, 120 h 
following 
administration 
1.5 (1.5 – 2.2)  
 
 
0.4 (0.4 – 0.5) 
Artemether: 0.1 
(0.1 – 0.2)  
N.D. 4.9 (4.6 – 
6.1) 
 
 
1.3 (1.2 – 
1.5) 
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Abdulla et al 
(2008) 
Benin, 
Kenya, 
Mali, 
Mozambiq
ue, 
Tanzania 
1.5 – 4 (based 
on number of 
tablets per 
weight group) 
 
Crushed 
tablets 
 
Dispersible 
 
Artemether (+ 
Lumefantrine) 
0 – 12 years 
5 – 35 kg 
(u.m.) 
 
91 patients 
 
 
93 patients 
 
 
Blood samples taken at 
1 and 2 h following 
administration 
 
 
 
 
 
0.2 (90) 
Artemether: 0.6 
(96) 
 
0.2 (102) 
Artemether: 0.6 
(88) 
N.D. N.D. 
Sidhu et al 
(1998) 
 
Values reported 
for artemisinin. 
Vietnam 10  
 
Artemisinin 
2 – 12 years 
23 patients 
 
Adults 
16 – 45 years) 
31 patients 
(u.m.) 
Blood samples collected 
at 0, 2.5 or 4, 8 h in 
children and 0, 2.5 or 4, 
10 h in adults following 
administration 
 
Clearance (CL/F) 
13.2 (8) L.h-1kg-1 
 
402 (5) L.h-1 
(9.3 L.h-1kg-1 based 
on median weight 
46.5 kg) 
Distribution 
Volume 
(V/F) 
36.7 (9) 
L.kg-1 
 
1504 (6) L. 
(34.4 L.kg-1 
based on 
median 
weight 46.5 
kg) 
 
*AUC0 – 12 
ACT: Artemisinin combination therapy; DHA: Dihydreoartemisnin; MSM: Moderately severe malaria; UM: Uncomplicated malaria 
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Despite the high morbidity and mortality caused by PEM in children, 
pharmacokinetic studies of essential drugs have declined since the 1970 (Oshikoya et 
al., 2010), with no known published studies in the artemisinin compounds. The 
current recommendation for the treatment of uncomplicated malaria for normally 
nourished children is the same as children with PEM (WHO, 2010). 
It is important to consider the potential pathophysiological effect of 
malnutrition on absorption, distribution, metabolism and excretion of the artemisinin 
compounds. The absorption of lipids and fats are specifically reduced which may 
affect the more lipid soluble drugs (Murphy et al., 2002) like artemether. 
Artemether is primarily bound to α1- acid glycoprotein (AAG) (Aweeka and 
German, 2008, White et al., 1991), in a reversible state of equilibrium which is 
generally maintained between bound and unbound drug fractions. Only free 
(unbound) drug fractions can distribute into tissue compartments thus any changes in 
their concentration might have an effect in artemether distribution. AAG 
concentration is decreased in disease state and malnutrition, which substantially 
increase plasma free drug in plasma. As a result, there may be greater amount of 
free-drug fraction of artemether in plasma and children with malnutrition may 
experience variations in their response to drug treatment or be at risk of increased 
drug toxicity (Oshikoya and Senbanjo, 2009). 
 In addition to decreased drug absorption, physiological effects of PEM can 
result in reduced drug-binding capacity, altered volume of distribution (Vd), 
increased half-life (t1/2), altered drug biotransformation and reduced elimination and 
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clearance (CL). These changes might have potential efficacy and safety issues in 
children with PEM, and thus might require drug-dosage adjustment (Oshikoya and 
Senbanjo, 2009, Oshikoya et al., 2010).  
PEM can significantly impact on the degree of hepatic metabolism with 
animal studies showing a 55% reduction of total hepatic CYP activity (Cho et al., 
1999). It also affects glucuronidation, a major DHA metabolism pathway, due to 
decreased blood glucose which is essential in the synthesis of glucuronic acid 
(Hamberg et al., 1990). 
A review done by Mercer and Sarr Sallah (2011) has highlighted the potential 
effects of PEM on the pharmacokinetic properties of ACT, which might have an 
impact on efficacy and safety of these drugs on children with PEM. The review 
discussed the effect of PEM on the absorption, metabolism and excretion of the ACT 
compounds with the extent of the effects dependent on the type and severity of PEM.  
The effects of PEM may lead to an increased total body weight, delayed or decreased 
absorption of lipid soluble ACT, reduced protein binding capacity, altered volume of 
distribution (Vd), increased half-life (t1/2), altered biotransformation and reduced 
elimination and clearance (CL), with a potential of altering the efficacy and safety of 
the ACT in children with PEM (Mercer and Sarr Sallah, 2011).  
Iron deficiency anaemia is a common condition associated with PEM as a 
result of low iron levels from poor nutrition (Macdougall et al., 1982). Another 
important factor highlighted in the review was the possible importance of iron 
deficiency.  Due to the importance of iron in the bioactivation of the artemisinin 
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compounds, it was suggested that low levels could alter the pharmacological and 
toxicological profile leading to a decrease in the pharmacological activity in infected 
red blood cells or decreased extracellular detoxification resulting in the alteration of 
the benefit:risk ratio (Mercer and Sarr Sallah, 2011). 
The use of ACT is increasing, especially in children under five years of age, 
who suffer the highest morbidity and mortality from malaria. Currently, the 
paediatric dosage is derived from adult based dosing regimen with no consideration 
regarding nutritional status. Protein energy malnutrition may have an impact on the 
absorption, distribution metabolism and detoxification of artemisinin drugs. Due to 
the prevalence of PEM in many malaria endemic countries, it is important to study 
the pharmacokinetic properties of these compounds in children with PEM.  
The primary aim of this chapter was to investigate whether the current dose 
of artemether/lumefantrine (AL) provides adequate plasma drug concentrations for 
maximal drug efficacy in children with PEM. Artemether and DHA plasma 
concentrations in Gambian children were assayed, after the first dose of 
artemether/lumefantrine combination, using liquid chromatography-tandem mass 
spectrometry (LC-MS/MS).  
The secondary aim of the study is to assess the effect of haemoglobin on the 
plasma concentration of artemether and its active metabolite, DHA. Artemether and 
DHA plasma concentrations were analysed against the haemoglobin levels of 
children. 
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5.2  Materials and methods 
5.2.1 Study design and population 
The study area and participants were the same as that described in Chapter 3, 
section 3.21 and 3.22. Briefly, children diagnosed with uncomplicated malaria and 
taking artemether/lumefantrine treatment were approached. Confirmation of a 
positive blood malaria smear, and haemoglobin concentration were available from 
the laboratory reports. 
5.2.1.1 Inclusion criteria 
• Diagnosis of uncomplicated malaria 
• Age between 12 – 59 months 
• Weight ≥ 5kg 
• Blood film of Plasmodium falciparum infection of 1,000 parasites/µL 
• Haemoglobin concentration of ≥ 7 g/dl 
• No medication containing artemisinin 4 weeks prior to recruitment 
• Willing to give informed consent  
5.2.1.2 Exclusion criteria 
• Diagnosis of complicated malaria 
• Age < 12 and ≥ 60 months 
• Weight < 5kg  
• Medication containing artemisinin within 4 weeks 
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• Unwilling/ unable to give informed consent 
• Haemoglobin concentration of < 8 g/dl 
5.2.2. Ethical approval and Informed consent 
The study received ethical approval from the University of Liverpool ethics 
committee (Ref. RETH000395) and The Gambia government-MRC joint committee 
(Ref. R10031). Parents/guardians and subjects were informed about the study in 
detail and questions and queries answered. Written consent was obtained in 
agreement for the study to be conducted.  
5.2.3. Measurements of clinical parameters 
Anthropometric measurements (weight, height) were taken. Weight was 
measured on a digital scale. Length was taken for children under the age of two years 
on a platform with a sliding headboard. Standing height was measured for children 
above two years with a height scale. Weight-for-height z scores (WHZ), weight-for-
age z scores (WAZ) and height-for-age z scores (HAZ) were calculated on the basis 
of the National Centre for Health Statistics (NCHS/WHO) reference data set, version 
3.2.2 software (WHO 2011). Z scores < -2 are suggestive of wasting (WAZ), 
underweight (WHZ) and stunting (HAZ). Scores < -3 suggest severe malnutrition. 
Age, sex and axillary temperature was recorded for every child.  
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5.2.4. Drug administration 
The study drug (artemether/lumefantrine) was dispensed to the patients by the 
local health centre pharmacies based on body weight according to WHO guidelines 
(table 1). The first dose was administered under supervision with flavoured full fat 
milk, to enhance artemether absorption. For children who could not swallow the 
tablet(s) whole, they were crushed and given to them followed by 150ml of milk. 
Tablets were administered whole to children who were able to swallow them with 
150 ml of milk. The dose was repeated if vomiting occurred within 30 min of 
administration.  
5.2.5 Blood sample collection and plasma separation 
An area on the forearm was identified and local anaesthetic applied. An 
intravenous cannula was inserted and a pre dose blood sample collected. The arm 
with the cannula was immobilised to maintain the cannula for a post dose blood 
collection. Venous blood samples were taken just prior to administering the first dose 
and at 120 min post dose. Samples were collected in sodium heparinised tubes and 
immediately placed on ice. They were centrifuged at 1,500 g for 15 min as soon as 
possible, within the hour. The plasma was stored at -80°C until shipment on dry ice 
to the University of Liverpool laboratory department. The maximum duration of 
sample storage was 20 months at -80°C.  
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5.2.6 Plasma sample analysis 
Plasma concentrations of artemether and DHA were determined by liquid 
phase extraction and liquid chromatography-tandem mass spectrometry. The 
optimised method described in chapter 4 was used.  
5.2.6.1 Instrumentation and chromatographic conditions 
A hybrid triple quadupole/ion trap mass spectrometer (4000 QTRAP) from 
AB Sciex (Manchester, UK) was operated in positive mode using the Turbolon Spray 
source. Chromatographic separation was achieved on C18 XDB analytical column 
(150 mm x 2.1 mm, 5 µm particle size). Retention times for artemether and DHA 
were 9.5 and 4.1 min, respectively, and 3.9 min for artemisinin. LC elution was 
accomplished with 20% v/v aqueous 10mM ammonium formate at a pH of 4.1 
(solvent A) and 80% v/v acetonitrile with 0.1% v/v formic acid (solvent B) in 
isocratic mode at a flow rate of 1mL/min for 6mins and the injection volume was 
50µL. 
The MRM ion pair m/z 316→267 for artemether, m/z 302→267 for DHA and 
m/z 300→209 for artemisinin which was used as an internal standard (I.S) were 
used.  The optimised acquisition parameters were as follows: Turbo (Heater) set at 
250°C; curtain gas (CUR), 40psi (99.9% nitrogen); nebulizer Gas (Gas 1), 60 psi 
(nitrogen); auxillary (turbo) Gas (Gas 2), 20 psi (nitrogen); collision-activated 
dissociation (CAD) Gas:4: IonSpray Voltage (IS), 5000 v. Calibration standards 
were prepared in concentrations ranging from 0.5 - 50 ng/ml and the standard curves 
were linear (r2 ≥ 0.99). No matrix effect was observed during method validation. 
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Average percentage recoveries for artemether, DHA and the internal standard were 
81, 94 and 75 % and inter and intra-day variation accuracy were assessed to be above 
80%. The lower limits of detection and quantification were 0.1 and 0.3 ng/ml 
respectively for artemether and 0.4 and 1 ng/ml for DHA. 
5.2.6.2 Sample preparation 
Liquid-liquid extraction was carried out as validated in chapter 4. Briefly, 
plasma (50 µl) was added to methyl t-butyl ether in a glass tube (900 µl). The 
mixture was vortexed, put on a tube rotator (30 min) and then on dry ice until the 
plasma was frozen. The liquid organic phase was extracted and left in a fume hood 
overnight at room temperature to dry. The residue was then reconstituted in methanol 
water (50:50 (v/v)) and 20 µl was injected into the LC-MS/MS system. 
5.2.7 Data analysis 
The chromatographic data (the peak area ratios of DHA to artemisinin and 
artemether to artemisinin) were analysed using Analyst® software version 1.5 (AB 
Sciex). Maximal plasma concentrations of artemether and DHA were obtained from 
the peak area ratio of the analytes to the peak area ratio of the internal standard 
(artemisinin). Statistical analysis was conducted using SPSS for windows, version 
20.0. Normality was tested using t test and chi-squared test. ANOVA was used to test 
for significance of drug concentration with different degrees of malnutrition and 
haemoglobin.  
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5.3  Results 
A total of fifty-one children were enrolled for the study. Three children 
vomited within 30 minutes of receiving the first dose, and dosing was repeated 15 
min after vomiting without any event. Table 5.3 summarises the demographics and 
anthropometric measurements of the study group. The mean ± SD for age, weight 
and height of the participants were 33.8 ± 15.26 months, 11.49 ± 2.89 kg and 90.14 ± 
12.79 cm respectively. The mean ±SD haemoglobin concentration was 9.59 ± 0.88 
g/dl.  
Table 5.3 Demography of the study population.  
Variable  Value 
Total number 51 
Gender Male (%) 
Female (%) 
19 (37.3) 
32 (62.7) 
Age (months) 33.8 ±15.26 
Weight (kg) 11.49 ±2.89 
Height (cm) 90.14 ±12.79 
Haemoglobin (g/dl 9.59 ± 0.88 
Study population demographics. Age, weight, height and haemoglobin concentration are 
mean ± SD values. 
 
Mean ± SD z-score for weight-for-height (WHZ), weight-for-age (WAZ) and 
height-for-age (HAZ) were -1.38 ± 1.61, -1.50 ± 1.36 and -1.07 ± 1.93 respectively 
(Table 5.4). Children were said to be malnourished and severely malnourished when 
the z-scores for WHZ, WAZ and HAZ were < -2 and < -3 respectively below the 
median of the WHO child growth standard. 21.6% (n=11) of the study population 
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were considered to be underweight with wasting and stunting accounting for 29.4% 
(n=15) and 21.6% (n=11) respectively. 
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Table 5.4 Nutritional status of the study population 
 Z score value No. (%)  
No. (%) Normal < -1 < -2 < -3 p value 
WHZ 30 (58.9) 6 (11.8) 8 (15.6) 7 (13.7) NA 
WAZ 16 (31.4) 24 (47.1) 5 (9.8) 6 (11.8) 
HAZ 20 (39.2) 20 (39.2) 8 (15.6) 3 (5.9) 
Weight (kg)      
WHZ 11.50±2.27 13.53±1.75 12.19±2.62 9.14±1.82 0.007
* 
WAZ 12.85±2.18 11.57±2.17 10.00±2.55 9.05±1.98 0.003
* 
HAZ 12.92±2.13 10.83±2.15 10.89±2.44 8.73±2.19 0.003* 
Height (cm)      
WHZ 85.45±9.32 99.83±6.79 97.65±12. 91.74±11.61 0.002
* 
HAZ 98.64±8.19 84.96±9.38 84.69±10.65 78.87±2.31 0.001* 
Age continuous WHZ 29.20±12.68 44.17±12.06 44.50±15.98 36.26±16.46 0.016 
Prevalence of different z scores of weight-for-height (WHZ), weight-for-age (WAZ) and height-for-age (HAZ). Weight, height and age continuous 
are expressed as mean±SD 
* ANOVA 
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 5.3.1 The effects of nutrition on pharmacokinetics 
Drug plasma concentrations of artemether and DHA in different nutritional 
categories are shown in a scatter plot (Figure 5.2) and summarised in Table 5.5. The 
overall mean ± SD Cmax for artemether and DHA were 138.44 ± 80.89 ng/ml 
(median; 157.3 ng/ml) and 58.84 ± 43.73(median; 48.79 ng/ml) ng/ml respectively, 
with observed high inter-patient variability. Mean ±SD Cmax values for artemether 
and DHA in wasted children were 124.46 ±84.26 ng/ml and 84.13 ± 62.59 ng/ml 
respectively. 
Plasma artemether concentrations were highest in the severely wasted 
children category while DHA was highest in the moderately wasted category. 
However, the differences were not considered significant when the values were 
adjusted for age, height and weight. Children with moderate wasting (Z-score < -2) 
had the lowest artemether concentration (124.46 ±84.26) and the highest DHA 
concentration (84.13 ±62.59) in the weight-for-height category, but again this was 
not significant. Plasma DHA concentrations in stunted (41.14 ± 23.52) and severely 
stunted children (42.32 ± 6.15) were lower compared to their normally nourished 
children (64.34 ± 53.82) but the difference was not statistically significant.  
Unlike the mildly wasted and stunted children who had plasma artemether 
concentration values close to their normally nourished counterparts, mildly 
underweight children, though not statistically significant, had higher mean ± SD 
artemether concentration (150.09 ±79.63) compared to their normally nourished 
counterpart (119.12 ± 84.22). 
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5.3.2 The effects of anaemia on Artemether and DHA plasma levels 
Table 5.6 summarises the anaemic status of the study group. Overall, 96.1 % of 
children in the study group were classified as anaemic (Hb < 11 g/dl) using the WHO 
classification, with 66.7 % (n = 34) having moderate anaemia (Hb 10.9 – 10g/dl). 
Mean artemether and DHA plasma concentrations were not affected by the anaemic 
status of the children (Table 5.7 and Figure 5.3).There were no differences in 
artemether and DHA concentrations in patients with different degrees of anaemia.  
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Figure 5.2 Scatter plot of Artemether and DHA concentration 
Scatter plot of artemether (ng/dl) in relation to wasting (A), underweight (B) and stunting (C) 
and DHA (ng/dl) in relation to wasting (D), underweight (E) and stunting (F). WHZ- 
wasting, WAZ – underweight, HAZ - stunting 
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Table 5.5 Artemether and DHA plasma concentration 2 h post dosage 
Plasma levels of artemether and DHA, in children under 5 years 2 h post dose of artemether/lumefantrine. Values are expressed as mean ± SD  
*ANOVA 
αAnalysis of covariance 
ǂ including weight as a confounding factor 
∞ including age, height and weight as a confounding factor 
≠ including height and age as a confounding factor 
 Z score value No.  
 Normal < -1 < -2 < -3 p value 
WAZ N=16 N=24 N=5 N=6  
Artemether 119.12±84.22 150.09±79.63 126.60±111.09 153.25±53.55 0.65*, 0.73ǂ,α 
DHA 54.23±37.02 64.54±48.64 40.27±15.31 63.84±54.45 0.67*, 0.67ǂ, 
      
WHZ N=30 N=6 N=8 N=7 NA 
Artemether 137.87±93.27 138.93±36.25 124.46±84.26 156.49±49.62 0.91*, 0.15∞,α 
DHA 54.77±36.81 46.75±28.76 84.13±62.59 57.77±52.24 0.33*, 0.34∞,α 
      
HAZ N=20 N=20 N=8 N=3  
Artemether 134.07±60.50 144.82±99.13 148.32±84.66 98.81±81.72 0.81*, 0.63≠,α 
DHA 64.34±53.82 62.90±40.05 41.14±23.52 42.32±6.15 0.536*, 0.63≠,α 
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Table 5.6 Anaemic status of children 
WHO classification No. (%) Hb (g/dl) 
≥ 11 (g/dl) 2 (3.9) 11.4 ±0.14 
10.9 – 10 (g/dl) 15 (29.4) 10.4 ±0.31 
9.9 – 7 (g/dl) 34 (66.7) 9.1 ±.65 
Anaemic status of the patients according to WHO classification. Results are expressed as 
mean ±SD.  
 
 
Table 5.7 Artemether and DHA plasma concentration in relation to anaemia 
 No 
(%) 
Hb (g/dl) Artemether 
(ng/ml) 
P value DHA (ng/ml) P value 
≥ 10 
g/dl 
17 
(33.3) 
10.51±0.45 138.47 ±73.74 
0.92 
57.90 ±36.65 
0.89 
≥ 9.9 
g/dl 
34 
(66.7) 
9.13 ±0.65 138.43 ±85.31 59.31 ±46.78 
Plasma levels of artemether and its active metabolite, DHA in relation to haemoglobin level 
in children under 5 years 2 h post dose of artemether/lumefantrine combination. Results are 
expressed as mean ± SD 
 
Table 5.8 shows the results of artemether and DHA plasma concentrations in 
relation to Hb levels reclassified in ranges of 1 g/dl. Children with Hb levels ≥ 11 
g/dl had mean plasma artemether concentration level of 55.56 ±5.19 ng/ml. This was 
was observed to be lower however, only two children were in that category. Children 
with Hb levels between 7.9 – 7g/dl showed the highest mean artemether 
concentration (162.90 ±27.41). There was no significant difference observed in the 
mean DHA plasma concentration. 
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Figure 5.3 Scatter plot Hb against Artemether and DHA 
Scatter plot of haemoglobin levels (g/dl) in relation to artemether (A) (r = 0.04) and DHA 
(B) (r = 0.10) plasma concentration (ng/dl)  
 
 
 
 
A 
B 
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Table 5.8 Artemether and DHA concentration in relation to Hb levels 
 No. (%) Hb (g/dl) Artemether 
(ng/ml) 
P 
value 
DHA (ng/ml) P 
value 
≥ 11 2 (3.9) 11.40 
±0.14 
55.56 ±5.19 
0.69 
43.86 ±46.07 
0.87 
≥ 10 15 (29.4) 10.4 ±0.31 149.52 ±71.4 59.77 ±36.76 
≥ 9 22 (43.1) 9.5 ±0.33 142.02 ±93.81 66.02 ±48.65 
≥ 8 9 (17.6) 8.67 ±0.24 121.50 ±78.44 35.89 ±32.00 
≥ 7 3 (5.9) 7.70 ±0.17 162.90 ±27.41 46.97 ±12.08 
Artemether and DHA concentration (ng/ml) in relation to haemoglobin levels (g/dl). Results 
are expressed as mean ± SD 
 
5.3  Discussion  
 Mortality and the severity of malarial infection in children have been linked 
to the comorbidity of PEM. The pathophysiological changes in PEM are known to 
alter drug pharmacokinetics resulting in impaired drug metabolism with possible 
toxicity, and altered response to treatment (Oshikoya and Senbanja, 2009). In this 
study, peak plasma concentration (Cmax) of artemether and DHA were analysed in 
children less than five years of age with different nutritional status. Children with 
malaria generally eat little during the acute phase of malaria and since dietary fat is 
known to enhance artemether bioavailability (White et al., 1999), full fat flavoured 
milk was given with the first dose of artemether/lumefantrine.  
The aim of the initial research proposal was to build a pharmacokinetic model 
of artemether and DHA in normally nourished children and malnourished children in 
order to compare the pharmacokinetic values in normally nourished children and 
children with different degrees of malnutrition. 100 children, who met the inclusion 
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criteria, were to be admitted in a health facility to perform serial venous blood 
sampling starting before the first dose and at 15mins, 30mins, 1hr, 2 hrs, 12hrs and 
24 hrs after the first dose. However, the research was conducted at the peak of the 
malaria season resulting in heavy patient population and admissions, limiting space 
in health facilities. The local ethics committee was contacted in order to revise the 
protocol for a more practical approach. Sample size, blood sample times and number 
were modified with the consent of the local ethics committee. 
As a result of the limitation the sample size was reduced (51). Although 
blood collection in children is limited by age, size and disease status (Reed, 1999), 
sparse sampling was adopted mainly due to heavy patient population and limited 
space in the health facilities. Taking into account the average tmax of artemether and 
DHA, 2 h post dose samples were used to analyse the Cmax of both artemether and 
DHA. Djimde et al (2011) also used a sparse sampling method and considered tmax of 
artemether to be between 1 and 2 h, talking the highest value from the two time 
points as the Cmax.  
The values obtained in this study for artemether and DHA were 138.44 ± 
80.89 ng/ml and 58.84 ± 43.73 ng/ml respectively. These results were comparable to 
a multi-centre study across Africa covering six countries with the same study 
population. They reported an artemether and DHA Cmax of 190±168 and 
63.7±65.0ng/ml respectively following oral administration of crushed 
artemether/lumefantrine tablets (Djimdé et al., 2011). The length of sample storage 
(20 months) prior to analysis is unlikely to have affected the levels obtained as 
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artemether and DHA are reported to be stable for at least 2 years when stored at -
80°C (Ali et al., 2010).  
 Other studies have published data on the pharmacokinetics of artemether and 
DHA in children with uncomplicated malaria (Hietala et al., 2010, Mwesigwa et al., 
2010) but the study design and sampling time’s makes comparing their data and the 
one obtained in this study difficult. Following intense pharmacokinetic sampling 
beginning just before the administration of the last dose of artemether/lumefantrine 
Mwesigwa et al. (2010) reported Cmax and AUC0-∞ of artemether values of 34 ng/ml 
and 168 ng/ml respectively with DHA values 119 ng/ml and 382 ng/ml respectively. 
Whilst Cmax values of artemether and DHA in children reported by Djimdé et al. 
(2011) were similar to those earlier reported in adults (Lefèvre et al., 2001), 
Mwesigwa (2010) reported a 2 to 3 fold increase of Cmax and AUC0-∞ values of 
artemether in children compared to adults (German et al., 2009, Lefèvre et al., 2002). 
In order to obtain full pharmacokinetic parameters in children, population 
pharmacokinetics (PPK) modelling is been increasingly developed and used (Jamsen 
et al., 2012, Ogungbenro et al., 2009). Pharmacokinetic information obtained through 
PPK studies in children is also used in paediatric drug development to obtain clinical 
efficacy and safety of drugs, which often lack in paediatric drug development De 
Cook et al., 2011). 
Despite differences in drug responses in children compared to adults, the 
paediatric dosing for majority of drugs are derived from adult dosing regimens based 
on bodyweight. With an estimation that ≥ 50% of drugs used have never been tested 
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for efficacy and safety in this population (Ogungbenro et al., 2009). This is as a 
result of both ethical and practical challenges. Unlike adults, research in healthy 
children is considered unethical, thus all paediatric pharmacokinetic studies are 
performed in children suffering from a disease. In addition to the limited availability 
of the number of samples in this vulnerable population, there are limitations on the 
volume and number of samples that can be collected per child, resulting in sparse 
sampling (Jamsen et al., 2012, Cock et al., 2011). Table 5.9 summarises traditional 
pharmacokinetic studies versus population pharmacokinetic studies. 
Table 5.9 Summary of traditional pharmacokinetics versus population 
pharmacokinetics 
 pharmacokinetics Population pharmacokinetics 
Population Health volunteers Patients 
Target patient population 
- paediatric 
- elderly 
Specific disease state 
 
Sampling data Dense Sparse 
 
Relationships of PK/PD Limited 
Extensive 
- make predictions on steady state 
concentrations 
- dosage guidelines 
- determine therapeutic window 
 
Inter-individual 
variability minimised 
Demographics 
Pathophysiological 
Concomitant medication 
 
 
In Addition, pharmacokinetic data obtained through PKK modelling can help 
in detecting differences in efficacy and safety in sub-groups within the studies age 
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interval, helping to identify subgroups in which exposure differs from the overall 
study population (White, 2013). 
PPK approach offers the possibility of achieving information on 
pharmacokinetic from relatively sparse data, allowing information to be borrowed 
across individuals to obtain parameter estimates. It also allows the analysis of data 
from a variety of unbalanced designs, including data from paediatric and elderly 
patients (Hennig et al, 2006, Shoemaker and Cohen., 1996). The two common PPK 
analysis methods used are; the two-stage approach and the nonlinear mixed-effects 
modelling approach.  
The nonlinear mixed-effects modelling approach is often used in PPK where 
there are limited sparse sampling. This involves the simultaneous evaluation of data 
from all individuals in a population. It results in less biased estimates where residual 
error is present. It can be used in sparse data situations where traditional two-stage 
approach is not applicable. It considers population study samples and uses individual 
data of observational type which may be sparse, unbalanced and fragmentary (Mould 
and Upton, 2013). 
PEM continues to be a major health problem but pharmacokinetic studies of 
drugs in that population has declined over the decades (Oshikoya and Sammons 
2010). Pharmacokinetic studies of antimalarial drugs in children with PEM are 
limited despite the high prevalence of children with PEM especially in malaria 
endemic countries. The effect of nutritional status on the efficacy of ACT in children 
showed that artemether/lumefantrine therapy was an effective antimalarial for 
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children with chronic malnutrition showing 99% parasite clearance by the 3rd day 
(Verret et al., 2011). However, this is the first pharmacokinetic study of artemether in 
children with PEM. 
 Results obtained showed that the Cmax of both artemether and DHA were 
not influenced by PEM nonetheless further studies involving more pharmacological 
parameters such as tmax, AUC and clearance in combination with bigger sample size 
are needed for better evaluation. Peak plasma concentration and AUC of chloroquine 
in children with kwashiorkor have shown to be significantly lower when compared to 
their normally nourished counterpart (Walker et al., 1987). Given the fact that 
chloroquine, like artemether is also metabolised by hepatic CYP 3A4/5 (Kim et al., 
2003), extreme spectrums of PEM should be considered in future pharmacokinetic 
studies of artemether and DHA.  
Another aim of this study was to evaluate the effect of haemoglobin on 
artemether plasma concentration. Anaemia is a common accompaniment of PEM 
with iron deficiency being the commonest cause seen in more than 85% of anaemic 
children with PEM (Ejaz and Latif, 2010). Considering the fact that iron is important 
in the activation of the artemisinin compounds, haemoglobin levels were analysed 
against the Cmax values of both artemether and DHA. The results obtained showed 
no correlation between the level of haemoglobin and plasma artemether 
concentrations. Although children with Hb ≥ 11 g/dl showed lower plasma 
artemether concentration, they only constituted 3.9% of the study population limiting 
the statistical interpretation. The lower level of Cmax might be multifactorial and 
because samples were obtained from only one time point, Cmax might have been 
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missed. One explanation might be that children with higher haemoglobin levels have 
higher iron contents in their red blood cells thus exhibiting quicker bioactivation 
resulting in lower tmax values. Although it might be challenging to obtain a study 
group of children with normal haemoglobin levels due to the common association of 
malaria infection and anaemia (Menendez et al., 2000), a large study group of 
children with normal haemoglobin levels will be imperative for better analysis. 
Studies evaluating the association between iron status and malaria have 
discovered that iron deficiency is a protective factor for malaria, showing a decreased 
malarial incidence with decreasing levels of stored iron (Sazawal et al., 2006, 
Nyakeriga et al., 2004). Although the protection offered by iron deficiency against 
malaria has been explained arise via an immune-mediated mechanism (Nyakeriag et 
al. 2004), it would be important to note the importance of host haemoglobin in the 
development of the malaria parasite. Iron is an important component in haemoglobin 
formation. The parasite degrades and detoxifies host haemoglobin (Medhi et al., 
2009). In the presence of low haemoglobin, the amount of iron present might have an 
influence on parasite maturity, but most importantly on artemisinin activation. 
Selectivity of the artemisinin compounds towards parasite infected red blood cells 
over red blood cells is provided by the higher iron content in infected cells. 
Finally, a number of limitations have to be highlighted. Although the sample 
size enabled the research to be conducted within a short time frame, it has its 
limitations. It might not be representative of the population under study and thus 
cannot offer a conclusive result. The study should be conducted in a larger sample 
size to ensure a better representative of the population and more accurate statistical 
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analysis. The sparse sampling adopted in this study has limited the degree of 
pharmacokinetic analysis thus cannot offer a more conclusive result. The Cmax values 
were obtained from only one time point and may not represent an accurate and true 
Cmax value. Analysing samples at different time points will enable a broader 
pharmacokinetic analysis including tmax, volume of distribution and clearance, to 
name a few. The inclusion of severely anaemic children and children with extreme 
spectrums of PEM (kwashiorkor and marasmus) would give a wider understanding 
of other important pharmacokinetic properties.  
The findings in this study have shown that PEM and anaemia might not have 
a significant effect on the peak plasma concentration of artemether and DHA. 
However, to enable more definitive results and a better pharmacokinetic profile 
evaluation, the study should be conducted in a larger sample size and across several 
study sites in different countries. 
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6  Final Discussion 
Malaria is one of the leading causes of death in children under five years of 
age accounting for 7% of infant mortality. The use of artemisinin combination 
therapy (ACT) was proposed by the WHO in 2006 to address the resistance of 
Plasmodium falciparum to traditional antimalarials and improve treatment outcomes 
(WHO, 2006). ACT is now the recommended drug of choice for uncomplicated 
malaria in children ≥ 5 kg and or 6 months of age (WHO, 2010).  
The few pharmacokinetic of ACT carried out in children have suggested that 
children might be receiving sub optimal levels of ACT (WHO, 2002, Sidhu et al., 
1998), thus might experience lower cure rate (Li et al., 2004, Looareeswan et al., 
1998) due to the physiological and developmental differences in children (Kearns et 
al., 2003, Johnson et al., 2003). In addition, protein energy malnutrition (PEM), a 
common co-morbidity with malaria in African children (Fillol et al., 2009), may also 
have an effect on the pharmacokinetics of ACT.  
PEM has been linked to around half of all infant mortality including malaria 
(Black et al., 2010). With PEM linked to the morbidity of malaria in children 
(Ehrhardt et al., 2006, Friedman et al., 2005, Verhoef et al., 2002, Deen et al., 2002), 
a huge proportion of children with PEM will be taking ACT. Among the sample of 
children with uncomplicated malaria studied in The Gambia, a high level of 
malnutrition (31.6%) was noticed when compared with the prevalence of PEM in 
children within the general population (17.4%). 
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However, the study did not examine the relationship between the two co-
morbidities. Just because the relationship between malaria and malnutrition was not 
analysed, it should not overshadow the importance of high prevalence of PEM in 
children with malaria. Though the cause and effect of the two co-morbidities has not 
been confirmed, the results obtained in this study reaffirms and strengthens the 
presence of PEM in children with malaria. The physiological changes that occur in 
children with PEM directly or indirectly affect the disposition of drugs.  
PEM is associated with deficiencies of various mineral including iron, which 
is of significance in the bioactivation of the artemisinin compounds. Though the 
exact mechanism of action of the artemisinin compounds is still a matter of debate, 
the role of iron is well established. It is known that the compounds are activated in 
the presence of iron from haem to cause highly reactive free radicals rearranging and 
forming carbon centred radicals, which target and inhibit specific parasite molecules 
resulting in parasite death (Meshnick et al, 1996, Posner et al., 1995, Meshnick et al., 
1991).  
The effect of decreased iron was initially studied in vitro. Several studies 
have used iron chelators to demonstrate the involvement of iron with the observation 
that they either inhibit bioactivation or iron-related oxidative stress (Meshnick et al., 
1993, Wei and Sadrzadeh 1994, Stocks et al., 2007). In order to further understand 
the mechanism by which iron chelators inhibit artemisinin toxicity, the effect of 
artesunate was studied in HL-60 cells in the presence of the iron chelator, 
deferoxamine (DFO). Although the toxicity of artesunate was inhibited, DFO had no 
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effect on bioactivation, as evidenced by the decrease in the parent compound 
(Chapter 2). However it is important to note the significant decrease in the metabolite 
biomarker. 
Figure 6.1 Proposed mechanism of DFO on the artemisinin compounds 
 
DFO inhibits the formation of reactive oxygen species with subsequent inhibition of cell 
death 
 
From this, it would be safe to conclude that chelatable iron might not make a 
significant contribution to the bioactivation of the artemisinin compounds, but plays 
an important role in inhibiting the cascade of events leading to cell death. Studying 
the different proposed mechanism of action of the compounds, the presence of DFO 
was shown to inhibit the effect of artesunate in all subsequent steps, which include 
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ROS formation, mitochondrial membrane potential depolarisation, caspase activation 
and cell death.These results appear to be in line with the idea that artemisinin 
bioactivation causes an accumulation of iron which in turn causes the formation of 
ROS in the lysosomes in cells, which is analogous to the parasite food vacoule 
(Hamacher-Brady et al., 2011). Lysosomes are an important source of redox active 
free iron that is sensitive to artemisinin generated ROS forming reactive hydroxyl 
radical in a fenton reaction (Kurz et al. 2008, Uchiyama et al., 2008). The removal of 
toxic iron in cells inhibits the fenton reaction thus preventing the formation of 
reactive oxygen species, and inhibiting the cascade of reactions that result in cell 
death. 
With the in vitro study showing that chelating iron reduces artesunate 
toxicity, it would be important to assess the effects of iron deficiency anaemia on the 
artemisinin compound. Anaemia is one of the commonest micronutrient deficiencies 
associated with PEM (Ejaz et al., 2010), with iron deficiency being the commonest 
cause of anaemia. Iron deficiency has been associated with decreased parasitaemia 
and malaria associated morbidity and mortality (Gwamaka et al., 2012, Jonker et al., 
2012, Nyakeriga et al., 2004). This has been explained to be as a result of specific 
defect in the production on particular immunoglobins, it would be important to also 
look at the possible low haemoglobin in red blood cells as another factor. Iron 
deficiency might lead to decreased haem derived from haemozoin formed when the 
plasmodium parasite digests haemoglobin in the red blood cells, and with in-vitro 
studies showing the chelation of iron leading to decreased cell death, it would be 
important to assess the effect of iron deficiency anaemia on the artemisinin 
compounds. 
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As one of the determinants of treatment response, optimal plasma drug 
concentrations are essential for effective treatment outcome in malaria (Price et al., 
2007). In order to analyse artemether and DHA plasma concentrations, plasma 
samples were analysed in 50 children. Plasma concentrations of artemether and DHA 
were measured using a sensitive LC-MS/MS method developed and optimised for 
the simultaneous analysis of both artemether and DHA in small plasma volumes 
(Chapter 4). Although over the years, different methods have been developed to 
analyse drugs in plasma, mass spectrometry is now considered the preferred method 
as it offers better sensitivity and selectivity with simultaneous analysis of multiple 
compounds (Grebe and Singh, 2011). Our method was validated according to 
established recommendations (Chandramouli et al., 2010) which included assessment 
of precision and accuracy, matrix effect and recovery.  
Artemether and DHA plasma concentration was not influenced by the 
anaemic status of the children. Even though this study showed no association 
between the degree of anaemia with drug plasma concentrations, the importance of 
iron deficiency in children should not be overlooked. Iron is essential in the 
activation of the artemisinin compounds in red blood cell and low levels could have a 
significant influence in the pharmacological profile of the drugs. This can lead to a 
decrease in toxicity of the malaria parasite or a decrease in extracellular 
detoxification which might ultimately lead to an increase in plasma concentration 
thus altering the benefit: risk ratio. The alteration of the benefit: risk balance might 
lead the revision of the ACT treatment protocol in children with malnutrition. 
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Artemether and DHA plasma concentrations measured in children with 
uncomplicated malaria in Gambian children were also analysed in relation to their 
nutritional status as defined by WHO. PEM is associated with villous atrophy which 
might influence drug absorption, and has been associated with altered plasma drug 
concentrations in relation to other antimalarial drugs. The plasma concentrations of 
antimalarial drugs are much lower in malnourished children compared to normally 
nourished children (Salako et al., 1996, Tréluyer et al., 1996). In addition, PEM has a 
significant impact on the cytochrome (CYP) enzymes including CYP3A4 and 
CYP3A5 (Mao et al., 2006), which are important in the pharmacokinetics of 
artemether and DHA. The nutritional status of the children did not have any 
significant influence on the plasma concentrations of artemether and DHA. 
The lack of a significant difference in drug plasma concentrations in this 
study between the normally nourished and children with PEM cannot be used as 
conclusive evidence that PEM does not affect artemether drug metabolism. Volume 
of distribution (Vd), an important factor in determining the peak concentration of 
drugs, and is affected differently by marasmus, kwashiorkor and marasmic-
kwashiorkor. Whilst kwashiorkor causes a decrease in Vd in some drugs, marasmus 
might have the opposite effect (Oshikoya et al., 2010). Although some of the 
children included fit the classification of severe malnutrition, none of them were 
classified as either marasmus or kwashiorkor. 
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6.2 Future research arrears 
 Based on the findings reported in this thesis, there are several key areas 
which warrant further research. 
6.2.1. Explore the relationship between PEM and malaria 
An important finding in this thesis was the higher prevalence of underweight 
and wasted in children with uncomplicated malaria. Although the association 
between malaria and PEM is still controversial, and whilst recent studies have 
observed an increased risk of malaria related morbidity (Ehrhardt et al., 2006, 
Friedman et al., 2005, Verhoef et al., 2002, Deen et al., 2002) and mortality (Müller 
et al., 2003, Rice et al., 2000) in children with PEM, the contribution of malaria as a 
causal factor for PEM has also been suggested (Nyakeriga et al., 2004). 
Understanding the effect of PEM on malaria and vice versa in malaria endemic areas 
may help in addressing public health interventions. Thus further studies on the 
relationship between malnutrition and malaria are needed for better understanding of 
any association. 
6.2.2 Detailed pharmacokinetic studies of artemisinin compounds in children with 
Protein energy malnutrition 
 PEM is shown to affect pharmacokinetics of drugs in children and despite it 
being a major contributor to infant mortality and co-morbidity, such studies have 
decreased over recent years (Oshikoya et al., 2010). With the strong association 
between PEM and malaria in children, a huge proportion of children taking ACT as 
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the first line of malaria treatment will suffer from some aspect of PEM. Very few 
studies have looked at the pharmacokinetics of antimalarial drugs in this vulnerable 
population and to the end of writing this thesis; no data has been published on the 
pharmacokinetics of the artemisinin compounds in children with PEM. There is a 
need to not only study the plasma levels of these drugs in a larger sample size, but 
also assess the rate of absorption, distribution, clearance and half-life, as they all 
affect drug response outcomes. It should also be noted that PEM is a spectrum of 
diseases with marasmus at one end and kwashiorkor at the other, with intermediate 
states of varying degrees. The type and severity of PEM impacts differently on 
pathophysiological changes in children. This in turn results in varying effects on drug 
pharmacokinetic parameters. It would be important to evaluate the pharmacokinetics 
of the artemisinin compounds at the two ends of the spectrum to gain better 
understanding of their differential effects and help formulate appropriate dosing 
schedules in children with different degrees of PEM. 
6.2.3 Effect of protein energy malnutrition on treatment response to the artemisinin 
compounds 
 Artemisinin compounds are well tolerated with no reported toxicity in 
children with studies in general reporting good clinical outcomes (Djimdé et al., 
2011, Hietal et al., 2010, Abdullah et al., 2008).The endoperoxide bond, which is 
responsible for its antimalarial activity, is activated by cellular iron. There is high 
rate of iron deficiency anaemia in children with PEM. With red blood cells being the 
target for the artemisinin compounds, it would be important to study the effect of low 
haemoglobin on the efficacy of the drug. Early and late analysis of the parasite 
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density in red blood cells will help gain a better understanding of the importance of 
in-vivo activation of the compounds by iron. It will also help to assess drug 
sensitivity and therapeutic index in the presence of low iron. Obtaining this data will 
help to further bridge the gap between in-vitro and in-vivo work on these compounds. 
6.3 Conclusion 
 Although the in-vitro studies in this thesis (Chapter 2) have demonstrated that 
iron chelators inhibit artemisinin toxicity, the effect was possibly due to the chelation 
of toxic iron resulting from rather than inhibiting the bioactivation of the compounds. 
There is a high prevalence of PEM in children with uncomplicated malaria in The 
Gambia (Chapter3). Coupled with the fact that PEM alters drug metabolism, it was 
important to assess the pharmacokinetics of artemether in this vulnerable group. 
Thus the analysis of artemether and DHA plasma levels in children with differing 
degrees of malnutrition and anaemic status was undertaken (Chapter 5) together with 
the development of a sensitive LC-MS/MS method (Chapter 4).Even though no 
artemether and DHA plasma concentration differences between different nutritional 
or anaemic states was observed, the study was limited by sample size, and needs to 
be undertaken in a larger number of patients in the future. Overall, the thesis has 
highlighted the importance of treatment with the artemisinin compounds in children, 
and in particular, shown the high prevalence of PEM in these children, which should 
be further investigated in order to ensure that dosing regimens can be optimised as 
much as possible to maximise efficacy in this vulnerable patient population.
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8 Appendices 
8.1 BCA Protein Assay 
Standards Preparation of different concentrations 
Vial Concentration 
(mg/ml) 
Volume of 
H2O 
(µl) 
Volume BSA 
(µl) 
Protein 
(µl/µg) 
A 2 0 200 18 
B 1.5 66 200 13.5 
C 1 100 100 (A) 9 
D 0.75 100 100 (B) 6.75 
E 0.5 100 100 (C) 4.5 
F 0.25 100 100 (E) 2.25 
G 0.125 100 100 (F) 1.125 
H 0 100 0 0 
 
 
9 µl of each standard are added in a 96-well plate in duplicates 
1.5 µl of samples are added to appropriate wells in duplicates 
Mix BCA assay reagent A & B (50:1) 
200 µl of BCA reagent is added to wells in both standard and samples 
Incubate plate at 37ºC for 30 min 
96-well plate is read at 570 emission and 590 absorption 
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8.2 Consent Form 
I have read the information sheet/ The information sheet has been read to me. I have had the 
opportunity to ask questions about it and any questions that I have asked have been answered 
to my satisfaction.  I consent voluntarily for my child/ward to be a participant in this 
research. 
 
Name of Participant _____________________________________________     
    
Signature of Participant ___________________                                 Date _______________ 
         Day/month/year 
    
If illiterate 
I have witnessed the accurate reading of the consent form to the parent/guardian to the 
potential participant, and the individual has had the opportunity to ask questions. I confirm 
that the individual has given consent freely.  
 
Name of Witness _____________________________________________     
    
Signature of Witness ___________________                                 Date _______________ 
         Day/month/year 
 
Name of Participant ______________________________- 
Date _______________ 
       Day/month/year  
         Thumb print 
 
I have accurately read out the information sheet to the potential participant, and to the best of 
my ability made sure that the participant understands that the following will be done: 
1. The child/ward will be admitted for 24 hours 
2. The pills will be given under supervision while on admission and with milk 
3. An indwelling cannulla will be inserted in the child/ward’s arm for serial blood 
withdrawal 
I confirm that the participant was given an opportunity to ask questions about the study, and 
all the questions asked by the participant have been answered correctly and to the best of my 
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ability. I confirm that the individual has not been coerced into giving consent, and the 
consent has been given freely and voluntarily.  
   A copy of the parent information sheet has been provided to the parent/guardian. 
Name of Researcher/person taking the consent________________________  
Signature of Researcher /person taking the consent__________________________ 
Date ___________________________   
        Day/month/year 
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8.3 Parent information leaflet 
 
PHARMACOKINETICS OF ARTEMETHER/LUMEFANTRINE 
(COARETEM) IN MALNOURISHED CHILDREN 
PARENT INFORMATION LEAFLET 
 
 INTRODUCTION 
Malaria is one of the most common diseases in The Gambia and also one of the leading 
causes of childhood death. Many of the children who have malaria also suffer from 
malnutrition.  Childhood deaths in Africa climbed due to parasite resistance to chloroquine, 
the then first line therapy, which prompted the introduction of artemisinin combination 
therapy (ACT), as the first line therapy in many parts of Africa. Although the artemisinin 
compounds are well tolerated and rapidly clears the parasite from the blood, it is associated 
with high relapse due to its short action. In order to counter this, WHO recommended that it 
should be used with a longer acting antimalarial drug to mop up and remaining parasites. 
 
 WHAT IS THE STUDY ABOUT? 
Little is known regarding the effect of these drugs in children and whether optimum drug 
exposure is achieved with current dosing regimens. Optimum dosing will minimise the risk 
for treatment failure, drug toxicity and drug resistance. Paediatric doses were formulated 
from adults based regimens adjusted for body weight with no regards to the effect of 
malnutrition. It is expected that a lot of these drugs will be administered in the coming years 
especially in children as they are more susceptible to having malaria. The study will compare 
the effectiveness of coartem between normally nourished and malnourished children and to 
see if the current dose regimen is as effective in malnourished children as it is in normally 
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nourished children. This will help formulate proper dose regimens to increase the 
effectiveness of the drug and reduce the harmful effects. 
 WHY HAS MY CHILD BEEN CHOOSEN? 
Your child/ward has been diagnosed with malaria and as a result will be given coartem. The 
study requires children between the ages 6 months up and including 5 years who are taking 
coartem.  
 WHAT WILL HAPPEN IF WE AGREE TO TAKE PART? 
After making sure that you understand what the study entails, we will ask you to sign or 
thumb print a consent form. Taking part will involve admitting your child/ward for twenty-
four hours. His/her weight, height, mid upper arm circumference, temperature, respiratory 
rate, blood pressure and pulse will be taken. After admission, a little amount of blood will be 
collected just before he/she drinks the medicine, which will be taken with milk to help 
absorb the drug better.  If the medicine is vomited, within an hour, he/she will have to repeat 
the dose.  Blood samples will be collected at various intervals (6 times) within the 24 hours. 
The blood collected will be used to study the level of drug in their boold and how long it 
stays there and also to see if different genes will cause the different levels. 
 HOW WILL BLOOD BE COLLECTED 
A needle (cannula) will be inserted in his/her arm but before that a cream will be applied on 
the site to minimise the pain caused by he needle prick. Small amounts will be collected (less 
than half a teaspoon) just before they take the medicine and 6 different times (15mins, 
30mins, 1hr, 2 hrs, 12hrs and 24 hrs after the first dose) in various tubes. The blood collected 
will be minimal and cause no harm to your child/ward. 
 WHAT WILL HAPPEN TO THE SAMPLES COLLECTED? 
The samples will be stored in a freezer in Royal Victoria Teaching Hospital until the study is 
finish and will be transported to the Department of Pharmacology at the University of 
Liverpool where they will be kept in a locked freezer. The samples will only be identified by 
a code, for increased security.  Once this study has been completed the samples will made 
anonymous, so it cannot be traced back to your child.  We might wish to use this anonymous 
sample in the future for other research and we would ask an ethics committee for permission 
to do this. 
 ARE THERE ANY RISKS OR BENEFITS TO TAKING PART? 
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There are no anticipated risks in taking part in the studies. There might not be direct 
benefits for your child/ward but information obtained from the study will help in the 
better management for other children in the future. 
 DOES MY CHILD/WARD HAVE TO TAKE PART? 
No. Your child/ward’s participation is voluntary. If you do not wish to participate, 
this will not affect your child’s right to proper management in the hospital. If you are 
not sure then we can arrange for someone to talk to you and help you make up your 
mind. 
 WHAT IF I CHANGE MY MIND? 
This is not a problem. If you/your child change your mind, you can withdraw from 
the study at any point. 
 WHO IS ORGANISING THIS RESEARCH? 
The research is being organised by the Department of Pharmacology at the 
University of Liverpool in collaboration with the Royal Victoria Teaching Hospital 
and it is also part of the PhD programme I am doing.  
 HAS THE STUDY BEEN CHECKED? 
Yes. All studies involving patients must be approved by the ethics committee in The 
Gambia before it starts. The committee is satisfied that your child’s rights will be 
respected, that any risks have been reduced to a minimum and balanced against 
possible benefits, and that you have been given sufficient information on which to 
make an informed decision to take part or not. The Liverpool Paediatric Research 
Ethics Committee has also reviewed and approved this study. 
 HOW DO I GET MORE INFORMATION? 
The person who gave you this information can discuss the study with you more. You can 
also contact 
Dr Mariama A Sarr Sallah 
Telephone number – 9925301 
Email – mariama@liv.ac.uk 
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8.4 Participant questionnaire 
PARTICIPANT DATA QUESTIONNAIRE 
         Date  
    
1 Serial Number        
        
2 Child Initial       
        
3 Parent/guardian Initial      
        
4 DOB/Age       
        
5 Sex a. Male                                 b. Female     
        
6 Symptoms     Duration   
  
    
     
        
 
 
 
 
 
7 Weight        
        
Numbers of Days 
One  Two  Three  Four or more 
a. Fever          
b. Vomiting          
c. Headache          
d. Diarrhoea          
e. Abdominal pain         
f. Weakness/Lethargic        
g. Other          
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8 Height       
        
9 Z score      
        
10 Mid upper arm circumference      
        
11 Temperature       
        
12 Pulse       
        
13 Respiratory rate        
   
        
14 Malaria parasite count      
        
15 Haemoglobin       
        
16 Full blood count       
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8.4 Consent Form 
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RECRUITMENT ADVERTISEMENT
 
STUDY ON COARTEM                                                                                                
Malaria is a serious disease that 
affects mostly children, especially 
during the rainy season. Continuous 
studies are always been done to help 
minimise the burden of the disease. 
 
The resistance of malaria to 
chloroquine led to the introduction of 
coartem (the pills in the packet) which 
are given in hospitals and health 
centres for the treatment of malaria. 
 
These pills are effective and make you 
feel better within a day or two. The 
pills are known to be safe in children 
but studies are still going on to 
improve its safety and effectiveness.  
 
In order to help achieve this, children 
between 6 months up to and including 
5 years with malaria are needed to 
take part in the study. They will be 
admitted for 24 hours and will receive 
their normal pills, which will be taken 
with milk under supervision.  
 
Their weight, height and mid upper 
arm circumference will be measured 
to assess how well nourished they 
are. A cream will be applied on an 
identified place on their arm were a 
needle will be inserted. The cream will 
minimise the pain of the needle. Blood 
will be taken at various times from 
this needle (7 times) during the 
course of the admission.  
The children will be checked regularly 
by a nurse and will be given additional 
treatment if needed. Food will also be 
provided to both children and parent 
during the course of admission.  
For further enquires, a member of the 
team will always be around to answer 
any question you have 
 
 
 
or contact  Fama Jaye,  
Tel: 7676210 
 
 Mariama Sarr Sallah 
Tel: 9925301/7925301 
 
